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Background: Pancreatic cancer diagnosis and staging can be difficult in 10–20% of patients. Positron
emission tomography (PET)/computed tomography (CT) adds precise anatomical localisation to functional
data. The use of PET/CT may add further value to the diagnosis and staging of pancreatic cancer.
Objective: To determine the incremental diagnostic accuracy and impact of PET/CT in addition to standard
diagnostic work-up in patients with suspected pancreatic cancer.
Design: A multicentre prospective diagnostic accuracy and clinical value study of PET/CT in suspected
pancreatic malignancy.
Participants: Patients with suspected pancreatic malignancy.
Interventions: All patients to undergo PET/CT following standard diagnostic work-up.
Main outcome measures: The primary outcome was the incremental diagnostic value of PET/CT in
addition to standard diagnostic work-up with multidetector computed tomography (MDCT). Secondary
outcomes were (1) changes in patients’ diagnosis, staging and management as a result of PET/CT;
(2) changes in the costs and effectiveness of patient management as a result of PET/CT; (3) the incremental
diagnostic value of PET/CT in chronic pancreatitis; (4) the identification of groups of patients who would
benefit most from PET/CT; and (5) the incremental diagnostic value of PET/CT in other pancreatic tumours.
Results: Between 2011 and 2013, 589 patients with suspected pancreatic cancer underwent MDCT and
PET/CT, with 550 patients having complete data and in-range PET/CT. Sensitivity and specificity for the
diagnosis of pancreatic cancer were 88.5% and 70.6%, respectively, for MDCT and 92.7% and 75.8%,
respectively, for PET/CT. The maximum standardised uptake value (SUVmax.) for a pancreatic cancer diagnosis
was 7.5. PET/CT demonstrated a significant improvement in relative sensitivity (p = 0.01) and specificity
(p = 0.023) compared with MDCT. Incremental likelihood ratios demonstrated that PET/CT significantly
improved diagnostic accuracy in all scenarios (p < 0.0002). PET/CT correctly changed the staging of
pancreatic cancer in 56 patients (p = 0.001). PET/CT influenced management in 250 (45%) patients.
PET/CT stopped resection in 58 (20%) patients who were due to have surgery. The benefit of PET/CT was
limited in patients with chronic pancreatitis or other pancreatic tumours. PET/CT was associated with a gain
in quality-adjusted life-years of 0.0157 (95% confidence interval –0.0101 to 0.0430). In the base-case
ABSTRACT
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model PET/CT was seen to dominate MDCT alone and is thus highly likely to be cost-effective for the UK
NHS. PET/CT was seen to be most cost-effective for the subgroup of patients with suspected pancreatic
cancer who were thought to be resectable.
Conclusion: PET/CT provided a significant incremental diagnostic benefit in the diagnosis of pancreatic
cancer and significantly influenced the staging and management of patients. PET/CT had limited utility
in chronic pancreatitis and other pancreatic tumours. PET/CT is likely to be cost-effective at current
reimbursement rates for PET/CT to the UK NHS. This was not a randomised controlled trial and therefore
we do not have any information from patients who would have undergone MDCT only for comparison.
In addition, there were issues in estimating costs for PET/CT. Future work should evaluate the role of
PET/CT in intraductal papillary mucinous neoplasm and prognosis and response to therapy in patients with
pancreatic cancer.
Study registration: Current Controlled Trials ISRCTN73852054 and UKCRN 8166.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Overall survival for patients with pancreatic cancer remains poor. Challenges in the care of patientswith pancreatic cancer include late presentation and difficulties in early diagnosis. Standard diagnosis
of patients with pancreatic cancer consists of a computed tomography (CT) scan, a magnetic resonance
imaging (MRI) scan and camera tests. Additional imaging tests may be able to identify pancreatic cancer
and the stage of disease more effectively. This would mean that patients would receive the most
appropriate treatment at the right time. Positron emission tomography (PET)/CT is a nuclear medicine
scan that gives a functional image of the body along with the CT scan. This study used PET/CT in patients
with suspected pancreatic cancer as well as standard tests to see if the diagnosis and treatment of these
patients could be improved. In total, 550 patients had PET/CT scans. The PET/CT added significantly to
the accuracy of standard tests, improving the diagnosis of pancreatic cancer. PET/CT influenced the
management of 45% of patients. PET/CT was able to correctly stage the extent of the tumours in a
greater number of patients than standard diagnostic tests. This meant that the addition of PET/CT changed
the management of these patients to more appropriate therapies. The biggest benefit was seen for those
patients who were due to have surgery. We calculated that the use of PET/CT was likely to be good value
for money for the NHS. This study suggests that PET/CT is likely to be beneficial in the diagnosis and
management of patients with suspected pancreatic cancer.
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Scientific summary
Background
Pancreatic cancer is one of the major causes of cancer death. In the UK population in 2011 the incidence
of pancreatic cancer was 8773 (15.7 per 100,000 in 2012) and in 2012 there were 8662 deaths from
pancreatic cancer. The 5-year survival rate for all patients with pancreatic cancer persists at 7%. Median
survival for patients with advanced disease is between 3 and 6 months; this can be improved with
chemotherapy. The 5-year survival rate is 10–15% following surgical resection and increases to 20–30%
with adjuvant chemotherapy. Pancreatic cancer diagnosis is challenging and patients may be relatively
asymptomatic during its early course. Standard diagnostic practice consists of contrast-enhanced
multidetector computed tomography (MDCT), endoluminal ultrasound (EUS) and magnetic resonance
imaging (MRI) for equivocal liver lesions. There are up to 10–20% of patients in whom an accurate
diagnosis is difficult. Combined positron emission tomography and computed tomography (PET/CT) adds
precise anatomical localisation to functional data. The use of PET/CT may add further value to the
diagnosis and staging of pancreatic cancer.
Objectives
The primary objective was to determine the incremental diagnostic accuracy and impact of PET/CT in
addition to standard diagnostic work-up in patients with suspected pancreatic cancer. Secondary objectives
were to (1) evaluate changes in diagnosis, staging and patient management through the addition of
PET/CT; (2) determine the cost-effectiveness of the addition of PET/CT in the diagnosis, staging and
management of pancreatic cancer; (3) evaluate the impact of PET/CT in chronic pancreatitis; (4) identify
which groups of patients would most benefit from PET/CT; and (5) report the incremental diagnostic value
of PET/CT for particular types of pancreatic tumour.
Methods
Design and interventions
This study was a multicentre prospective diagnostic accuracy and clinical value study of PET/CT in
suspected pancreatic malignancy. Following standard diagnosis and staging with MDCT, eligible patients
underwent PET/CT within 2 weeks of informed consent. All PET/CT scans were centrally reviewed.
Diagnosis, staging and planned management were recorded before (D1) and after (D2) PET/CT. Actual
diagnosis, staging and management were then recorded (D3). The reference standard (D4) was based on
histology or clinical outcome after 12 months’ follow-up.
Setting
The study took place in 18 UK pancreatic tertiary referral centres.
Participants
Patients with suspected pancreatic malignancy defined as one or more of (1) focal lesion in the pancreas/
bulky pancreas/dilated pancreatic duct (±metastases) detected on MDCT scan (±MRI/EUS/ultrasound);
(2) jaundice due to distal obstruction (not due to calculi) defined as serum bilirubin > 35 µmol/l; and
(3) serum carbohydrate antigen 19-9 (CA19.9) > 37 kU/l.
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Sample size
A previous meta-analysis reported a sensitivity of 81% and specificity of 66% for the diagnosis of
pancreatic cancer with standard MDCT. The primary objective of this study was to investigate the
incremental value of PET/CT. To be of clinical value to the diagnostic work-up the addition of PET/CT
should increase sensitivity from 81% to 90% and specificity from 66% to 80%. Using methodology for a
paired design, the number of diseased and non-diseased subjects required to have 80% power to detect
these differences at the 5% (two-sided) significance level ranges between 87 and 281 (diseased) and
57 and 221 (non-diseased) depending on the assumption made about the correlation between the test
errors (false positives and false negatives). To ensure adequate power, the largest of these (281 diseased
patients = 600 pancreatic cancer patients assuming 47% prevalence) was the initial target for recruitment.
An interim analysis was carried out after 200 patients were recruited and the reference standard obtained.
The sample size was then revised down to 500 patients.
Follow-up
All patients were followed up after consent for 12 months or until death if before 12 months. The follow-up
consisted of 3-monthly clinic visits and data collection as standard for the diagnosis and that centre.
Outcome measures
The primary outcome measure was incremental diagnostic value (sensitivity and specificity) of PET/CT in
addition to standard diagnostic work-up with MDCT. The secondary outcome measures included (1) changes
in patients’ diagnosis, staging and management as a result of the addition of PET/CT; (2) changes in the costs
of patient management as a result of the addition of PET/CT and effectiveness measured in terms of survival
and/or health-related quality of life; (3) incremental diagnostic value of PET/CT findings in chronic pancreatitis;
(4) identification of groups of patients who would benefit the most from PET/CT based on clinical outcome;
and (5) incremental diagnostic value of PET/CT findings in other pancreatic tumours.
Statistical methods
The analysis focused on investigating incremental diagnostic accuracy and incremental diagnostic impact.
Diagnostic accuracy was investigated by comparing the baseline diagnosis (D1) and the results of
the PET/CT scan with the reference diagnosis (D4); diagnostic impact was investigated by comparing the
baseline (D1) and post (D2) PET/CT diagnoses with the reference diagnosis (D4). The diagnostic impact
of standard work-up was estimated by comparing diagnostic decisions made at D1 with the reference
diagnosis made at D4 and expressing as sensitivities and specificities together with 95% confidence
intervals (CIs) (computed using binomial exact methods). To evaluate the accuracy of staging by standard
work-up the analysis was restricted to individuals with pancreatic malignancy diagnosed at the reference
diagnosis. The accuracy of the revised diagnoses made after PET/CT was assessed in the same way making
comparisons between diagnostic and staging decisions made at D2 and the final reference diagnosis.
The initial analysis of the incremental benefit of PET/CT over standard work-up was assessed through
comparing the sensitivity and specificity of diagnostic decisions D1 and D2 in both absolute and relative
terms. Tabulations were created of cross-classifications of the D1 and D2 diagnoses for diseased and
non-diseased patients to investigate the within-patient changes induced by the PET/CT scan with their
significance assessed using McNemar’s test for paired data. Subgroup analyses using generalised estimating
equation (GEE) regression modelling (taking account of paired data) were undertaken to investigate
whether test performance varied according to presenting conditions. The incremental accuracy of PET/CT
over standard work-up was investigated using regression modelling following the Knottnerus approach.
Further paired analysis was undertaken in a similar manner to investigate whether or not PET/CT introduced
changes to patient management plans and the levels of confidence associated with diagnostic decisions.
Quality assurance of the positron emission tomography and computed
tomography scans
A PET/CT Core Laboratory facility was set up as part of the National Cancer Research Institute (NCRI)
PET Research Network. PET/CT data were transferred in anonymised DICOM (Digital Imaging and
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Communications in Medicine) part 10 format. The laboratory ensured that images acquired from
participating centres were of comparable quality.
Health economics
Health economic analysis was conducted from a NHS perspective. Our cost-effectiveness analysis was
in three parts: model 1, in which we calculated the marginal cost per additional correct diagnosis of
pancreatic ductal adenocarcinoma (PDAC) using PET/CT and CT alone; model 2, in which we calculated
the budget impact of use of PET/CT; and model 3, in which we modelled the change in management of
patients as a result of use of PET/CT in diagnosis over a 1-year time horizon. We undertook sensitivity
analysis to explore uncertainty in costs (univariate) and model structure (structural). Probabilistic sensitivity
analysis assessed the likelihood that PET/CT is cost-effective at £20,000 per quality-adjusted life-year
(QALY) and £30,000 per QALY thresholds.
Results
Between January 2011 and April 2013 589 patients with suspected pancreatic cancer underwent MDCT and
PET/CT in 18 UK pancreatic centres, of whom 550 patients had complete diagnostic data (D1–D4) and in
range PET/CT (per protocol). In total, 261 patients (47%) had PDAC and 216 patients underwent resection.
For the diagnosis of pancreatic cancer, the sensitivity and specificity of MDCT and PET/CT were 88.5% and
70.6% and 92.7% and 75.8%, respectively. The median maximum standardised uptake value (SUVmax.)
was higher for patients who were confirmed to have pancreatic cancer than for patients who did not have
pancreatic cancer (7.5 vs. 5.7, respectively; p < 0.0001). PET/CT demonstrated a significant improvement in
relative sensitivity (p = 0.01) and specificity (p = 0.023) compared with MDCT. Incremental likelihood ratios
demonstrated that the results of the PET/CT significantly improved diagnostic accuracy in all scenarios
(p < 0.0002). PET/CT correctly changed the staging of pancreatic cancer in 56 (10%) patients (p = 0.001);
this was for stage IIb and IV. The PET/CT scan was perceived to have influenced the planned management
in 250 (45%) patients. A significantly higher proportion of patients (11% vs. 4%; p = 0.0002) followed
the management plan recommended after PET/CT (and not that recommended after MDCT) than the
MDCT management plan (and not that recommended after PET/CT). The most common change was from
resection to no resection, which occurred in 60 patients, representing 11% of all patients and 21% of
patients scheduled for some kind of resection after MDCT. PET/CT stopped resection in 58 (20%) patients
who were due to have surgery.
For the diagnosis of chronic pancreatitis the sensitivity and specificity of MDCT and PET/CT were 36.6%
and 98.4% and 46.3% and 98.4%, respectively. GEE subgroup analysis comparing the patients within
range for both uptake time and blood glucose level with those out of range for either showed a
statistically significant deterioration in sensitivity among out-of-range patients of 52.9% (p < 0.0001).
The sensitivities and specificities of MDCT and PET/CT for the diagnoses of (1) malignant cystic neoplasm,
(2) cholangiocarcinoma, (3) neuroendocrine tumour and (4) periampullary tumour were (i) 75% and
92.8% and 75% and 96.1%, (ii) 25% and 97.8% and 25% and 98.8%, (iii) 44.4% and 99.4%
and 44.4% and 98.7% and (iv) 71.1% and 95.9% and 65.8% and 97.2%, respectively. The sensitivity
and specificity of MDCT and PET/CT for the diagnoses of malignancy compared with benign disease were
97.4% and 47.0% and 97.7% and 68.7%, respectively. The 6- and 12-month survival rates for the overall
patient population were 82.8% (95% CI 79.7% to 86.0%) and 69.0% (95% CI 65.1% to 73.1%),
respectively. Patients who had a diagnosis of pancreatic cancer had 6- and 12-month survival rates of
71.4% (95% CI 66.0% to 77.2%) and 50.9% (95% CI 44.9% to 57.6%), respectively.
The cost of PET/CT differed according to the type of department the cost was sourced from within the
published NHS reference costs. In 2012–13 this was £795 per scan for the nuclear medicine department
and £563 for the clinical oncology department. Nuclear medicine was chosen as the most conservative cost
for the base case. Model 1 in the health economic analysis demonstrated that the incremental cost per
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additional accurate diagnosis was £15,309 (95% CI £15,072 to £15,460). Model 2 showed a budget impact
of £6.2M per year if 100% of newly diagnosed patients received PET/CT. Model 3 demonstrated that, in the
base case, the incremental cost of PET/CT was –£645 (95% CI –£2743 to £1314). The mean QALY gain
associated with PET/CT was 0.0157 (95% CI –0.0101 to 0.0430). PET/CT dominated MDCT as PET/CT was
both less costly and more effective. The lowest cost and highest QALY gain were seen for the PDAC with
resection group. Sensitivity analysis of the cost of PET/CT using increased costs savings was performed.
The cost saving was £912 per patient when we took our estimate from the clinical oncology department.
Structural sensitivity analysis involved varying our base-case assumption that all patients received a resection.
Some patients received bypass or open and shut laparotomy. For this model the incremental cost of PET/CT
was estimated as £419 (95% CI –£138 to £930) and the mean QALY gain associated with PET/CT was
0.0078 (95% CI –0.0012 to 0.0172), resulting in an incremental cost-effectiveness ratio (ICER) of £53,777
per QALY gained. The probability of PET/CT being cost-effective at a National Institute for Health and Care
Excellence (NICE) threshold of £20,000 per QALY was 18% and at a threshold of £30,000 per QALY was
28%. It should be remembered that overall QALY gains were small and so any change in costs had a big
impact on the ICER. Using clinical oncology costs within this model, the ICER was £19,445 per QALY, which
is cost-effective at the lower NICE threshold of £20,000 per QALY. For this combination of model and costs,
the probability of cost-effectiveness at a £20,000 per QALY threshold was 50%, rising to 60% at the upper
threshold. Of note, the most cost-effective subgroup was the PDAC with resection subgroup, with ICERs of
£4626 per QALY and £34,654 per QALY for the clinical oncology and nuclear medicine departments as
sources of costs, respectively. Overall, our base-case analysis showed that PET/CT dominated MDCT alone, in
particular for patients suspected of having pancreatic cancer after standard diagnostic work-up and who
were planned for surgery. The QALY gains were small and our analysis was sensitive to our source of
published costs and to structural assumptions in the model.
Conclusions
This is the first multicentre, prospective, large-scale study of PET/CT in the diagnosis and management of
patients with suspected pancreatic cancer. PET/CT demonstrated significantly increased relative sensitivity
and specificity compared with MDCT and provided significant incremental diagnostic benefit in addition
to MDCT in the diagnosis of pancreatic cancer. PET/CT altered the staging of pancreatic cancer in a
significant proportion of patients. PET/CT influenced management in 45% of patients and prevented
potentially futile resection in 20% of patients scheduled for surgery. PET/CT had limited use in chronic
pancreatitis and other pancreatic tumours. It is likely that PET/CT will be cost-effective for patients with
suspected pancreatic cancer at current reimbursement rates for PET/CT to the UK NHS.
Implications for health care
This study was designed to evaluate the diagnostic accuracy of PET/CT and its effects on management
and cost-effectiveness in patients with suspected pancreatic cancer in a prospective, multicentre manner.
Based on the evidence from the study, PET/CT adds significant benefit to patients in terms of diagnosis,
staging and management of pancreatic cancer. The most cost-effective use of PET/CT was in the subgroup
of patients who were suspected of having pancreatic cancer on MDCT and who were planned for surgery.
The evidence was limited on the use of PET/CT in patients with chronic pancreatitis, other pancreatic
tumours and pancreatic cysts.
Recommendations for future research
The role of PET/CT in the diagnosis and management of intraductal papillary mucinous neoplasm deserves
further evaluation. The role of alternative radiopharmaceuticals for PET/CT should be assessed in terms
of the diagnosis and prognosis of pancreatic cancer. The role of PET/CT as a response marker in the
treatment of pancreatic cancer needs to be evaluated. More data are needed on the prognosis of
MDCT-alone patients: (1) scrutiny of how patients fare with MDCT alone (PET/CT is not available; these
data would be useful for future economic modelling exercises); (2) extrapolation of what happens to
patients beyond the 12-month follow-up (resources were not available for us to do so in this study); and
(3) stronger data on unnecessary surgery to add to the strength of the conclusions.
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Chapter 1 Introduction
Background
Pancreatic cancer is one of the major causes of cancer death. In the UK in 2011 the incidence of pancreatic
cancer was 8773 (15.7 per 100,000 in 2012) and in 2012 there were 8662 deaths from pancreatic cancer.1
Over the past three decades considerable progress has been made towards understanding the biology of
pancreatic cancer, refining imaging systems and improving surgical outcomes and more recently there has
been a focus on biomarkers to enable targeted therapies. In spite of these advances the overall survival
figures for pancreatic cancer remain bleak. The 5-year survival rate for all patients with pancreatic cancer
persists at 7%.2,3 Most patients present with advanced disease because of late presentation and difficulties
in early diagnosis. Median survival for patients with advanced disease is between 3 and 6 months, but this
can be improved with systemic chemotherapy.4–6 The outlook for those patients who can undergo surgical
resection is better. In specialised centres, resection rates of > 15% can be achieved.7 Although surgery
cannot guarantee a cure, the 5-year survival rate does improve to 10–15% following resection8,9 and
increases to 20–30% with adjuvant chemotherapy.10–12 The pattern of disease recurrence following
resection includes both locoregional failure and distant metastases.13 The biggest risk factors for pancreatic
cancer are increasing age, smoking, new-onset diabetes mellitus, increased body mass index, ABO blood
group, chronic pancreatitis (15- to 25-fold risk), hereditary pancreatitis and an inherited predisposition for
pancreatic cancer (this may account for 10% of observed cases). Tobacco smoking is associated with a
twofold increase and because of the prevalence may account for around 30% of all cases with pancreatic
ductal adenocarcinoma (PDAC).14,15
Standard diagnostic practice
The diagnosis of pancreatic cancer can be challenging. Patients with pancreatic cancer may be relatively
asymptomatic during its early course, with vague presenting symptoms such as back and epigastric
pain.16,17 Until the systemic symptoms of weight loss, anorexia and obstructive jaundice appear, it can
be a difficult diagnosis to achieve. The role of imaging in such patients is to identify a pancreatic lesion,
determine its malignant potential and assess its resectability. At the same time, it must also correctly
identify inoperable carcinomas so that patients can receive appropriate therapy as soon as possible and be
spared unnecessary operations. Standard diagnostic practice [along with tumour marker carbohydrate
antigen 19-9 (CA19.9) estimation] currently consists of:
1. Contrast-enhanced multidetector computed tomography (MDCT) (perhaps following an initial
transabdominal ultrasound scan).
2. Endoluminal ultrasound (EUS) may be employed in cases in which further information is required.
Histology may also be obtained.
3. Therapeutic endoscopic retrograde cholangiopancreatography (ERCP) (or percutaneous transhepatic
cholangiography) to relieve jaundice and obtain cytological brushings.
4. Magnetic resonance imaging (MRI) may be used to evaluate equivocal liver lesions.
5. Laparoscopy and laparoscopic ultrasound may be used on a selective basis to stage a radiologically
resectable tumour.
Carbohydrate antigen 19-9 is the most commonly used marker in everyday practice. CA19-9 has a
sensitivity of 78% and specificity of 82% in discriminating between malignant and benign disease.18
False-positive results are obtained in benign obstructive jaundice, chronic pancreatitis, cholangitis, cirrhosis
and ascites. CA19-9 is most useful in assessing response to treatment in advanced cases and identifying
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early recurrence in resected cases.19,20 Novel markers, for example urine panel biomarkers,21 may improve
on the current standards in the future.
Initial imaging may include transabdominal ultrasound22 but the gold standard for pancreatic imaging is
MDCT. This technology provides three-dimensional multiplanar reconstruction techniques enabling
accurate determination of tumour involvement of the common bile duct, pancreatic duct and
peripancreatic vasculature. The sensitivity and specificity of MDCT in detecting pancreatic malignancy may
be between 97% and 81% and 72% and 66%, respectively.23,24 The positive predictive value (PPV) for
predicting unresectability (89–100%) is high but the PPV of computed tomography (CT) for predicting
resectability (45–79%) is low.25,26 Pancreatic carcinoma typically manifests as a hypoattenuating focal mass
relative to the enhancing pancreatic parenchyma on contrast-enhanced CT. However, approximately 11%
of carcinomas are isoattenuating with the pancreas and their detection relies on secondary signs such as
interruption of the pancreatic duct, distal pancreatic atrophy and mass effect.27 Chronic pancreatitis can
show many of the features of adenocarcinoma on CT imaging, including having the appearance of a focal
mass, appearing isodense or hypodense to the pancreatic parenchyma, pancreatic duct dilatation and
pancreatic atrophy. This can lead to up to 10% of pancreatic resections being performed for benign
disease.28 Limitations of CT also include resolution to identify small tumours or differentiate a tumour in a
diffusely enlarged or bulky pancreas. Bulky/diffuse enlargement on CT may be associated with malignancy
in 8.7% of cases.29 Furthermore, the sensitivity of CT for small hepatic and peritoneal metastases is also
limited. MRI can be helpful as an adjunct to CT, particularly for evaluation of small hepatic lesions that
cannot be fully characterised by CT.30
Endoluminal ultrasound is employed to visualise the whole pancreas, the related vasculature and the
associated lymph nodes and allows for EUS-guided fine-needle aspiration (FNA) of pancreatic lesions and
suspicious lymph nodes. EUS can be superior to MDCT at detecting and determining the T stage of
pancreatic tumours, with sensitivities ranging from 72% to 90%.31,32 FNA with EUS is usually indicated
when there is diagnostic uncertainty whether the lesion is inflammatory or malignant. The sensitivity and
specificity of EUS and FNA in detecting pancreatic cancer are 85% and 98%, respectively.33 ERCP is used
therapeutically to relieve obstructive jaundice and obtain cytological brushings. Percutaneous biopsy is
reserved only for patients with unresectable disease. Essentially, pancreatic biopsy (EUS or percutaneous)
should not be performed on patients with resectable disease because of the risks of seeding, the
false-negative rate, the complication rate and poor accuracy in cystic tumours, chronic pancreatitis and
autoimmune pancreatitis.34 Selective laparoscopy and laparoscopic ultrasound based on CA19.9 levels are
used in patients with radiological resectable disease to identify distant metastases and avoid unnecessary
laparotomy. The addition of platelet/lymphocyte ratio to the CA19.9 measurement has been useful in
determining which patients should undergo laparoscopy.35,36
18Fluorine-2-fluoro-2-deoxy-D-glucose positron emission
tomography in pancreatic cancer
Positron emission tomography (PET) is a functional imaging technology that enables visualisation,
characterisation and quantification of biological processes in vivo. By using positron-emitting radiotracers,
PET provides unique information about the molecular and metabolic changes associated with disease.
Glucose metabolism is often increased in malignant tumours resulting in increased cellular uptake of the
glucose analogue 18fluorine-2-fluoro-2-deoxy-D-glucose (FDG). Imaging the metabolic activity of tumours
provides sensitive and specific information about the extent of disease. PET imaging is a whole-body
technique and therefore may be helpful in looking for metastases. The extent to which PET may influence
diagnosis and management in solid tumours has been assessed in a large cohort study by the National
Oncologic PET Registry (NOPR), which assessed 22,975 cases from 1178 centres.37,38 These patients
underwent FDG-PET scans for a diagnosis of suspected cancer, cancer staging, restaging and suspected
recurrence. Prostate, pancreatic and ovarian cancers represented 30% of cases. The post-PET plan was
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threefold more likely to lead to treatment than non-treatment [28.3% vs. 8.2%; odds ratio 3.4,
95% confidence interval (CI) 3.2 to 3.6]. Overall, intended management was changed in 36.5% (95% CI
35.6% to 37.2%) of cases. An analysis of a further cohort demonstrated a similar management change in
33–35% of cases. FDG-PET scanning has been assessed in pancreatic cancer. There have been a variety of
studies evaluating the accuracy of FDG-PET in pancreatic carcinoma; however, its usefulness at detecting
early lesions remains unclear.39 One of the larger studies assessed the role of FDG-PET in 112 patients
with suspected pancreatic cancer40 and demonstrated a sensitivity and specificity for FDG-PET of 73%
and 60% and for CT of 89% and 65%. FDG-PET had a similar accuracy to CT but did not provide any
additional information in patients with equivocal CT findings. Pancreatic cancer is associated with a
marked desmoplastic response and stromal inflammatory cells in and around the neoplasm may be
responsible for the uptake of FDG. In the study by Lytras et al.,40 10 of the 12 patients with false-positive
results had chronic pancreatitis. Orlando et al.24 conducted one of the first meta-analyses to compare
FDG-PET with CT in studies of patients with pancreatic cancer. Sensitivity and specificity for CT were 81%
(95% CI 72% to 88%) and 66% (95% CI 53% to 77%), respectively. The addition of PET to positive CT
resulted in a sensitivity and specificity of 92% (95% CI 87% to 95%) and 68% (95% CI 51% to 81%).
A further meta-analysis has shown that the role of the addition of FDG-PET in the diagnostic work-up of
these patients remains to be proven and it cannot be recommended as standard practice.41
Positron emission tomography/computed tomography in
pancreatic cancer
Combined PET/CT was developed to add precise anatomical localisation to functional data.42 PET and CT
are acquired concurrently and co-registered, merging functional information from PET with the anatomical
information from CT. Several studies/meta-analyses have demonstrated that FDG-PET/CT is more accurate
than FDG-PET43–45 in solid tumours, including pancreatic tumours. In pancreatic cancer, a study by Heinrich
et al.46 found that FDG-PET/CT had a sensitivity of 89% for the detection of pancreatic cancer, altered
treatment planning in 16% of 59 patients and was cost saving. Another study demonstrated that the
sensitivity and specificity of FDG-PET/CT was 88% and 89%, respectively, in patients being assessed for
pancreatic cancer and changed the management of six (11%) patients.47 These patients were found to
have extrapancreatic disease that prevented them from undergoing pancreatic resection. Another study
assessed two groups of patients, a diagnosis and staging group and a screening group, for progressive or
recurrent disease.39 The accuracy rate for FDG-PET/CT for diagnosis and staging was 91.2% and 85.3%,
respectively. In the restaging group FDG-PET/CT had a sensitivity of 90%. Management changes resulting
from PET/CT have been demonstrated in a number of studies.48–50 The additional feature of PET/CT is
semiquantitative analysis of glucose uptake (FDG activity) in suspicious pancreatic lesions. Determination
of FDG activity is obtained by calculating the standardised uptake value (SUV) in a given region of interest.
An SUV of > 3.5 may indicate pancreatic malignancy; one study revealed a maximum SUV (SUVmax.) in
malignant lesions of 6.5 ± 4.6 and a SUVmax. in benign lesions of 4.2 ± 1.5.51 Another study demonstrated
an average SUVmax. for malignant lesions of 6.72 ± 3.84 and an average SUVmax. for benign disease of
2.56 ± 1.22 (p < 0.01). A definitive cut-off value is difficult to define for pancreatic malignancies and
therefore qualitative data should also be included in clinical studies such as FDG tracer uptake patterns.51,52
The use of contrast-enhanced PET/CT may represent a complete diagnostic staging procedure without the
need for separate MDCT. One study found that contrast-enhanced FDG-PET/CT was superior to FDG-PET
(p = 0.035) and there was a trend (p = 0.07) for contrast-enhanced FDG PET/CT to be superior to
unenhanced PET/CT53 in assessing resectability. The sensitivity and specificity of contrast-enhanced PET/CT to
detect malignancy ranges from 100% to 96% and from 94% to 90%, respectively, in several studies.52,54
The use of radiopharmaceuticals such as 18fluorine-fluorothymidine (FLT) has been investigated in small
numbers of patients. FLT-PET assesses the proportion of cells undergoing active proliferation and this
process occurs before a change in glucose metabolism. This may be useful in monitoring response to
therapy. The role of FLT-PET/CT in the diagnostic pathway of pancreatic cancer is not clear.55 Fused PET and
MRI has also been assessed in small numbers of patients with an accuracy of 96.6%.56
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Rationale for the study
The diagnosis of pancreatic cancer has improved with the use of MDCT, EUS and ERCP and the additional
use of MRI. There are, however, up to 10–20% of patients in whom an accurate diagnosis is difficult.
This proportion is increasing, in part because of the larger numbers of asymptomatic patients undergoing
cross-sectional imaging.57,58 Invasive methods of diagnosis such as EUS with or without FNA can add to the
accuracy of MDCT but may require an inpatient stay and have a recognised complication rate (1–2%).59
Currently, patients with chronic pancreatitis, autoimmune pancreatitis, cystic lesions, small tumours of
< 2 cm, a bulky or diffusely enlarged pancreas on CT, a dilated pancreatic duct and no mass on CT,
small-volume metastatic disease and suspected recurrent disease (with no mass on CT) following resection
are the most challenging patients to diagnose. A major goal of accurate diagnosis and staging is to
avoid major pancreatic resection in patients who will not benefit; about 10–15% of patients who have a
pancreatic resection have benign disease on final histology28 and up to 20% of patients will develop
recurrent disease 3–6 months post resection.60 Functional imaging techniques such as PET/CT may add to
staging of pancreatic cancer by diagnosing small-volume metastatic disease and differentiating between
benign and malignant lesions and it is vital, therefore, that a well-designed prospective study answers
this question. A number of studies have addressed the diagnostic accuracy of PET/CT and changes in
management as a result of PET/CT. The main drawbacks of previous PET/CT studies tend to be that they
have been single-centre studies with small numbers of patients and variability in the PET/CT imaging
protocol used to assess suspected pancreatic cancer. This prospective multicentre study aims to address
these issues in a large group of patients to identify whether there is a role for PET/CT in addition to
standard diagnostic work-up in pancreatic cancer.
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Chapter 2 Methods
Design and setting
This study was a multicentre prospective diagnostic accuracy and clinical value study of PET/CT in suspected
pancreatic malignancy (Figure 1). The study was carried out in 18 major pancreatic centres with annual referrals
of > 120 pancreatic patients per year. To achieve the study objectives the case mix included pancreatic cancer,
chronic pancreatitis and other benign and malignant neoplasms of the pancreas. For example, of 400 patients
referred to the Liverpool pancreatic multidisciplinary team (MDT) each year, approximately 47% have
pancreatic cancer and 53% have other tumours and chronic pancreatitis. The case mix for each centre
incorporated a mix of benign and malignant cases and it was important that eligible patients were drawn from
both groups to satisfy the aims of the study. The study was approved by the North West 1 Research Ethics
Committee – Cheshire [following reorganisation this committee was superseded by National Research Ethics
Service (now part of the Health Research Authority) Committee North West – Greater Manchester East
(Cheshire)]. Following informed consent patients were registered and enrolled onto the study.
Participants
Eligible patients for this study included those with suspected pancreatic malignancy as defined in the
inclusion criteria.
Inclusion criteria
1. Patients with suspected pancreatic malignancy as defined by one or more of:
i. focal lesion in the pancreas/bulky pancreas/dilated pancreatic duct (±metastases) detected on MDCT
scan [±MRI/EUS/ultrasound]
ii. jaundice because of distal obstruction of the common bile duct or ampulla (not because of calculi)
defined as serum bilirubin > 35 µmol/l
iii. serum CA19.9 > 37 kU/l.
2. Able to attend for PET/CT scan.
3. Able to undergo MDCT scan.
4. Able to attend for 12 months of follow-up.
5. Fully informed written consent given.
Exclusion criteria
1. Patients aged < 18 years.
2. Pregnancy.
3. Patients with poorly controlled diabetes.
Interventions
18Fluorine-2-fluoro-2-deoxy-D-glucose positron emission
tomography/computed tomography
Patients underwent FDG PET/CT scanning within a maximum of 2 weeks following informed consent.
PET/CT was performed under carefully controlled conditions to ensure maximum accuracy of results. Patients
fasted for 6 hours prior to the scan. To ensure accurate SUV measurements patients’ weight was obtained
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Patients with presumed pancreatic disease will be referred from either primary or secondary
care in accordance with the standard protocol of that region to the participating centres
Standard practice to discuss all referrals at the pancreatic MDT meeting at the participating centre
Eligible patient seen as an outpatient or as an inpatient,
study discussed and informed consent obtained
Registration
PET/CT scan undertaken within 2 weeks of consent (all patients)
D1
Management and follow-up decided by local clinician (at least 3-monthly appointments)b
PET/CT scan requested by clinician
Central PET/CT scan report QA
Diagnosis, staging and management
decision made by clinician 
unblinded, using usual diagnostic 
strategya based on the MDT outcome
D2
Diagnosis, staging and management
decision made by clinician 
unblinded to PET/CT scan results,
 based on investigator decision 
or second MDT meeting
Pathology QA all biopsies, 10% resections
D4
Reference standard for clinical 
judgement in all patients made by 
independent person within 
12 months of consent. Diagnosis
made by two independent clinicians
using reference standard blinded
to D1 and D2 previous diagnoses
and scan results
D3Actual diagnosis and management
Eligible patients will include one or more of the following:
• focal lesion in the pancreas/bulky pancreas (+/– metastases) detected on contrast-enhanced MDCT 
   scan (+/– MRI/EUS)
• jaundice due to distal obstruction of the common bile duct or ampulla (not due to calculi) 
   defined as serum bilirubin of > 35 µmol/l
• elevated CA19.9 value of > 37 kU/l
FIGURE 1 Schematic of the study design. a, Usual diagnostic strategy defined as contrast-enhanced
MDCT ± EUS ±MRI; b, follow-up clinical evaluation defined using information on improvement/deterioration in
clinical symptoms ± CA19.9± CT± EUS ± survival (does not include original PET/CT scan). D1, diagnosis, staging and
management plan after MDCT; D2, diagnosis, staging and management plan after PET/CT; D3, actual diagnosis,
staging and management; D4, diagnosis reference standard; QA, quality assurance.
METHODS
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without shoes and coat and using a calibrated class III device that satisfied requirements defined in the
Non-Automatic Weighing Instruments Directive 2003 [see http://eur-lex.europa.eu/legal-content/EN/TXT/?
uri=CELEX:32009L0023 (accessed 27 June 2016)] and blood glucose was recorded using a calibrated
Boehringer Mannheim glucometer (Boehringer Ingelheim Ltd, Bracknell, UK). For diabetes mellitus
patients only patients with a fasting blood glucose not exceeding 10.0 mmol/l were scanned to reduce
false-negative FDG PET/CT results. Patients drank between two and three glasses of water before the PET/CT
scan to ensure good hydration, which contributes to a good-quality scan. Metal denture and other metallic
devices were removed whenever possible to reduce CT artefacts, which distort FDG uptake measurements
including SUV measurements in the vicinity of the artefact. Tracer was injected via a butterfly cannula under
quiet conditions. For two-dimensional scanning 350–530 MBq of FDG was injected. In patients requiring a
larger dose because of a larger body weight Administration of Radioactive Substances Advisory Committee
(ARSAC) certificate holder approval was obtained before giving the larger dose. For three-dimensional
scanning 150–350MBq was injected. Patients remained quiet and inactive during the uptake period in a
warm room to avoid artefacts including skeletal muscle FDG uptake and brown adipose tissue uptake.
Patients emptied their bladders just prior to positioning on the scanner bed to avoid artefacts from FDG
activity in the urinary bladder. The PET/CT emission scan started at 90 minutes after FDG injection. Scanning
was carried out on a standard PET/CT table top, beginning at the groin and ending at the base of the orbits
and with arms up if a single whole-body scan was performed. Routine local acquisition parameters were
used. Data were reconstructed using ordered subsets expectation maximisation reconstruction parameters
with CT for attenuation correction. The PET/CT scan was first reported at the local participating centre.
Central positron emission tomography/computed tomography reporting
A central PET/CT reporting facility was established at the Paul Strickland Scanner Centre at Mount Vernon
Hospital, Northwood, Middlesex. Data transfer was via secure FTP server from the National Cancer
Research Institute (NCRI) PET Core Laboratory. All PET/CT scan reports were reviewed by an expert in
clinical PET/CT who was independent of the local centre. The majority of PET/CT scans were reviewed at
the Paul Strickland Scanner Centre using the agreed standard proforma. Central review of PET/CT scans
was also performed at Aintree University Hospital (Liverpool), St James’s University Hospital (Leeds), the
Royal Free Hospital (London) and Southampton General Hospital using the agreed standard proforma.
Objectives
Primary objective
l To determine the incremental diagnostic accuracy and impact of PET/CT in addition to standard
diagnostic work-up in patients with suspected pancreatic cancer.
Secondary objectives
l To evaluate changes in diagnosis, staging and associated intended patient management as a result of
the addition of PET/CT.
l To determine the cost-effectiveness of the addition of PET/CT in the diagnosis, staging and
management of pancreatic cancer.
l To evaluate the impact of the addition of PET/CT in differentiating pancreatic malignancy from
chronic pancreatitis.
l To identify which groups of patients would most benefit from PET/CT.
l To report the incremental diagnostic value of PET/CT for particular types of pancreatic tumour.
Outcome measures
The primary outcome measure was the incremental diagnostic value (sensitivity and specificity) of PET/CT in
addition to standard diagnostic work-up with CT. The secondary outcome measures included (1) changes
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in patient management as a result of the addition of PET/CT; (2) changes in the costs of patient
management as a result of the addition of PET/CT and effectiveness measured in terms of survival and/or
health-related quality of life (HRQoL); (3) the incremental diagnostic value (sensitivity and specificity) of
PET/CT findings in chronic pancreatitis; (4) the identification of groups of patients who would benefit the
most from PET/CT based on clinical outcome; and (5) the incremental diagnostic value (sensitivity and
specificity) of PET/CT findings in other pancreatic tumours.
Diagnostic pathway following multidetector computed
tomography and positron emission tomography/
computed tomography
Diagnosis, staging and management following MDCT (D1) and PET/CT (D2) were categorised by the
investigator according to one or more of the following options.
l Diagnosis:
¢ PDAC
¢ periampullary cancer
¢ cholangiocarcinoma
¢ benign cystic neoplasm
¢ malignant cystic neoplasm
¢ pancreatic pseudocyst
¢ chronic pancreatitis
¢ autoimmune pancreatitis
¢ acute pancreatitis
¢ neuroendocrine tumour
¢ lymphoma
¢ metastasis from non-pancreatic primary neoplasm
¢ recurrent pancreatic cancer post resection
¢ normal pancreas
¢ other
l Staging:
¢ resectable [Union for International Cancer Control (UICC) tumour, node, metastasis (TNM)
classification stage 0, IA, IB, IIA, IIB; see Appendix 1]61
¢ borderline resectable, for example defined as up to 2 cm of portal/superior mesenteric vein
involvement for 180o circumference
¢ unresectable (UICC TNM stage III and IV)
¢ other
l Management:
¢ resection (± previous laparoscopy)
¢ biopsy (EUS/percutaneous)
¢ drainage procedure, for example stent or surgical bypass
¢ chemotherapy/trial
¢ best supportive care
¢ clinical follow-up ± further investigation
¢ no further management required
¢ other.
METHODS
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For all of the diagnosis, staging and management options listed in D1 and D2 a level of certainty was
categorised as:
l very certain
l moderately certain
l uncertain.
Planned treatment and follow-up
The patient then underwent planned management (D3). All patients were followed up for at least
12 months or until death if before 12 months. The patient completed a short quality of life questionnaire
[European Quality of Life-5 Dimensions (EQ-5D)] [see www.euroqol.org/about-eq-5d.html (accessed
27 June 2016) and Appendix 2] after consent and at each 3-monthly outpatient review. The EQ-5D is a
standardised instrument for use as a measure of health outcome and provides a simple descriptive profile
and a single index value for health status that can be used in the clinical and economic evaluation of
health care.
Target conditions
The analyses of test accuracy and staging considered the following target conditions:
1. pancreatic cancer (for the primary objective)
2. stage of pancreatic cancer (UICC TNM classification for resectable, borderline resectable and
unresectable disease)
3. chronic pancreatitis
4. particular types of pancreatic tumour.
Reference standard(s)
The reference standard for diagnosis was a clinical judgement made by an independent expert based on
histology (either biopsy or resection) or clinical outcome at the 12-month assessment. The expert agreed
on the appropriate staging for each patient with pancreatic cancer and the appropriate management,
to be used as reference diagnoses (D4). The process is described below:
l Stage 1. The expert initially received a patient histology report for the target conditions (1–4) and
information about the clinical status of the patient at 12 months (but excluding all information from
investigations made at baseline and the PET/CT test results). This was according to the minimum data
set of the Royal College of Pathologists,62 in a standard format for resection histology; this included
pathological staging (pTNM) for tumours.
l Stage 2. If the expert was unable to make a firm reference diagnosis based on the above information,
results of baseline investigations were released but not the PET/CT investigation. The two-stage process
was planned so that the expert’s initial decision was not contaminated by the standard work-up of
either set of test results and never by the PET/CT scan results and to avoid incorporation bias. Finally,
the expert was asked to judge the appropriateness of management for each patient and if a change
prompted by PET/CT was appropriate.
Quality assurance
Radiology quality assurance
Central radiology review of 10% of the MDCT scans was carried out by Dr Jonathan Evans, Consultant
Radiologist (Royal Liverpool and Broadgreen University Hospitals NHS Trust), for quality assurance. CT scans
selected from each centre for central reporting were requested by the Liverpool Clinical Trials Unit (LCTU).
Anonymised CT images in DICOM (Digital Imaging and Communications in Medicine) format were
provided on disk and sent to the Department of Radiology, Royal Liverpool and Broadgreen University
Hospitals NHS Trust. On receipt disks were loaded into an RA600 import workstation (GE Healthcare,
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Chalfont St Giles, UK). The scan was opened on the RA600 and the images exported from the RA600 to
the Picture Archiving and Communication System (PACS; Carestream Health Inc., Hemel Hempstead, UK).
Once all of the images had arrived on the PACS, they were post processed and the radiologist was able to
report the images. MDCT scans were reported using the agreed standard proforma.
Pathology quality assurance
Central pathology review was carried out by Professor Fiona Campbell, Consultant Gastrointestinal
Pathologist (Royal Liverpool and Broadgreen University Hospitals NHS Trust). The histology slides from all of
the biopsies and approximately 10% of all resection specimens (with at least two specimens selected from
each centre) were requested after completion of actual diagnosis and management (D3). Slides were sent
directly to the Department of Pathology, Royal Liverpool and Broadgreen University Hospitals NHS Trust,
and reported using the agreed standard proforma. Slides were returned to each centre when reviewed.
Positron emission tomography/computed tomography quality assurance
A PET/CT Core Laboratory facility was set up as part of the NCRI PET Research Network Clinical Trials Network
at the PET imaging centre at St Thomas’s Hospital, London. PET/CT data were transferred in anonymised
DICOM part 10 format. The submitted images were required to include the attenuation-corrected PET, the
non-attenuation-corrected PET and the CT images. The recommended method for electronic data transfer
from the NHS PET centres was via the NHS Secure File Transfer Service. All other sites with appropriate internet
access used the NCRI Core Laboratory secure FTP server. The laboratory ensured that images acquired from
participating centres were of comparable quality.
Sample size estimation and re-estimation
A previous meta-analysis24 reported a sensitivity of 81% and specificity of 66% for the diagnosis of
pancreatic cancer with standard MDCT. The primary objective of this study was to investigate the
incremental value of PET/CT. To be of clinical value to the diagnostic work-up the addition of PET/CT
should increase the sensitivity from 81% to 90% and the specificity from 66% to 80%.
An appropriate sample size, accounting for the paired design, was then obtained using methodology from
Alonzo et al.63 For sensitivity it was based on:
n1 =
Z (1− β) + Z (1−
α
2)
logγ1
 !2 ðγ1 + 1)TPRB− 2TPPR
γ1TPR
2
B
 
/π, (1)
where TPRB is the true positive rate (sensitivity) without PET/CT, TPPR is the proportion of diseased patients
who test positive before and after PET/CT, α and β are the significance level and power of the study,
respectively, π is the prevalence of disease and γ1 = TPRA/TPRB is the ratio of true positive rates with and
without PET/CT.
For specificity we were interested in the true negative rates so the formula used was:
n2 =
Z (1− β) + Z (1−
α
2)
logγ2
 !2
(γ2 + 1)TNRB− 2TNNR
γ2TNR
2
B
 
/(1− π), (2)
where TNRB is the true negative rate (specificity) without PET/CT, TNNR is the proportion of non-diseased
patients who test negative before and after PET/CT, α and β are the significance level and power of the
study, respectively, π is the prevalence of disease and γ2 = TNRA/TNRB is the ratio of true negative rates with
and without PET/CT. The chosen sample size would be the larger of n1 and n2.
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A complication with these formulae is that knowledge of the correlation between tests for a patient,
driven by TPPR and TNNR, is generally required. However, it can be noted that TPPR ≥ (1 + γ1)TPRB – 1 and
TNNR ≥ (1 + γ2)TNRB – 1 and that, moreover, the required sample size is largest when TPPR = (1 + γ1)
TPRB – 1 and TNNR = (1 + γ2)TNRB – 1. These can then be used to find an upper bound on the required
sample size.
Applying the formulae to ensure 80% power (β = 0.2) for a two-sided test at the 5% significance level
(α = 0.05) with relative sensitivity γ1 = 10/9 and relative specificity γ2 = 40/33 yielded an upper bound
of n = 600 as the initial sample size. However, as it was acknowledged that this would likely be an
overestimate of the total number of patients required, an interim analysis after 200 patients was
conducted to estimate the correlation between tests and estimate the disease prevalence so that the
sample size could be re-estimated.
Interim analysis
The interim analysis used data from the 187 patients of the first 200 registered who had complete data
(for D1–D3 diagnoses) by the cut-off date of 28 May 2012. Of these, 82 were deemed to have pancreatic
cancer according to D3, giving a prevalence of 43.9% (which was consistent with the original assumption
of 47%; p = 0.39).
Interim results (Tables 1 and 2) were used to estimate the correlation between tests and hence the
estimated required total sample size, based on the formulae in the previous section from Alonzo et al.63
From Table 1 (diseased patients), TPPR = 66/82 = 80.5% and TPRB = 69/82 = 84.1%. Thus, both quantities
are larger than originally assumed. Applying these updated estimates into the sample size formula for n1
gives 341.6.
From Table 2 (non-diseased patients), TNNR = 69/105 = 65.7% and TNRB = 73/105 = 69.5%. Applying
these updated estimates into the sample size formula for n2 gives 144.2.
Hence, taking the maximum of the two figures and rounding up, the estimated sample size is 342.
However, it was noted that this estimated sample size was primarily driven by the numbers of discordant
test results, both of which were small, and as a consequence there was considerable uncertainty in the
estimate. The bootstrap 80% CI of the estimated sample size was 231 to 464. To ensure that there was a
good chance that the study was adequately powered for the primary analysis, the upper value was chosen,
with a specific target of 500 agreed on to account for possible dropouts (estimated at 5.5% after the first
200 registered patients).
TABLE 1 Interim analysis results for patients positive at D3
Diseased patients
Pre PET/CT
Positive Negative
Post PET/CT Positive 66 3
Negative 3 10
TABLE 2 Interim analysis results for patients negative at D3
Non-diseased patients
Pre PET/CT
Positive Negative
Post PET/CT Positive 21 4
Negative 11 69
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Statistical methods
Primary analysis
The primary outcome measure was relative sensitivity and relative specificity of the PET/CT scan (in range
as per protocol) compared with the baseline MDCT scan with respect to a diagnosis of PDAC. These were
obtained by comparing each diagnosis with the reference diagnosis made at D4 for the target conditions
(pancreatic malignancy, chronic pancreatitis, other tumour types) with standard errors accounting for
pairing obtained using the formula from Alonzo et al.63
The analyses were repeated both using patients who were outside the range for uptake time and/or blood
glucose and excluding such patients to assess the impact on estimates.
The homogeneity of patients across sites was assessed by comparing disease prevalences using a funnel
plot.64 This involved plotting prevalence against sample size and observing whether the points lay outside
of 95% or 99% control limits.
Estimation of incremental diagnostic benefit
The incremental accuracy of PET/CT over standard work-up was investigated using regression modelling
following the Knottnerus approach summarised by Chan et al.65 This approach allows the modelling of a
sequence of tests through creative construction of indicator variables, which takes into account the
non-independence of test results, but does not alter the value of previous test results when subsequent tests
are added to the model. It also allows expression of the incremental diagnostic value as likelihood ratios.
Impact of positron emission tomography/computed tomography on certainty
of diagnosis
Assessment of clinicians’ perceived certainty of diagnosis before and after the PET/CT scan was evaluated
using both the clinicians’ qualitative assessment at D2 and quantitative (0–1 scale) assessments at D1 and
D2. For the qualitative assessment a binomial test of whether the number of cases in which the uncertainty
was perceived is significantly greater than the number of cases in which the uncertainty was perceived to
increase was conducted. For the quantitative assessment a Wilcoxon signed-rank test was used to assess
whether there was a significant change in perceived uncertainty from D1 to D2.
To assess whether clinicians’ perceptions were in line with the true benefit of PET/CT, the quantitative
assessment (on a 0–1 scale) was treated as if it represented the clinicians’ estimated probability that their
diagnosis (with respect to PDAC) was truly correct. The accuracy of these predictions was then assessed
using a Brier score, defined as:
BS =
1
N
∑
N
i ¼ 1
(pi − oi)
2, (3)
where pi is the clinicians’ certainty regarding the diagnosis for patient i, oi is an indicator variable for
whether the diagnosis was eventually correct (taking value 1 if the diagnosis matches the D4 diagnosis and
0 otherwise) and N is the total number of patients. A smaller Brier score implies a better forecast.
The Brier score penalises both general poor predictive ability and also poor calibration. The worst possible
Brier score for an exactly calibrated forecast is 0.25, occurring if an event has a (correctly determined)
50% chance of occurring. However, it is possible to obtain worse scores for poorly calibrated forecasts, for
example estimating something with a 50% chance of occurring has a 100% chance gives an expected
Brier score of 0.5.
Bootstrap resampling was used to assess whether or not the change in Brier score between D1 and D2
was statistically significant.
METHODS
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Note that the accuracy of this method depends on the assumption that the clinicians interpreted the
certainty score as a probability with respect to the binary diagnosis of PDAC or not PDAC. If instead they
interpreted it as the probability that the precise diagnosis (including either type of PDAC or precise other
condition) was correct, or certainty measured on some scale other than probability, the Brier score results
could be misleading.
Secondary analyses
Impact of positron emission tomography/computed tomography on
diagnosis, staging and management
The impact of PET/CT on patient management was assessed by considering data from the D2 form on
whether the PET/CT scan was perceived to have influenced patient management and also data from the
D3 form on which management (D1, D2 or neither) the patient eventually followed. In the latter case a
formal test was performed to assess whether a greater proportion of patients followed D2 than D1.
Counts of the most clinically important management changes occurring between D1 and D2 were collated
(change from resection to no resection, change from no resection to resection, change from some form
of chemotherapy to no chemotherapy, change from no chemotherapy to some form of chemotherapy,
change from no further investigation to some form of further investigation). In addition, the number of
cases in which PET/CT was perceived to have either directly identified a secondary malignancy or else
suggested the need for further investigation in the case of a secondary malignancy was collated.
Benefit of positron emission tomography/computed tomography in
chronic pancreatitis
The same general methodology was applied to assess the diagnostic accuracy of PET/CT in diagnosing
chronic pancreatitis.
Benefit of positron emission tomography/computed tomography
in subgroups
The benefit of PET/CT in relation to different patient groups [male vs. female, aged < 65 years vs. ≥ 65 years,
World Health Organization (WHO) performance status > 0 vs. WHO performance status= 0, presence or
absence of eligibility criteria] was assessed by fitting appropriate generalised estimating equation (GEE)
models to test for differences in sensitivities and specificities and also relative sensitivities and specificities
across different patient groups.
Benefit of positron emission tomography/computed tomography in other
pancreatic tumours/disease
The same general methodology was applied to assess the diagnostic accuracy of PET/CT for malignant
cystic neoplasm, cholangiocarcinoma, periampullary carcinoma and neuroendocrine tumour and also the
diagnostic accuracy of PET/CT for malignant compared with benign pancreatic disease.
Additional analyses
Analysis of the standardised uptake value
Among PET/CT scans for which an apparent tumour was identified the distribution of SUVmax. in patients
with and without pancreatic cancer was performed. A Mann–Whitney U-test was performed to compare
the distributions in the two groups. In addition, the value of SUVmax. as a direct diagnostic tool for
pancreatic cancer was assessed by estimating the receiver operating characteristic curve.
Survival analysis
Overall survival and survival for patients with or without pancreatic cancer and also with or without
malignant disease was calculated using Kaplan–Meier estimates. To avoid issues of left truncation, survival
times were taken from the date of the PET/CT scan as registered patients were required to have had a
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PET/CT scan to appear in the final set of patients. Withdrawal from the study before the end of 12 months’
follow-up was assumed to be non-informative censoring. Cox proportional hazards modelling was used to
estimate hazard ratios (HRs) between these diagnostic groups, to evaluate the impact of other baseline
demographic characteristics on patient survival and to assess the relationship between SUVmax. and survival
among patients with PDAC.
Summary of changes to the protocol
Protocol version 1 (12 January 2010) to protocol version 2 (1 March 2011)
l Alteration of inclusion criterion from ‘able to attend for 12 months’ follow-up’ to ‘able to attend for up
to 12 months’ follow-up’ to reflect the potentially unpredictable and poor prognosis of patients with
pancreatic malignancy.
l Addition of the exclusion criterion ‘patients with poorly controlled diabetes’.
l Inclusion of a random blood glucose test at baseline to the schedule of assessments.
l Clarification that the post-PET/CT diagnosis (D2) could be conducted either at the MDT meeting or by
the investigator because of capacity constraints at MDT meetings.
l Confirmation that the NCRI PET Research Network PET Core Laboratory at St Thomas’s Hospital,
London, would provide the core laboratory function and that central clinical reporting would be
conducted at the Paul Strickland Scanner Centre.
l Clarification that only serious adverse events as defined in the protocol should be reported to the
co-ordinating centre within 24 hours of a site becoming aware of an event.
Protocol version 2 (1 March 2010) to protocol version 3 (1 September 2011)
l Frequency of the Independent Safety and Data Monitoring Committee (ISDMC) meeting defined to be
every 6 months to reflect the recruitment period.
l Alteration to the PET/CT protocol:
¢ suitable fasting blood glucose level of patients able to undergo a PET/CT scan increased from
7 mmol/l to 10 mmol/l to more adequately accommodate patients with diabetes mellitus, following
a recommendation of the Trial Steering Committee
¢ specific instructions included for research sites for preparation of patients with type I and type II
diabetes mellitus, following a recommendation of the Trial Steering Committee
¢ redefinition of injected activity to take account of variation in scanning equipment in scanning
centres and redefinition of the position of the patient for scanning to prevent unnecessary
exposure to radiation-sensitive tissues: ‘begin scanning at the groin and end at the vertex’ altered
to ‘begin scanning at the groin and end at the base of the orbits’.
Protocol version 3 (1 September 2011) to protocol version 4 (10 September 2012)
l Sample size redefined following the interim analysis.
l Clarification on the requirement of the PET/CT scan to be performed within 2 weeks of the baseline
assessment. The time limit was recommended to ensure that patients did not suffer unnecessary delays
in diagnosis and management decisions because of participation in the study.
l Clarification on the scheduling and format of follow-up visits.
Public and patient involvement
In this study patient involvement included (1) contribution to the study design, (2) consideration of the
acceptability of extra-diagnostic tests for the patient pathway, (3) advice on the original grant application
and study protocol and (4) membership of the Trial Steering Committee.
METHODS
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Chapter 3 Results
Recruitment
The first patient was recruited in January 2011 and recruitment was completed in April 2013. Follow-up
was carried out until April 2014. Figure 2 describes the participant flow in the study. In total, 619 patients
were registered and 589 patients underwent PET/CT scanning. Of these, 583 were included in the
intention-to-treat (ITT) analysis and 550 were included in the in-range/per-protocol analysis; 33 patients
either had a blood glucose level of > 10 mmol/l at the time of their PET/CT scan or underwent a PET/CT
scan that was outside the 90-minute uptake time by ± 10 minutes. Diagnostic information was incomplete
for six patients. A total of 316 patients completed the 12-month follow-up.
Patients were registered from 18 sites in the UK. Table 3 shows the number of patients registered, number
with a D4 diagnosis and number with a D4 diagnosis and within-range uptake time and blood glucose
Patients screened
(n = 910)
Registered
(n = 619)
Patients with no PET/CT performed
(n = 30)
• DNA, n = 7
• Abnormal blood glucose, n = 12
• Unfit for scan, n = 5
• Consultant decision not to scan, n = 1
• Consent withdrawn before scan, n = 3
• Proceeded/treatment before scan, n = 1
• No reason given, n = 1
12-month follow-up
(n = 316)
Patients did not complete 
12-month follow-up
(n = 234)
• Consent withdrawn, n = 13
• Lost to follow-up, n = 25
• Intercurrent illness, n = 4
• Consultant decision, n = 7
• Death, n = 177
• Other, n = 8
Patients undergoing PET/CT scan 
with reference standard diagnosis 
included in the ITT analysis (D4)
(n = 583)
Out-of-range  patients
(n = 33)
• Patients with out-of-range 
   uptake, n = 18
• Abnormal blood glucose, n = 15
Patients undergoing PET/CT scan
(n = 589)
Patients with incomplete D forms
(n = 6)
Patients undergoing in-range 
PET/CT scan with reference 
standard diagnosis included in 
the per-protocol analysis (D4)
(n = 550)
(a)
FIGURE 2 (a) Participant flow in the study; and (b) Standards for the Reporting of Diagnostic Accuracy Studies
(STARD) flow diagram. Positive, pancreatic cancer; negative, not pancreatic cancer. (continued )
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Registered
619
30 – no PET/CT performed
19Out of range Out of range
PrePET/CT
PostPET/CT
Reference
standard
Positive
Reference
standard
Negative
PostPET/CT
335
281
227 54
Positive Negative
4 31
35
248
Positive
Positive
Negative
Negative
Reference
standard
Positive
Reference
standard
Negative
31
15 16
Positive Negative
15 188
203
Positive Negative
14
(b)
FIGURE 2 (a) Participant flow in the study; and (b) Standards for the Reporting of Diagnostic Accuracy Studies
(STARD) flow diagram. Positive, pancreatic cancer; negative, not pancreatic cancer.
TABLE 3 Recruitment and PDAC prevalence by site
Site
Patients
registered
Patients with
a D4 diagnosis
Patients with a D4
diagnosis and
within-range PET/CT
and blood glucose
Prevalence of PDAC
(among per-protocol
patients) (%)
Royal Liverpool Hospital 226 224 212 44.3
Royal Free Hospital, London 11 11 9 22.2
University College Hospital, London 20 20 18 44.4
St Bartholomew’s Hospital, London 25 18 17 29.4
Glasgow Royal Infirmary 34 30 27 51.8
Nottingham City Hospital 3 3 3 0.0
University Hospital Birmingham 31 31 31 61.3
Freeman Hospital, Newcastle upon
Tyne
4 3 3 100.0
Royal Marsden Hospital, London 21 21 18 77.8
St James’s University Hospital, Leeds 44 44 41 51.2
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for each of the sites that had at least one registered patient. The level of attrition or screening failure
between registration and D4 was broadly similar across all sites.
Table 3 also shows the prevalence of PDAC, as judged via the D4 diagnosis, among those patients with a
D4 diagnosis and a PET/CT scan within range. There was considerable variation in prevalence between
sites, which may relate to the different numbers of patients recruited from sites. To investigate the
variation in prevalence between sites a funnel plot of prevalence against number of patients recruited was
constructed (Figure 3).
All but two of the centres lie within the 95% confidence limits of the funnel. The Royal Marsden Hospital
and Royal Blackburn Hospital had prevalences that were higher than expected, although still within the
99% confidence limits. Overall, there was some evidence against an assumption of homogeneity across
sites (p = 0.005).
TABLE 3 Recruitment and PDAC prevalence by site (continued )
Site
Patients
registered
Patients with
a D4 diagnosis
Patients with a D4
diagnosis and
within-range PET/CT
and blood glucose
Prevalence of PDAC
(among per-protocol
patients) (%)
Southampton General Hospital 109 93 92 44.6
Aberdeen Royal Infirmary 1 1 0 –
King’s College Hospital, London 7 5 4 75.0
Royal Blackburn Hospital 10 9 9 88.9
University Hospitals Coventry and
Warwickshire NHS Trust
10 9 7 71.4
Portsmouth Hospitals NHS Trust 51 49 47 44.7
Ninewells Hospital, Dundee 7 7 7 28.6
Abertawe Bro Morgannwg
University Health Board, Swansea
5 5 5 20.0
+
+ +
++
+
+
+
+
+ +
+
++
+
Royal Blackburn
Royal Marsden
1.0
0.8
0.6
Pr
ev
al
en
ce
0.4
0.2
0.0
0 50 100
Number of patients
150 200
95%
99%
+
+
FIGURE 3 Funnel plot of prevalence by site with 95% and 99% control limits.
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Baseline characteristics
The baseline characteristics of all registered patients, patients with a D4 diagnosis and patients with a D4
diagnosis whose PET/CT uptake time was within range and whose blood glucose was < 10 mmol/l are
detailed in Table 4. In general, there was little difference between the patient demographics of all patients
and the patient demographics of those with a D4 diagnosis, suggesting that it was reasonable to
assume that the patients for whom complete data were available are representative of the overall patient
population. Some baseline characteristics (smoking status, height, weight, etc.) were determined at the
baseline assessment rather than at registration and these were therefore available for < 619 patients.
The majority of participants had a WHO performance status of at least 0 or 1. The main eligibility criterion
for entry into the study was an abnormality of the pancreas found on CT scan. The incidence of diabetes
was around 17% in this population.
TABLE 4 Baseline characteristics
Characteristic
All registered patients
(n= 619), n (%)
Patients with D4 (ITT)
(n= 583), n (%)
Patients with D4 and
in range (per protocol)
(n= 550), n (%)
Age (years)
Median (IQR) 66 (15) 66 (15) 66 (15)
Range (21–87) (21–87) (21–87)
Sex
Male 353 (57) 328 (56) 304 (54)
Female 266 (43) 255 (44) 246 (46)
Height (cm), mean (SD)a 167.3 (10.9) 167.3 (10.9) 167.1 (11.0)
Weight (kg), mean (SD)a 74.9 (17.3) 75.0 (17.3) 75.2 (17.3)
WHO performance status at baseline
0 294 (48) 283 (49) 264 (48)
1 276 (46) 253 (43) 244 (44)
2 40 (6) 38 (7) 35 (6)
3 9 (1) 9 (2) 7 (1)
4 0 (0) 0 (0) 0 (0)
Diabetes
None 484 (78) 476 (82) 456 (83)
Type 1 12 (2) 11 (2) 10 (2)
Type 2 96 (16) 90 (15) 79 (14)
Missing 27 (4) 6 (1) 5 (1)
Eligibility criteriab
Criterion 1 570 (92) 538 (92) 476 (87)
Criterion 2 172 (28) 159 (27) 148 (27)
Criterion 3 130 (21) 127 (22) 117 (21)
Previous resection
Yes (of pancreas) 11 (2) 11 (2) 8 (1)
Yes (other) 33 (5) 33 (6) 30 (5)
No 575 (93) 539 (92) 512 (93)
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Reference standard
The reference standard (D4) for diagnosis was a clinical judgement made by an independent expert based on
histology (either biopsy or resection) or clinical outcome at the 12-month assessment. For the 583 patients
who had PET/CT (ITT population), the reference standard was based on histology (resection) in 242 patients
and biopsy in 249 patients, with 92 patients having clinical follow-up data. For the 550 patients who
underwent PET/CT within range (per-protocol population), the reference standard was based on histology
(resection) in 233 patients and biopsy in 230 patients, with 87 patients having clinical follow-up data.
Reference standard diagnosis (D4) of patients
The frequency of each confirmed diagnosis type (the D4 reference standard) is provided in Table 5.
If patients had more than one diagnosis, the primary diagnosis was used. The largest single group of
patients was those with pancreatic cancer. Other types of tumour included cholangiocarcinoma,
periampullary carcinoma and neuroendocrine tumour. The other main groups consisted of those patients
with benign cystic neoplasms and chronic pancreatitis. The overall disease frequencies represent the typical
case mix found in a UK pancreatic MDT and reflect UK practice.
Reference standard staging for patients with in-range positron emission
tomography/computed tomography
For patients with a tumour the reference standard stagings are detailed in Table 6. All tumour types are
included in the second column and patients with PDAC only are included in the third column. Overall,
20% of patients with pancreatic cancer had locally advanced or metastatic disease.
TABLE 4 Baseline characteristics (continued )
Characteristic
All registered patients
(n= 619), n (%)
Patients with D4 (ITT)
(n= 583), n (%)
Patients with D4 and
in range (per protocol)
(n= 550), n (%)
Smoking statusc
Never 221 (37) 216 (37) 205 (37)
Past 223 (37) 227 (39) 216 (39)
Current 132 (22) 128 (22) 118 (21)
Missing 24 (4) 12 (2) 11 (2)
Concurrent medical conditionsc
Yes 515 (86) 501 (86) 475 (86)
No 81 (14) 80 (14) 73 (13)
Missing 4 (1) 2 (0) 2 (0)
Concomitant medicationc
Yes 546 (91) 531 (91) 500 (91)
No 51 (9) 51 (9) 49 (9)
Missing 3 (0) 1 (0) 1 (0)
IQR, interquartile range.
a Among patients with complete data (n= 562 for height, n= 573 for weight).
b Criterion 1: focal lesion in the pancreas/bulky pancreas/dilated pancreatic duct (±metastases) detected on MDCT
(±MRI/EUS/ultrasound); criterion 2: jaundice because of distal obstruction of the common bile duct or ampulla
(not because of calculi) defined as serum bilirubin > 35 µmol/l; criterion 3: serum CA19.9 > 37 kU/l.
c All patient data based on the n= 600 with a baseline assessment.
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Reference standard management for patients with an in-range positron
emission tomography/computed tomography scan
The management outcomes for patients are detailed in Table 7. Patients may have had more than one
management outcome, for example resection plus adjuvant therapy. The majority of patients who
underwent resection had a right-sided (standard or pylorus-preserving Whipple) procedure. Twenty-six
patients were found to be inoperable at the time of surgery and underwent either surgical bypass or open
and shut laparotomy.
Patient withdrawals
Out of the 619 registered patients a total of 280 patients withdrew from the trial. Of these, 187 patients
died; the other reasons for withdrawal are detailed in Table 8. The median study duration for all patients
who withdrew was 159 days.
TABLE 5 Reference standard diagnosis (D4) for all patients with a PET/CT scan and for patients with an in-range
PET/CT scan
Reference standard diagnosis (D4)
Number (%) of patients
(ITT) (n= 583)
Number (%) of within-range
patients (per protocol) (n= 550)
PDAC 278 (48) 261 (47)
Periampullary carcinoma 39 (7) 37 (7)
Cholangiocarcinoma 43 (7) 42 (8)
Benign cystic neoplasm 64 (11) 63 (11)
Malignant cystic neoplasm 7 (1) 7 (1)
Pancreatic pseudocyst 4 (1) 4 (1)
Chronic pancreatitis 36 (6) 32 (6)
Autoimmune pancreatitis 10 (2) 8 (1)
Acute pancreatitis 27 (5) 25 (5)
Neuroendocrine tumour 26 (4) 24 (4)
Lymphoma 1 (0) 1 (0)
Metastases from non-pancreatic primary neoplasm 6 (1) 6 (1)
Normal pancreas 22 (4) 21 (4)
Other 20 (3) 19 (3)
TABLE 6 Tumour stage of patients at D4
Confirmed stagea at D4
Number (%) of patients:
all tumours (n= 550)
Number (%) of patients: PDAC
(%) (n= 261)
0 1 (0) 0 (0)
IA 15 (3) 5 (2)
IB 16 (3) 5 (2)
IIA 31 (6) 20 (8)
IIB 111 (20) 79 (30)
III 26 (5) 17 (7)
IV 63 (11) 52 (20)
Other/unknown 287 (52) 83 (32)
a Staged according to the UICC TNM classification.61
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TABLE 7 Confirmed management at D4 for all patients with an in-range PET/CT scan
Outcome n (%)
Resection 216 (39)
Standard Whipple procedure 60 (28)
Pylorus-preserving Whipple procedure 102 (47)
Left pancreatectomy 35 (16)
Total pancreatectomy 8 (4)
Other 11 (5)
Surgical bypass 22 (4)
Laparotomy 4 (1)
Biopsy 135 (25)
EUS 96 (71)
ERCP 12 (9)
Percutaneous 9 (7)
Other/unknown 18 (13)
Chemotherapy 249 (45)
Neoadjuvant 7 (3)
Adjuvant 100 (40)
Palliative 142 (57)
Best supportive care 28 (5)
Clinical follow-up 52 (9)
No further investigation 29 (5)
TABLE 8 Patient withdrawals: all registered patients (n= 619)
Patient withdrawals n (%)
Patients withdrawn/died 280 (45)
Reason for withdrawal
Consent withdrawn 20 (7)
Lost to follow-up 26 (9)
Intercurrent illness preventing further follow-up 5 (2)
Consultant decision following other changes in patient’s condition 14 (5)
Death 187 (67)
Other 28 (10)
Study duration (days from registration to withdrawal from study) including deaths
Median 187
IQR 230
Range 0–466
n 280
continued
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Adverse events
There were no adverse events related to the study procedure. One adverse event was recorded as
lymphangitis carcinomatosis, which was related to the patient’s original condition.
Central review
The majority of the PET/CT scans were reviewed at the Paul Strickland Scanner Centre at Mount Vernon
Hospital using the agreed standard proforma. Central review of the PET/CT scans was also performed at
Aintree University Hospital, St James’s University Hospital, the Royal Free Hospital and Southampton
General Hospital using the agreed standard proforma. There were 40 instances in which there was
discordance between the site PET/CT report and the central PET/CT report. To date, two sites have been
notified regarding abnormal uptake not seen in the local reports.
Quality assurance of computed tomography and histology
Review of pathological samples was completed on samples received from 12 of the recruiting research
sites. Review of samples from the remaining six sites is currently still ongoing. Central pathology review
has not produced any disparities that would have significantly affected patient management. Radiological
review of baseline CT scans is currently ongoing and has been completed in one-third of cases.
Diagnostic accuracy and incremental benefit of positron emission
tomography/computed tomography for pancreatic cancer
Patients with positron emission tomography/computed tomography and a
D4 diagnosis (intention-to-treat population, n = 583)
Among the 583 patients with a D4 diagnosis the overall disease prevalence (pancreatic cancer) was 47.7%
(95% CI 43.6% to 51.7%). Table 9 provides the 2 × 2 table for MDCT and PET/CT diagnosis by PDAC
status (D4).
TABLE 8 Patient withdrawals: all registered patients (n= 619) (continued )
Patient withdrawals n (%)
Study duration (days from registration to withdrawal from study) excluding deaths
Median 159
IQR 349
Range 0–538
n 92
IQR, interquartile range.
TABLE 9 Multidetector computed tomography and PET/CT diagnosis against PDAC disease status
Diagnosis PDAC No PDAC
MDCT positive 243 92
MDCT negative 35 213
PET/CT positive 251 73
PET/CT negative 27 232
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The sensitivity and specificity of the initial MDCT scan (D1) diagnosis were 87.4% (95% CI 83.5% to
91.3%) and 69.8% (95% CI 64.7% to 75.0%), respectively. The sensitivity and specificity of the
subsequent PET/CT scan (D2) diagnosis were 90.3% (95% CI 86.8% to 93.7%) and 76.1% (95% CI
71.3% to 80.9%), respectively.
Table 10 shows the MDCT- and PET/CT-based diagnoses among patients with and without PDAC. Of main
interest were the numbers of discordant patients (those whose diagnosis differed at each stage) as this
drives the relative sensitivity and specificity of PET/CT compared with MDCT. In each case there was a
greater number of cases in which the PET/CT diagnosis was correct than in which the MDCT diagnosis was
correct, indicating that PET/CT performs better.
Table 11 provides the relative sensitivity and specificity for PET/CT compared with MDCT with the
corresponding 95% CIs and two-sided p-values. Using all patients with a D4 diagnosis, including those out
of range for either blood glucose or uptake time, the relative sensitivity did not attain statistical significance
(1.03; p = 0.083). In contrast, the 9% improvement in specificity was statistically significant (p = 0.005).
There were corresponding improvements in PPV and negative predictive value (NPV) but only the effect on
PPV was statistically significant.
Patients with positron emission tomography/computed tomography within
the uptake range and a blood glucose of < 10 mmol/l (per-protocol
population, n = 550)
Among the 550 patients with a D4 diagnosis and within-range uptake and blood glucose, the overall
disease prevalence was 47.5% (95% CI 43.3% to 51.6%). Table 12 provides the 2 × 2 table for MDCT
and PET/CT diagnosis by PDAC status (D4).
TABLE 10 Cross-tabulated diagnoses at D1 and D2
Diagnosis
Patients with PDAC Patients without PDAC
PET/CT positive PET/CT negative PET/CT positive PET/CT negative
MDCT positive 234 7 58 35
MDCT negative 16 20 16 197
TABLE 11 Relative sensitivity, specificity, PPV and NPV for PET/CT compared with MDCT
Measure MDCT PET/CT Relative p-value
Sensitivity (95% CI) (%) 87.4 (83.5 to 91.3) 90.3 (86.8 to 93.7) 1.03 (1.00 to 1.07) 0.083
Specificity (95% CI) (%) 69.8 (64.7 to 75.0) 76.1 (71.3 to 80.9) 1.09 (1.03 to 1.15) 0.005
PPV (95% CI) (%) 72.5 (67.8 to 77.3) 77.5 (72.9 to 82.0) 1.07 (1.00 to 1.14) 0.037
NPV (95% CI) (%) 85.9 (81.6 to 90.2) 89.6 (85.8 to 93.3) 1.04 (0.99 to 1.10) 0.101
TABLE 12 Multidetector computed tomography and PET/CT diagnosis against PDAC disease status
Diagnosis PDAC No PDAC
MDCT positive 231 85
MDCT negative 30 204
PET/CT positive 242 70
PET/CT negative 19 219
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The sensitivity and specificity of the initial MDCT scan (D1) diagnosis were 88.5% (95% CI 84.6% to
92.4%) and 70.6% (95% CI 65.3% to 75.8%), respectively. The sensitivity and specificity of the
subsequent PET/CT scan (D2) diagnosis were 92.7% (95% CI 89.5% to 95.9%) and 75.8% (95% CI
70.8% to 80.7%), respectively.
Table 13 shows the MDCT- and PET/CT-based diagnoses among patients with and without PDAC. The
numbers of discordant patients (those whose diagnoses differed at each stage) drive the relative sensitivity
and specificity of PET/CT compared with MDCT. In each case there was a greater number of cases in
which the PET/CT diagnosis was correct than in which the MDCT diagnosis was correct, indicating that
PET/CT performs better.
Excluding patients with out-of-range uptake or blood glucose leads to an improvement in the sensitivity of
PET/CT (92.7% vs. 90.3%) and the analysis based only on these per-protocol patients shows a significant
improvement in both relative sensitivity (1.05; p = 0.010) and specificity (1.07; p = 0.023) (Table 14).
The PPV and NPV are specific to the prevalence of the disease in the population, which has to be
estimated from the data. Here, the relative NPV was statistically significant (p = 0.031) but the relative PPV
did not attain statistical significance.
Assessment of incremental diagnostic benefit
The estimated incremental likelihood ratios demonstrate that the results of PET/CT significantly improve
diagnostic accuracy in all scenarios (Figure 4). All results are significant with a bootstrap p-value of
< 0.0002. A positive diagnosis from MDCT increased the odds of PDAC by 201% (95% CI 157% to
269%), whereas a negative diagnosis decreased the odds by 84% (95% CI 79% to 88%).
Following a positive diagnosis from MDCT, a positive diagnosis at PET/CT further increased the odds of
PDAC by 55% (95% CI 28% to 85%). The most substantial incremental effect of PET/CT was a negative
diagnosis following a positive diagnosis from MDCT. In this case the odds of PDAC decreased by 95%
(95% CI 90% to 99%).
Following a negative diagnosis from MDCT, a positive diagnosis on PET/CT increased the odds of PDAC by
538% (95% CI 249% to 1127%). A second negative diagnosis on PET/CT following a negative diagnosis
from MDCT further decreased the odds of PDAC by 46% (95% CI 25% to 66%).
TABLE 13 Cross-tabulated diagnoses at D1 and D2
Diagnosis
Patients with PDAC Patients without PDAC
PET/CT positive PET/CT negative PET/CT positive PET/CT negative
MDCT positive 227 4 54 31
MDCT negative 15 15 16 188
TABLE 14 Relative sensitivity, specificity, PPV and NPV of PET/CT compared with MDCT: within-range patients
Measure MDCT PET/CT Relative p-value
Sensitivity (95% CI) (%) 88.5 (84.6 to 92.4) 92.7 (89.6 to 95.9) 1.05 (1.01 to 1.09) 0.010
Specificity (95% CI) (%) 70.6 (65.3 to 75.8) 75.8 (70.8 to 80.7) 1.07 (1.01 to 1.14) 0.023
PPV (95% CI) (%) 73.1 (68.2 to 78.0) 77.6 (72.9 to 82.2) 1.06 (1.00 to 1.13) 0.062
NPV (95% CI) (%) 87.1 (82.9 to 91.5) 92.0 (88.6 to 95.5) 1.06 (1.00 to 1.11) 0.031
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These results suggest that there is a substantial diagnostic benefit for patients of receiving a PET/CT scan
after a potential PDAC is detected on MDCT. Patients with no PDAC detected on PET/CT following a
positive MDCT scan are unlikely to have PDAC (NPV of 89%). In contrast, although a positive diagnosis on
PET/CT following a negative MDCT scan increases the odds of PDAC, the overall diagnosis is still highly
uncertain (PPV of 50%). This latter result suggests that if both tests are administered there is benefit in
combining the results rather than taking the PET/CT result alone. In particular, patients who were positive
on MDCT and PET/CT are much more likely to have PDAC than patients who are positive only on PET/CT
(PPV of 80% vs. 50%). The result of the MDCT is less important if the PET/CT result is negative (NPV of
93% if both tests are negative vs. NPV of 89% if the PET/CT scan is negative after a positive MDCT scan).
Certainty of diagnosis
Using the quantitative scale for assessing clinicians’ perceptions of diagnostic certainty (0 = no certainty
and 1 = absolute certainty), there was a significant increase in the median certainty score after the PET/CT
scan [0.80, interquartile range (IQR) 0.25] compared with before (0.68, IQR 0.34) (p < 0.0001) (Table 15).
A box plot of the distributions of perceived certainty before and after the PET/CT scan is shown in Figure 5.
Positive MDCT
LR = 3.009 (2.575 to 3.694)
Negative MDCT
LR = 0.163 (0.116 to 0.210)
Negative PET/CT
LR = 0.047 (0.009 to 0.103)
Positive PET/CT
LR = 1.547 (1.275 to 1.853)
Negative PET/CT
LR = 0.543 (0.339 to 0.747)
Positive PET/CT
LR = 6.375 (3.488 to 12.273)
Pre-test
FIGURE 4 Tree diagram of incremental likelihood ratios (LRs). The values of the LRs are given following positive or
negative MDCT and then positive or negative PET/CT. Figures in parentheses represent 95% CIs.
TABLE 15 Perceived certainty of diagnosis before and after PET/CT
Time point Median (IQR)a p-value
Before PET/CT 0.68 (0.34) < 0.0001 (Wilcoxon)
After PET/CT 0.80 (0.25)
a On a scale from 0 (no certainty) to 1 (absolute certainty).
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A similar pattern was observed using a qualitative assessment of whether certainty after PET/CT was more,
less or the same as that before PET/CT. In 322 (59%) cases clinicians were more certain following PET/CT
and in 25 (5%) cases they were less certain. In 201 (37%) cases the level of certainty was the same before
and after PET/CT. Clinicians were 12 times more likely to believe that they were more certain in their
diagnosis than they were to be less certain (p < 0.0001) following PET/CT.
Assessing the accuracy of clinicians’ perceived certainty using the Brier score (Table 16) also indicated that
clinicians’ predictions (interpreting their level of certainty as a probability) were significantly improved by the
PET/CT scan result (reduction in Brier score, i.e. prediction error, of 0.045, 95% CI 0.024 to 0.066; p < 0.001).
Changes in diagnosis, staging and management following
positron emission tomography/computed tomography
Changes in diagnosis following positron emission tomography/
computed tomography
The discordance of diagnoses following MDCT and then PET/CT can be seen in Table 17. This table shows
the MDCT- and PET/CT-based diagnoses among patients with and without PDAC. The numbers of discordant
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FIGURE 5 Distribution of perceived diagnostic certainty pre and post PET/CT.
TABLE 16 Brier scores of predicted diagnoses before and after PET/CT
Time point Brier score (PDAC diagnosis) Improvement in Brier score
Before PET/CT 0.218 0.045 (95% CI 0.024 to 0.066), p< 0.001
After PET/CT 0.173
TABLE 17 Cross-tabulated diagnoses after MDCT and PET/CT (within-range patients, per protocol) for
pancreatic cancer
Diagnosis
Patients with PDAC Patients without PDAC
PET/CT positive PET/CT negative PET/CT positive PET/CT negative
MDCT positive 227 4 54 31
MDCT negative 15 15 16 188
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patients (those whose diagnoses differed at each stage) drives the relative sensitivity and specificity of PET/CT
compared with MDCT. In each case there was a greater number of cases in which the PET/CT diagnosis was
correct than in which the MDCT diagnosis was correct, indicating that PET/CT performs better.
Positron emission tomography/computed tomography changed the diagnosis correctly for both the
diagnosis of pancreatic cancer and the diagnosis of not pancreatic cancer in 46 patients (8.3%). PET/CT
incorrectly changed the diagnoses in 20 patients (3.6%). Considering the diagnosis of malignancy in
general, PET/CT correctly changed the diagnosis in 48 patients (8.7%) and incorrectly changed the
diagnosis in 11 patients (2%) (Table 18).
Changes in staging following positron emission tomography/
computed tomography
For the purposes of examining change of stage, patients were grouped into four categories: (a) no tumour/
IA/IB/IIA, (b) IIB, (c) III and (d) IV (for the breakdown of changes in staging according to the groups see
Appendix 3). The accuracy of staging among patients in stages IA/IB/IIA was slightly worse under PET/CT
than under MDCT, with more incorrect (eight patients) than correct (six patients) changes. However, the
difference was not statistically significant (p = 0.79). Significantly more patients with stage IIB were
correctly staged by PET/CT than by MDCT, with 22 patients (21%) moving to the correct stage compared
with five patients (5%) moving to the wrong stage (p = 0.002). PET/CT had no significant effect on the
accuracy of staging for patients in stage III. Significantly more patients in staging group IV were changed
to the correct stage (27 patients) than moved to an incorrect stage (one patient) (43% vs. 2%; p < 0.001).
A summary of stage changes is provided in Table 19.
Overall, the effect of PET/CT was to change to the correct staging group significantly more often than to
change from the correct group to an incorrect group (p < 0.001). However, the majority of the benefit was
in correct changes to stage IIB or stage IV.
Changes in planned management
Using the question from the D2 (post-PET/CT scan) form, ‘Has the PET/CT scan influenced your planned
management of this patient’s disease?’, the PET/CT scan was perceived to have changed the planned
management in 250 (45%) patients. The proportion whose management was affected was slightly higher
among patients whose final diagnosis was not pancreatic cancer [139 (48%) vs. 111 (43%) with
pancreatic cancer] but the difference was not statistically significant (Table 20).
TABLE 18 Cross-tabulated diagnoses after MDCT and PET/CT (within-range patients, per protocol) for malignancy
Diagnosis
Patients with malignancy Patients without malignancy
PET/CT positive PET/CT negative PET/CT positive PET/CT negative
MDCT positive 369 5 46 42
MDCT negative 6 4 6 72
TABLE 19 Change in stage for four staging categories following PET/CT
Change summary n (%)
Remained correct 221 (56)
Remained incorrect 94 (24)
Changed to correct 56 (14)
Changed from correct to incorrect 14 (4)
Changed between incorrect groups 8 (2)
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Using the questions from the D3 (confirmed diagnosis) form, ‘Did the patient follow the course of
treatment recommended at D1?’ and ‘Did the patient follow the course of treatment recommended
at D2?’, 70% of patients did not undergo a change in management throughout the study Table 21).
In total, 15% underwent a change in management from either that considered at D1 (pre PET/CT) or that
considered at D2 (post PET/CT). A significantly higher proportion of patients (11% vs. 4%; p = 0.0002)
followed the management plan recommended after PET/CT (and not that recommended after MDCT) than
followed the MDCT management plan (and not that recommended after PET/CT).
Clinically important changes resulting from positron emission tomography/
computed tomography
Table 22 details the frequency of different types of clinically important management changes. The most
common change was changing from resection to no resection, which occurred in 61 patients, representing
11% of all patients and 21% of patients scheduled for some kind of resection after MDCT. Changing
from no further investigation to some form of further investigation/clinical follow-up occurred in
58 patients, representing 11% of all patients and 13% of those initially not scheduled for further
investigation. In total, 13% of patients not thought to need surgical resection following MDCT were
then planned for resection following PET/CT. Changes relating to the commencement or cessation of
chemotherapy were less common.
TABLE 20 Influence of PET/CT scan on patients’ planned management
Group No, n (%) Yes, n (%) Missing, n (%)
All patients 293 (53) 250 (45) 7 (1)
Patients with pancreatic cancer 148 (57) 111 (43) 2 (1)
Patients without pancreatic cancer 145 (50) 139 (48) 5 (2)
TABLE 21 Management followed at confirmed diagnosis (D3) (N= 540)
Management
D2 followed, n (%)
Yes No
D1 followed Yes 376 (70) 23 (4)
No 58 (11) 83 (15)
TABLE 22 Frequencies of clinically important management changesa
D1 change to D2 n (%)
As a result of
PET/CT, n (%)
Clinically significant,
n (%)
Resection to no resection 61 (21) 58 (20) 58 (20)
No resection to resection 34 (13) 19 (7) 19 (7)
Chemotherapy to no chemotherapy 8 (10) 1 (1) 1 (1)
No chemotherapy to chemotherapy 41 (9) 24 (5) 24 (5)
No further investigation to further investigation 58 (13) 31 (7) 31 (7)
PET/CT identified or perceived to have led to
identification of a secondary malignancy
5 (NA) 5 (NA) 5 (NA)
NA, not applicable.
a Percentages refer to percentages of patients with the D1 management type.
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Impact of positron emission tomography/computed tomography
on the diagnosis of chronic pancreatitis
The prevalence of chronic pancreatitis in the patient cohort was 41 patients (7.5%, 95% CI 5.3% to 9.6%).
The small number of patients diagnosed with chronic pancreatitis (Table 23) means that a statistical
comparison of the diagnostic tests will have a low power to detect small or moderate effects.
Table 24 shows the MDCT- and PET/CT-based diagnoses among patients with and without chronic
pancreatitis. There was a greater number of cases in which the PET/CT diagnosis was correct than in which
the MDCT diagnosis was correct for patients with a diagnosis of chronic pancreatitis.
Both MDCT and PET/CT had a relatively high specificity (98.4% in each case) but low sensitivity.
The sensitivity of the PET/CT scan was higher than that of the MDCT scan (46.3% vs. 36.6%); however,
this effect did not attain statistical significance (relative sensitivity 1.27; p = 0.066) (Table 25).
Similarly, although the improvement in sensitivity for the PET/CT scan translated into an improvement in
PPV, the effect was not significant. Although a positive diagnosis of chronic pancreatitis on PET/CT or
MDCT greatly increases the odds of a patient having chronic pancreatitis, there was still considerable
uncertainty about the diagnosis (PPV 65.2% for MDCT and 70.4% for PET/CT). Moreover, the NPVs were
very close to the original prevalence, reflecting that the tests have poor negative likelihood ratios (0.65 and
0.56 for MDCT and PET/CT, respectively).
TABLE 23 Multidetector computed tomography and PET/CT diagnosis against chronic pancreatitis status
Diagnosis Chronic pancreatitis No chronic pancreatitis
MDCT positive 15 8
MDCT negative 26 501
PET/CT positive 19 8
PET/CT negative 22 501
TABLE 24 Cross-tabulated diagnoses at D1 and D2
Diagnosis
Patients with chronic pancreatitis Patients without chronic pancreatitis
PET/CT positive PET/CT negative PET/CT positive PET/CT negative
MDCT positive 14 1 5 3
MDCT negative 5 21 3 498
TABLE 25 Sensitivity, specificity, PPV and NPV for MDCT and PET/CT in relation to a diagnosis of chronic
pancreatitis
Measure MDCT PET/CT Relative p-value
Sensitivity (95% CI) (%) 36.6 (21.8 to 51.3) 46.3 (31.1 to 61.6) 1.27 (0.98 to 1.55) 0.066
Specificity (95% CI) (%) 98.4 (97.3 to 99.5) 98.4 (97.3 to 99.5) 1.00 (0.99 to 1.01) 1.000
PPV (95% CI) (%) 65.2 (45.8 to 84.7) 70.4 (53.1 to 87.6) 1.08 (0.82 to 1.41) 0.582
NPV (95% CI) (%) 95.1 (93.2 to 96.9) 95.8 (94.1 to 97.5) 1.01 (0.99 to 1.03) 0.436
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The role of PET/CT in distinguishing between pancreatic cancer and chronic pancreatitis was assessed.
Very few patients were misdiagnosed as having chronic pancreatitis rather than PDAC. Two patients
(with PDAC at D4) were suspected of having chronic pancreatitis after MDCT, which reduced to one after
PET/CT (the breakdown of chronic pancreatitis diagnoses at D1 and D2 can be found in Appendix 4).
One patient had confirmed PDAC and chronic pancreatitis and was diagnosed as PDAC only after both
MDCT and PET/CT. The level of agreement between the diagnoses at D1 and D2 and the diagnosis at
D4 was measured using Cohen’s kappa. Diagnosis of PDAC was grouped with the diagnosis of chronic
pancreatitis and PDAC because of the very small number of patients with chronic pancreatitis and PDAC.
At D1, the weighted Cohen’s kappa was 0.58 (95% CI 0.51 to 0.65), whereas at D2 this increased to 0.67
(95% CI 0.60 to 0.73). The increase in Cohen’s kappa was 0.083 (95% CI 0.021 to 0.134), indicating a
statistically significant improvement in agreement with the D4 diagnosis (p = 0.004). It should be noted
that most of this improvement was likely because of improvement in the diagnosis of PDAC rather than
improvement in the diagnosis of chronic pancreatitis.
Subgroup analyses
Out-of-range patients
A GEE subgroup analysis (Table 26) comparing the patients within range for both uptake time and blood
glucose with those out of range for either showed a statistically significant deterioration in sensitivity
among out-of-range patients at just 52.9% (p < 0.0001). There was evidence that the relative sensitivity of
PET/CT compared with MDCT was much lower among those patients, being worse than that of MDCT
(relative sensitivity 0.75; p = 0.005). There was also some evidence of lower sensitivity of MDCT among
this group. There was no evidence of a difference in PET/CT or MDCT specificity or relative specificity for
this group.
Among patients who had an out-of-range uptake time (Table 27) there was some evidence of lower
PET/CT sensitivity (71.4%), although this did not attain statistical significance. There was no evidence of
differences in specificity.
Among patients who had a blood glucose level of > 10 mmol/l (Table 28) there was evidence of
considerably lower PET/CT sensitivity (40.0%; p = 0.0001); although the sensitivity of MDCT was also
impacted, there was nevertheless also strong evidence of reduced relative sensitivity for these patients,
TABLE 26 Effect of out-of-range values (n= 33)
Measure MDCT PET/CT Relative
Sensitivity (95% CI) (%) 70.6 (45.8 to 87.2),
p= 0.040a
52.9 (30.3 to 74.5),
p< 0.0001a
0.75 (0.54 to 1.04),
p= 0.005a
Specificity (95% CI) (%) 56.3 (32.4 to 77.5),
p= 0.230a
81.3 (55.3 to 93.8),
p= 0.190a
1.44 (1.00 to 2.07),
p= 0.097a
a p-value of the interaction with the within-range population.
TABLE 27 Effect of out-of-range uptake time (n= 18)
Measure MDCT PET/CT Relative
Sensitivity (95% CI) (%) 85.7 (41.9 to 98.0),
p= 0.891a
71.4 (32.7 to 92.8),
p= 0.146a
0.83 (0.58 to 1.19),
p= 0.153a
Specificity (95% CI) (%) 54.5 (26.8 to 79.7),
p= 0.269a
81.8 (49.3 to 95.4),
p= 0.264a
1.50 (0.95 to 2.38),
p= 0.141a
a p-value of the interaction with the remaining patients.
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with PET/CT performing worse than MDCT (relative sensitivity 0.67; p = 0.027). Again, there was no
evidence of differences in specificity.
These results confirm the necessity for PET/CT to be administered after the correct uptake time and the
unsuitability of PET/CT for patients with poorly controlled blood glucose.
Further generalised estimating equation subgroup analyses
In the remaining analyses the subgroup of patients with the per-protocol uptake time and within-range
blood glucose was considered. Tables 29–34 present the results of univariate GEE analyses for the effect
of sex, age (dichotomised at < 65 years or ≥ 65 years), WHO performance status (0 vs. 1, 2 or 3; see
Appendix 5) and eligibility criteria. There was no evidence of any differences in sensitivity or specificity for
either test with respect to sex (see Table 29) or age (see Table 30). However, both MDCT and PET/CT had
significantly higher sensitivity among patients with a WHO status of ≥ 1 than among those with a WHO
status of 0, but conversely had significantly lower specificity (see Table 31). Both MDCT and PET/CT had
TABLE 29 Effect of sex on sensitivity and specificity
Measure
MDCT PET/CT Relative
Male Female Male Female Male Female
Sensitivity (95% CI) (%) 88.1
(81.7 to 92.5)
89.0
(81.9 to 93.5)
92.7
(84.2 to 96.8)
93.2
(87.0 to 96.6)
1.05
(0.99 to 1.12)
1.05
(0.99 to 1.11)
p= 0.826 p = 0.958 p= 0.905
Specificity (95% CI) (%) 66.4
(58.8 to 73.3)
75.8
(67.6 to 82.4)
74.5
(67.2 to 80.7)
77.3
(69.3 to 83.8)
1.12
(1.00 to 1.25)
1.02
(0.94 to 1.11)
p= 0.085 p = 0.191 p= 0.215
Prevalence of D4-positive diagnosis of PDAC by sex: male 46.3%, female 49.4%; p= 0.514.
TABLE 30 Effect of age (< 65 years vs. ≥ 65 years) on sensitivity and specificity
Measure
MDCT PET/CT Relative
< 65 years ≥ 65 years < 65 years ≥ 65 years < 65 years ≥ 65 years
Sensitivity (95% CI) (%) 89.3
(82.1 to 93.8)
87.9
(81.6 to 92.3)
92.0
(85.3 to 95.7)
93.3
(88.0 to 96.4)
1.03
(0.98 to 1.09)
1.06
(1.01 to 1.12)
p= 0.732 p = 0.701 p= 0.404
Specificity (95% CI) (%) 73.3
(65.3 to 80.1)
68.2
(60.4 to 75.0)
77.0
(69.2 to 83.4)
74.7
(67.2 to 80.9)
1.05
(0.98 to 1.12)
1.10
(1.01 to 1.19)
p= 0.338 p = 0.629 p= 0.630
Prevalence of D4-positive diagnosis of PDAC by age: < 65 years 45.3%, ≥ 65 years 49.2%; p= 0.42.
TABLE 28 Effect of blood glucose of > 10mmol/l (n = 15)
Measure MDCT PET/CT Relative
Sensitivity (95% CI) (%) 60.0 (29.7 to 84.2),
p = 0.016a
40.0 (15.8 to 70.3),
p= 0.0001a
0.67 (0.38 to 1.17),
p= 0.027a
Specificity (95% CI) (%) 60.0 (20.0 to 90.0),
p = 0.632a
80.0 (30.9 to 97.3),
p= 0.730a
1.33 (0.76 to 2.35),
p= 0.463a
a p-value of the interaction with the remaining patients.
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TABLE 31 Effect of WHO status at baseline (0 vs. ≥ 1) on sensitivity and specificity
Measure
MDCT PET/CT Relative
WHO 0 WHO ≥ 1 WHO 0 WHO ≥ 1 WHO 0 WHO ≥ 1
Sensitivity (95% CI) (%) 84.2
(76.3 to 89.8)
91.8
(86.2 to 95.3)
86.8
(79.3 to 91.9)
97.3
(93.0 to 99.0)
1.03
(0.91 to 1.17)
1.06
(1.01 to 1.11)
p= 0.059 p = 0.012 p= 0.069
Specificity (95% CI) (%) 78.0
(70.7 to 83.9)
62.6
(54.3 to 70.2)
82.0
(75.0 to 87.4)
69.1
(60.9 to 76.2)
1.05
(0.99 to 1.12)
1.10
(1.00 to 1.22)
p= 0.004 p = 0.009 p= 0.882
Prevalence of D4-positive diagnosis of PDAC by WHO status: WHO 0 43.1%, WHO ≥ 1 48.0%; p = 0.039.
TABLE 32 Effect of eligibility criterion 1 (focal lesion in the pancreas/bulky pancreas/dilated pancreatic duct) on
sensitivity and specificity
Measure
MDCT PET/CT Relative
Criterion 1
not met
Criterion 1
met
Criterion 1
not met
Criterion 1
met
Criterion 1
not met
Criterion 1
met
Sensitivity (95% CI) (%) 76.5
(51.4 to 90.9)
89.3
(84.1 to 92.6)
88.2
(63.2 to 97.0)
93.0
(89.1 to 95.6)
1.15
(1.07 to 1.25)
1.04
(1.00 to 1.08)
p= 0.119 p = 0.277 p= 0.543
Specificity (95% CI) (%) 76.9
(57.2 to 89.2)
70.0
(64.1 to 75.2)
73.1
(53.3 to 86.6)
76.0
(70.5 to 80.8)
0.95
(0.89 to 1.01)
1.09
(1.02 to 1.16)
p= 0.459 p = 0.387 p= 0.171
Prevalence of D4-positive diagnosis of PDAC by criterion 1 status: criterion met 48.1%, criterion not met 39.5%; p= 0.36.
TABLE 33 Effect of eligibility criterion 2 (jaundice because of distal obstruction of the common bile duct or
ampulla) on sensitivity and specificity
Measure
MDCT PET/CT Relative
Criterion 2
not met
Criterion 2
met
Criterion 2
not met
Criterion 2
met
Criterion 2
not met
Criterion 2
met
Sensitivity (95% CI) (%) 87.6
(81.2 to 91.8)
90.1
(82.1 to 94.8)
91.1
(85.9 to 94.6)
95.6
(88.9 to 98.3)
1.04
(0.95 to 1.14)
1.06
(1.00 to 1.13)
p= 0.553 p = 0.436 p= 0.336
Specificity (95% CI) (%) 73.7
(67.7 to 79.0)
57.9
(44.8 to 69.9)
81.5
(75.9 to 86.0)
52.6
(40.0 to 65.1)
1.11
(0.98 to 1.24)
0.91
(0.73 to 1.14)
p= 0.020 p < 0.0001 p= 0.024
Prevalence of D4-positive diagnosis of PDAC by criterion 2 status: criterion met 61.5%, criterion not met
42.3%; p < 0.0001.
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significantly lower specificity among patients with jaundice because of distal obstruction of the common
bile duct or ampulla (see Table 33). Moreover, there was also evidence that PET/CT was not more effective
than MDCT for this group. There was no evidence of differences in sensitivity or specificity in relation to
the other eligibility criteria (see Tables 32 and 34).
Impact of positron emission tomography/computed tomography
on the diagnosis of pancreatic tumours
Malignant cystic neoplasm
The prevalence of malignant cystic neoplasm in the patient cohort was 1.5% (95% CI 0.5% to 2.5%).
The small number of patients diagnosed with malignant cystic neoplasm (Table 35) means that statistical
tests comparing the diagnostic tests have low power to detect small or moderate effects.
Both MDCT and PET/CT had a sensitivity of 75.0% (95% CI 45.0% to 99.9%). The specificity of PET/CT
was higher than that of MDCT [96.1% (95% CI 94.5% to 97.8%) vs. 92.8% (95% CI 90.6% to 95.0%)].
The 3.6% (95% CI 1.8% to 5.4%) improvement in specificity between tests was statistically significant
(p < 0.001) (Table 36). The very small number of cases of malignant cystic neoplasm meant that the
significant difference in specificity did not translate into a significant difference in either PPV or NPV.
Cholangiocarcinoma
The prevalence of cholangiocarcinoma in the patient cohort was 8.0% (95% CI 5.7% to 10.3%).
The small number of patients diagnosed with cholangiocarcinoma (Table 37) means that statistical tests
comparing the diagnostic tests have low power to detect small or moderate effects.
Both MDCT and PET/CT had a relatively high specificity (97.8% and 98.8%, respectively) but low sensitivity
(25% in each case). There were no significant differences in either sensitivity or specificity (Table 38).
TABLE 34 Effect of eligibility criterion 3 (serum CA19.9 > 37 kU/l) on sensitivity and specificity
Measure
MDCT PET/CT Relative
Criterion 3
met
Criterion 3
not met
Criterion 3
met
Criterion 3
not met
Criterion 3
met
Criterion 3
not met
Sensitivity (95% CI) (%) 89.7
(84.4 to 93.3)
85.7
(76.0 to 91.9)
92.9
(88.2 to 95.9)
92.2
(83.7 to 96.5)
1.04
(0.99 to 1.09)
1.08
(1.01 to 1.15)
p= 0.362 p = 0.580 p= 0.505
Specificity (95% CI) (%) 71.5
(65.6 to 76.7)
65.0
(49.2 to 78.1)
76.3
(70.6 to 81.2)
72.5
(56.8 to 84.1)
1.07
(0.94 to 1.22)
1.12
(0.95 to 1.31)
p= 0.404 p = 0.704 p= 0.730
Prevalence of D4-positive diagnosis of PDAC by criterion 3 status: criterion met 65.8%, criterion not met
42.5%; p< 0.0001.
TABLE 35 Multidetector computed tomography and PET/CT diagnosis against malignant cystic neoplasm status
Diagnosis Malignant cystic neoplasm No malignant cystic neoplasm
MDCT positive 6 39
MDCT negative 2 503
PET/CT positive 6 21
PET/CT negative 2 521
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Similarly, although the improvement in sensitivity (for cholangiocarcinoma) for the PET/CT scan translated into
an improvement in PPV, the effect was not significant. Although a positive diagnosis of cholangiocarcinoma
on PET/CT or MDCT greatly increases the odds of a patient having cholangiocarcinoma, there was still
considerable uncertainty about the diagnosis (PPV 50% for MDCT and 65% for PET/CT). Moreover, the NPVs
were very close to the original prevalence reflecting that the tests have poor negative likelihood ratios
(0.77 and 0.76 for MDCT and PET/CT, respectively).
Neuroendocrine tumours
The prevalence of neuroendocrine tumours in the patient cohort was 4.9% (95% CI 3.1% to 6.7%).
The small number of patients diagnosed with neuroendocrine tumour (Table 39) means that statistical tests
comparing the diagnostic tests have low power to detect small or moderate effects.
TABLE 37 Multidetector computed tomography and PET/CT diagnosis against cholangiocarcinoma status
Diagnosis Cholangiocarcinoma No cholangiocarcinoma
MDCT positive 11 11
MDCT negative 33 495
PET/CT positive 11 6
PET/CT negative 33 500
TABLE 38 Sensitivity, specificity, PPV and NPV for MDCT and PET/CT in relation to diagnosis of cholangiocarcinoma
Measure MDCT PET/CT Relative p-value
Sensitivity (95% CI) (%) 25.0 (12.2 to 37.8) 25.0 (12.2 to 37.8) 1.00 (0.64 to 1.36) 1.000
Specificity (95% CI) (%) 97.8 (96.6 to 99.1) 98.8 (97.8 to 99.8) 1.01 (1.00 to 1.02) 0.094
PPV (95% CI) (%) 50.0 (29.1 to 70.9) 64.7 (42.0 to 87.4) 1.29 (0.86 to 1.94) 0.214
NPV (95% CI) (%) 93.8 (91.7 to 95.8) 93.8 (91.8 to 95.9) 1.00 (0.98 to 1.02) 0.954
TABLE 39 Multidetector computed tomography and PET/CT diagnosis against neuroendocrine tumour status
Diagnosis Neuroendocrine tumour No neuroendocrine tumour
MDCT positive 12 3
MDCT negative 15 520
PET/CT positive 12 7
PET/CT negative 15 516
TABLE 36 Sensitivity, specificity, PPV and NPV for MDCT and PET/CT in relation to diagnosis of malignant
cystic neoplasm
Measure MDCT PET/CT Relative p-value
Sensitivity (95% CI) (%) 75.0 (45.0 to 99.9) 75.0 (45.0 to 99.9) 1.00 (0.54 to 1.46) 1.0
Specificity (95% CI) (%) 92.8 (90.6 to 95.0) 96.1 (94.5 to 97.8) 1.04 (1.02 to 1.05) < 0.001
PPV (95% CI) (%) 13.3 (3.4 to 23.3) 22.2 (6.5 to 37.9) 1.67 (0.97 to 2.87) 0.066
NPV (95% CI) (%) 99.6 (99.1 to 99.9) 99.6 (99.1 to 99.9) 1.00 (0.99 to 1.01) 0.967
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Both MDCT and PET/CT had a very high specificity (99.4% and 98.7%, respectively) but low sensitivity
(44.4% in both cases). The relative specificity and relative sensitivity of MDCT and PET/CT were not
significantly different (Table 40).
The slightly lower specificity for PET/CT meant that the PPV was estimated to be lower for PET/CT.
However, the difference was not statistically significant. Similarly, the NPV was slightly lower but again the
difference was not significant.
Periampullary carcinoma
The prevalence of periampullary carcinoma in the patient cohort was 6.9% (95% CI 4.8% to 9.0%).
The small number of patients diagnosed with periampullary carcinoma (Table 41) means that statistical
tests comparing the diagnostic tests have low power to detect small or moderate effects.
Both MDCT and PET/CT had a relatively high specificity (95.9% and 97.2%, respectively) but relatively low
sensitivity (71.1% and 65.8%, respectively) (Table 42). The relative specificity of PET/CT compared with
MDCT was statistically significant (p = 0.034) but the practical improvements were outweighed by the
observed, although non-significant, reduction in sensitivity.
TABLE 40 Sensitivity, specificity, PPV and NPV for MDCT and PET/CT in relation to diagnosis of neuroendocrine
tumour
Measure MDCT PET/CT Relative p-value
Sensitivity (95% CI) (%) 44.4 (25.7 to 63.2) 44.4 (25.7 to 63.2) 1.00 (0.67 to 1.33) 1.000
Specificity (95% CI) (%) 99.4 (98.8 to 99.9) 98.7 (97.7 to 99.6) 0.99 (0.98 to 1.00) 0.159
PPV (95% CI) (%) 80.0 (59.8 to 99.9) 63.2 (41.5 to 84.8) 0.79 (0.55 to 1.13) 0.191
NPV (95% CI) (%) 97.2 (95.8 to 98.6) 97.2 (95.8 to 98.6) 1.00 (0.98 to 1.01) 0.977
TABLE 41 Multidetector computed tomography and PET/CT diagnosis against periampullary carcinoma status
Diagnosis Periampullary carcinoma No periampullary carcinoma
MDCT positive 27 21
MDCT negative 11 491
PET/CT positive 25 14
PET/CT negative 13 498
TABLE 42 Sensitivity, specificity, PPV and NPV for MDCT and PET/CT in relation to diagnosis of periampullary
carcinoma
Measure MDCT PET/CT Relative p-value
Sensitivity (95% CI) (%) 71.1 (56.6 to 85.5) 65.8 (50.7 to 80.9) 0.92 (0.74 to 1.11) 0.432
Specificity (95% CI) (%) 95.9 (94.2 to 97.6) 97.2 (95.9 to 98.7) 1.01 (1.00 to 1.03) 0.034
PPV (95% CI) (%) 56.3 (42.2 to 70.3) 64.1 (49.0 to 79.2) 1.14 (0.90 to 1.44) 0.278
NPV (95% CI) (%) 97.8 (96.5 to 99.1) 97.5 (96.1 to 98.8) 1.00 (0.98 to 1.01) 0.633
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Although PET/CT gave an improved PPV, the relative PPV was not significantly different from 1. Moreover,
the estimated NPV was worse for PET/CT than for MDCT, although this differences was also non-significant.
Malignant compared with benign disease
The prevalence of any malignant disease among the patient population was 69.8% (95% CI 66.0% to
73.7%). Table 43 provides the 2 × 2 table for MDCT and PET/CT diagnosis by malignant or benign disease
status (D4).
Both MDCT and PET/CT scans had high sensitivity with respect to detecting any malignancy (97.4% and
97.7%, respectively) but there was no evidence that PET/CT had better sensitivity (p = 0.763) (Table 44).
In contrast, the specificity of PET/CT was considerably higher than that for MDCT (68.7% vs. 47.0%,
relative sensitivity 1.46; p < 0.0001). The improvement in specificity also corresponded with a statistically
significant improvement in PPV, increasing from 80.9% for MDCT to 87.8% for PET/CT (p = 0.0002).
The NPV also improved but by a non-significant margin (relative NPV 1.05; p = 0.24).
Incremental diagnostic benefit for malignancy versus benign
Using the Knottnerus method, estimates of the incremental likelihood ratios corresponding to a positive or
negative PET/CT diagnosis with respect to whether the tumour was malignant or benign were obtained.
In each case, the results of the PET/CT scan had a statistically significant impact on the odds of malignancy.
The results suggest particular benefits of administering PET/CT after a positive MDCT scan. A positive
PET/CT assessment following a positive MDCT assessment was estimated to increase the odds of
malignancy by a further 88.7% (95% CI 55.4% to 134.8%) whereas a negative PET/CT assessment
following a positive MDCT assessment reduced the odds of malignancy by 97.2% (95% CI 94.4% to
99.5%), meaning that malignancy is very unlikely for these patients (NPV 89.4%). A positive PET/CT
assessment following a negative MDCT assessment increased the odds of malignancy by 680% (95% CI
106% to 2735%). However, there was still considerable uncertainty in the diagnosis of these patients
(PPV 50.0%). A negative PET/CT assessment following a negative MDCT assessment decreased the odds
of malignancy by 60.6% (95% CI 25.6% to 90.3%) and these patients were very unlikely to have a
malignancy (NPV 94.7%) (Figure 6).
TABLE 43 Multidetector computed tomography and PET/CT diagnosis against malignancy status
Diagnosis Malignant Benign
MDCT positive 374 88
MDCT negative 10 78
PET/CT positive 375 52
PET/CT negative 9 114
TABLE 44 Sensitivity, Specificity, PPV and NPV of MDT-CT and PET/CT in relation to diagnosis of malignant disease
Measure MDCT PET/CT Relative p-value
Sensitivity (95% CI) (%) 97.4 (95.8 to 99.0) 97.7 (96.1 to 99.2) 1.00 (0.99 to 1.02) 0.763
Specificity (95% CI) (%) 47.0 (39.4 to 54.6) 68.7 (61.6 to 75.7) 1.46 (1.32 to 1.61) < 0.0001
PPV (95% CI) (%) 80.9 (77.3 to 84.5) 87.8 (84.7 to 90.9) 1.08 (1.04 to 1.13) 0.0002
NPV (95% CI) (%) 88.6 (82.0 to 95.2) 92.7 (88.1 to 97.3) 1.05 (0.97 to 1.13) 0.240
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Additional analyses
Analysis of maximum standardised uptake value
A SUVmax. measurement for the primary tumour was available only if a primary tumour was identified. In
addition, in a further 49 cases no SUVmax. was recorded despite identification of a primary tumour (Table 45).
The following analyses use only the data from the 362 patients for whom a primary tumour was identified
and the SUVmax. was recorded.
Distribution of maximum standardised uptake value
The distribution of the SUVmax. was positively skewed, with a median of 7.0 (Table 46).
The median SUVmax. was higher for patients who were confirmed to have pancreatic cancer at D4
(median 7.5) than for patients who did not have pancreatic cancer (median 5.7) diagnosis (Wilcoxon
test, p < 0.0001).
Positive MDCT
LR = 1.837 (1.621 to 2.144)
Negative MDCT
LR = 0.055 (0.027 to 0.100)
Negative PET/CT
LR = 0.028 (0.005 to 0.056)
Positive PET/CT
LR = 1.887 (1.554 to 2.348)
Negative PET/CT
LR = 0.433 (0.106 to 0.795)
Positive PET/CT
Pre-test
LR = 7.800 (2.056 to 28.385)
FIGURE 6 Tree diagram of incremental likelihood ratios (LRs). The values of the LRs are given following positive or
negative MDCT and then positive or negative PET/CT. Figures in parentheses represent 95% CIs.
TABLE 45 Maximum standardised uptake value data completeness
D4 diagnosis No primary tumour identified
Primary tumour identified
SUVmax. missing SUVmax. reported
Positive 12 20 229
Negative 127 29 133
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Diagnostic accuracy of the maximum standardised uptake value for
pancreatic ductal adenocarcinoma
Although the level of SUVmax. provided statistically significant discrimination between patients with and
without pancreatic cancer, the level of discrimination achieved was quite poor. Figure 7 demonstrates that
the area under the curve (AUC) is 0.64 (95% CI 0.57 to 0.70). The optimal cut-off point, if the aim is to
minimise the sum of the error probabilities of the test, is 6.2, meaning that all tumours with a SUVmax.
> 6.2 would lead to a positive diagnosis of PDAC. However, such a test has an estimated sensitivity of only
70.3% and specificity of only 59.4%.
Diagnostic accuracy of the maximum standardised uptake value for
chronic pancreatitis
Patients with chronic pancreatitis for whom a primary tumour was identified on the PET/CT scan tended
to have a lower SUVmax. than those without chronic pancreatitis. However, note that only 20 of the
41 patients with chronic pancreatitis had an identified primary tumour with a measured SUVmax.
The SUVmax. level was a statistically significant indicator of the presence of chronic pancreatitis; however,
the level of discrimination was relatively modest. The estimated AUC was 0.75 (95% CI 0.64 to 0.85)
(Figure 8). The optimal cut-off point, if the aim is to minimise the sum of the error probabilities of the test,
is 6.4, meaning that all tumours with a SUVmax. < 6.4 would lead to a positive diagnosis of chronic
pancreatitis. Such a test has an estimated sensitivity of 85% and specificity of 60%. This cut-off value is
also very similar to the optimal value for assessing PDAC, suggesting that an approach of assuming PDAC
for a SUVmax. of > 6.3 and chronic pancreatitis for a SUVmax. of < 6.3 has some merit.
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FIGURE 7 Receiver operating characteristic curve for the diagnosis of PDAC based on SUVmax.
TABLE 46 Distribution of SUVmax.
Group
Percentiles
0 25 50 75 100
All 1.4 4.9 7.0 10.1 55.0
D4 positive 2.2 5.8 7.5 10.3 55.0
D4 negative 1.4 3.7 5.7 9.5 33.1
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Survival analysis
In total, 186 patients (among the 550 with a per-protocol PET/CT scan and a D4 diagnosis) were observed
to die. Assuming non-informative dropout, estimated 6-month survival was 82.8% (95% CI 79.7% to
86.0%) whereas 12-month survival was 69.0% (95% CI 65.1% to 73.1%). Survival was substantially
lower in patients with a confirmed diagnosis of PDAC, with 6-month survival being 71.4% (95% CI
66.0% to 77.2%) and 12-month survival being 50.9% (95% CI 44.9% to 57.6%) compared with 92.6%
(95% CI 89.6% to 95.7%) and 84.9% (95% CI 80.8% to 89.2%), respectively, for patients without
PDAC. Survival was lower in patients with any malignant disease than in patients with benign disease
(Table 47 and Figures 9 and 10).
Survival by stage of disease
Among patients with a D4 diagnosis of PDAC, 95% had staging information at D2. Patients assessed to
be in stage IA/IB at D2 or not assigned a stage had similar 12-month survival to those assessed to be in
stage IIA or IIB (68.3% vs. 65.5%) (Table 48 and Figure 11). Patients in stages III and IV had poorer
12-month survival (44.8% and 21.0%, respectively).
Effects of baseline variable on survival
Estimated HRs for a Cox proportional hazards model for survival in patients with pancreatic cancer are given
in Table 49. Only WHO status at baseline was significantly associated with survival, with patients with a WHO
status of 1 and a WHO status of 2 or 3 having significantly worse survival than those with a WHO status of 0.
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FIGURE 8 Receiver operating characteristic curve for the diagnosis of chronic pancreatitis based on SUVmax.
TABLE 47 Estimated 6-month and 12-month survival for different diagnosis groups
Group
Estimated survival (95% CI) (%)
6 months 12 months
All patients 82.8 (79.7 to 86.0) 69.0 (65.1 to 73.1)
Pancreatic cancer 71.4 (66.0 to 77.2) 50.9 (44.9 to 57.6)
No pancreatic cancer 92.6 (89.6 to 95.7) 84.9 (80.8 to 89.2)
Malignant disease 76.3 (72.1 to 80.7) 57.7 (52.8 to 63.0)
Benign disease 97.6 (95.3 to 100.0) 94.5 (91.0 to 98.0)
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FIGURE 9 Kaplan–Meier estimate of survival for all patients.
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FIGURE 10 Kaplan–Meier estimates of survival for patients with and without PDAC.
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TABLE 48 Estimated 12-month survival among PDAC patients by diagnosed stage at D2
Stage (determined at D2) No. of patients 12-month survival (95% CI) (%)
IA/IB/no tumour identified 87 68.3 (59.9 to 79.2)
IIA/IIB 66 65.5 (54.5 to 78.7)
III 29 44.8 (29.3 to 68.7)
IV 79 21.0 (13.4 to 33.1)
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FIGURE 11 Estimated survival among PDAC patients grouped by diagnosed stage at D2.
TABLE 49 Estimated effects of baseline variables on survival for patients with PDAC
Variable HR (95% CI) p-value
WHO status 0 1 0.03
WHO status 1 1.62 (1.09 to 2.40)
WHO status 2/3 1.79 (1.01 to 3.17)
Age (per 10 years) 1.10 (0.91 to 1.31) 0.32
Diabetes (type 1 or 2) 0.64 (0.37 to 1.10) 0.11
Female 0.99 (0.69 to 1.43) 0.96
Never smoked 1 0.94
Past smoker 1.01 (0.68 to 1.52)
Current smoker 1.10 (0.66 to 1.81)
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Chapter 4 Health economic analysis
Introduction
Positron emission tomography/computed tomography is widely used across the UK, although the economic
case for its benefits over MDCT alone is scant. The aim of the health economics component of this study,
using data from the Impact of combined modality positron emission tomography with computed tomography
scanning (PET/CT) in the diagnosis and management of pancreatic cancer (PET-PANC) cohort, was to model
the incremental cost-effectiveness of PET/CT compared with MDCT alone in the diagnosis and management
of patients with pancreatic cancer. The PET-PANC study was not a randomised controlled trial but a cohort
study, with the aim of collecting information on how PET/CT affects the diagnosis and management of
patients and HRQoL data, which were previously unavailable. The key point of our analysis was whether
PET/CT changed the diagnosis and management of patients over and above how they would have been
managed on the basis of MDCT alone. To date, there have been few published studies internationally that
could inform the modelling of PET/CT in the diagnosis and management of patients with pancreatic cancer in
a UK setting. This was the challenge for the PET-PANC health economists based at the Centre for Health
Economics and Medicines Evaluation in Bangor.
Existing economic evidence
Evidence on the cost-effectiveness of PET/CT in oncology generally is mixed but largely skewed towards
the procedure not being cost-effective. Some sensitivity analysis brings the incremental cost-effectiveness
ratio (ICER) below National Institute for Health and Care Excellence (NICE) thresholds of £20,000–30,000
per quality-adjusted life-year (QALY), but largely it is found not to be cost-effective in a UK context. This
seems to depend on the type of cancer screened for and the availability of reliable data. More research is
needed as and when reliable data become available.
A rapid review electronic database search for relevant economic evaluations concerning the use of PET/CT
imaging in oncology was undertaken, with searches undertaken in The Cochrane Library [Database of
Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA) database and NHS Economic
Evaluation Database (NHS EED)], EMBASE, PubMed and Web of Science. Studies were eligible for inclusion
if they included full health economic evaluations (cost-effectiveness, cost–utility, cost–benefit analyses)
comparing PET/CT (i.e. integrated PET and MDCT scan) with different invasive and non-invasive diagnostic
strategies in the clinical work-up of cancer patients. Databases were searched between March 2010 and
May 2012 (see Appendix 12 for an example of the search strategies).
Our inclusion criteria identified four studies66–69 (see Appendix 6). Two of these were from the UK,68,69
one was from Denmark66 and one was from Germany.67 One study was a cost-effectiveness analysis,66
one was a cost-effectiveness and cost–utility analysis67 and two were cost–utility analyses.68,69 Two studies
used decision-analytical models68,69 and the other two used Cox proportional hazards and generated
cost-effectiveness acceptability curves (CEACs).66,67 Cost-effectiveness was measured in terms of cost
per avoided thoracotomy66 and cost per QALY.67–69 The evidence on the cost-effectiveness of PET/CT
technology in oncology was mixed. Cost-effectiveness varied according to the type of cancer screened for
and varied further with the different assumptions made about the relevant costs and benefits.
Methods
Outcome measures
The outcome measure for the PET-PANC economic analysis was the QALY. Both NICE and the National
Coordinating Centre for Health Technology Assessment (NCCHTA) support the use of QALYs as an
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outcome measure in technology assessment.70,71 QALYs are an index of health gain, combining survival
and HRQoL.72 We calculated QALYs using the AUC approach by weighting survival by HRQoL weights
(HRQoL utilities values) over the 12-month follow-up period of the PET-PANC study. When possible, the
AUC was calculated in four parts representing each 3-month follow-up period. For each participant the
area under the HRQoL curve gives the total QALYs. HRQoL utilities were generated using European Quality
of Life-5 Dimensions three-level version (EQ-5D-3L)73 data (n = 452) collected in the PET-PANC study.
The EQ-5D is a validated generic health-related preference-based measure developed by the European
Quality of Life group. The EQ-5D provides a single index (utility) value for health status for each patient.
In our model, we calculated the difference in mean QALYs associated with the change in patient
management resulting from the use of PET/CT (over and above those for MDCT alone).
Life-years gained
When patients were alive at 12 months post baseline, life-days were assumed as 365; otherwise, life-days
were calculated by subtracting date of death from date of entry into the study. Life-years were calculated
as life-days divided by 365.
Resource use and costs in secondary and primary care
In the PET-PANC study we measured costs and outcomes from a NHS perspective. We recorded the type
and frequency of patient contacts with NHS secondary and primary care. These included investigations,
treatment and palliation and other elements of secondary, primary and pharmaceutical care. Within cancer
care, we focused on the costs of PET/CT, surgery, chemotherapy, radiotherapy, other drugs, outpatient
appointments and day care and inpatient stays. We collected this information as part of the case report
form (CRF). We took special care to check and maintain the quality of these data. This led to a complete
set of secondary and primary care use data for the 279 participants for whom cost data were available for
use in our economic model.
Sources of unit costs
We drew costs from a number of sources including the Unit Costs of Health and Social Care 201374 and
NHS reference costs for 2012–13.75 The Prescription Cost Analysis (PCA) 201376 was used for costing
drugs. Estimates of the costs of PET/CT were obtained from NHS reference costs. All costs are in
2012–13 pounds sterling unless stated otherwise. A table referencing unit costs for each resource use
category for secondary and primary care is provided in Appendix 7.
Missing data
No formal imputation was carried out on missing data; however, assumptions were made following the
death of a patient. For patients who died during the course of the study, the follow-up period in which
death occurred was calculated based on each follow-up period being 365/4 days long. EQ-5D utility data
were assumed to be equal to zero from the end of the follow-up period in which the patient died. No
assumption was made about costs for the follow-up period during which the patient died; however, costs
for subsequent follow-ups were assumed to be zero.
Cost-effectiveness analysis
Our cost-effectiveness analysis was in three parts: model 1, in which we calculated the marginal cost per
additional correct diagnosis of PDAC using PET/CT and MDCT alone; model 2, in which we calculated the
budget impact of use of PET/CT; and model 3, in which we modelled the change in management of
patients as a result of the use of PET/CT in diagnosis. All health economic modelling was performed in
Microsoft Excel® 2013 (Microsoft Corporation, Redmond, WA, USA).
Model 1: marginal costs of using positron emission tomography/computed
tomography per additional correct diagnosis
Our analysis presents a model in which we calculated the marginal cost per additional correct diagnosis of
PDAC using PET/CT and MDCT alone using national average unit costs for PET/CT and MDCT scans.75
Primary analyses consider the diagnosis of PDAC in the per-protocol (within-range uptake and blood
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glucose) cohort, whereas subgroup analyses consider the impact of PET/CT in the diagnoses of chronic
pancreatitis and malignancy. This analysis was based purely on the cost of PET/CT diagnostics compared
with the cost of MDCT alone. These analyses extend only to the point of diagnosis and exclude any costs
beyond the initial scan pertaining to the ongoing care and management of the patient.
Model 2: budget impact of use of positron emission tomography/
computed tomography
We calculated the wider budget impact for commissioners for various scales of use of PET/CT. Based on
the results from model 1 and published figures for PDAC prevalence (8773 new diagnoses in 2011)
[see www.cancerresearchuk.org/cancer-info/cancerstats/ (accessed 24 May 2016)], we estimated the annual
cost of routine use of PET/CT and the number of additional correct diagnoses, based on a range of
percentages of patients with access to the service. As with model 1, we note that these analyses extend
only to the point of diagnosis.
Model 3: change in management of patients as a result of use of positron
emission tomography/computed tomography in diagnosis – incremental
decision model
For each management strategy (e.g. resection, chemotherapy), patients in the PET-PANC study were
prescribed either strategy X or strategy no X following CT scanning at time point D1. In some cases this
management strategy was changed following PET/CT scanning (D2). Figure 12 presents a schematic of this
change for the management strategy of resection, where a, b, c and d represent the numbers of patients
following each branch of the schematic.
We mapped the data from diagnoses at D1 and D2 into two arms of a decision model, representing
hypothetical management if diagnosis was via CT alone or PET/CT. This is represented in Figure 13.
To assess the cost-effectiveness of the addition of PET/CT, only incremental costs and effects require
consideration. From Figure 13 it can be seen that these incremental effects are represented entirely by the
patients who experienced a change of management following D2.
The impact of change in management strategies on costs, QALYs and life-years was modelled with
regression models using data gathered in the PET-PANC study. Regression inputs reflect the categories of
data collected on the CRF. To account for multiple treatments, QALYs and life-years gained (LYG) were
modelled as decrements (1 –QALY) and (1 – LYG) and combined additively. Costs were also combined
additively. When patients were moved from resection to no resection, this change indicated that the
D
D2
D2
b
aResection
Resection
No resection
Resection
No resection
No resection d
c
FIGURE 12 Study schematic (example of resection).
b + d
a + cResectionCT PET/CT
CT
No resection
Resection
No resection c + d
a + b
FIGURE 13 Decision-analytical model (example of resection).
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cancer had progressed beyond a state where resection would be beneficial, and bypass surgery or an open
and shut laparotomy may have been performed. To adjust for this in the primary model, resection data
were entered into the regression model as ‘resection: no metastases’ and ‘resection: with metastases’,
the latter reflecting the case in which resection was not the optimal management.
In-house data indicated that bypass surgery is associated with increased mortality and a longer recovery
phase than resection. A structural sensitivity analysis adjusted for this. Patients who were indicated a
change of ‘stop resection’ were clinically assessed based on D3 and D4 and categorised whether the
planned surgery would have been a bypass, open and shut laparotomy or resection, with costs and utilities
adjusted accordingly in the model. Cost and utility adjustments for bypass and open and shut laparotomy
were extracted from the study by a further breakdown of patient notes in the ‘resection’ and ‘drainage
procedure’ categories of the CRF. For this model, ‘resection’ was entered as a single variable in the
regression to avoid double counting.
Cost-effectiveness was assessed according to the ICER for the intervention, calculated as:
ICER =
Incremental cost
Incremental QALY
: (4)
An intervention with a lower ICER is deemed to be more cost-effective than one with a higher ICER. NICE
considers an ICER of < £20,000–30,000 per QALY to mean that a health technology represents good
value for money for the NHS in the UK.
Primary analysis was based on QALYs for the within-range cohort of patients (n = 550). As there are
varying costs for PET/CT by department (nuclear medicine, clinical oncology or medical oncology),
sensitivity analysis was carried out using alternative costing assumptions. Analyses are also presented for
LYG. Secondary subgroup analyses were also carried out on all patients (n = 583), patients with a
pancreatic cancer diagnosis at D1 (n = 316) and patients with a pancreatic cancer diagnosis at D1 who
were suitable for resection (n = 217). For all models to retain power, costs, QALYs and LYG were based on
those for the within-range patients. For the ‘within-range’ and ‘all patient’ groups, the cost of PET/CT was
presumed to be instead of the cost of MDCT. For the PDAC and PDAC with resection groups, the cost of
PET/CT was presumed to be in addition to the cost of MDCT.
A probabilistic sensitivity analysis (PSA) assessing the simultaneous uncertainty of model parameters is more
informative than univariate deterministic sensitivity analysis. Correlation between regression coefficients is
reflected in the PSA by use of Cholesky decomposition on the covariance matrix. Uncertainty in the cost
of the PET/CT scan was represented by a normal distribution, with an assumed standard deviation of
£50 to reflect uncertainty. For the PSA, when no patients experienced a given change in management,
0.1 patients were modelled as experiencing the change, to generate a distribution. This is to reflect
changes in management that may occur but did not necessarily occur in the PET-PANC study. PSA was
accomplished by drawing iteratively (10,000 times) from the generated distributions. CIs for incremental
costs and QALYs were generated from the bootstrap simulations. A CEAC was constructed to depict the
probability of the intervention being cost-effective for a given cost-effectiveness or payer threshold.
Results
Quality-adjusted-life-years
Figure 14 shows the progression of the EQ-5D data over time based on diagnosis. Health state is seen to
be worse for patients with PDAC, double cancer (pancreatic cancer plus another primary cancer) and
malignant disease than for patients with benign cysts. We note that the numbers with double cancer
are small (n = 15, 7, 9, 8 and 10 at the respective time points) and so we interpret these results, in
particular the ‘peak’ at 3 months, with extreme caution. For all other diagnoses and time points, n > 40.
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These progressions are in line with what would be expected in the different disease areas and support the
conclusion that patients within the study are representative of the wider population.
Table 50 shows the QALY breakdown by age as calculated by the EQ-5D AUC. It seems that younger
people have higher QALYs; however, care must be taken when interpreting these data as the numbers of
younger people in the sample are very low.
Unit costs
In a UK NHS setting the cost of a standard CT scan as required to diagnose pancreatic cancer is £86
(lower quartile £79, upper quartile £95).75 The corresponding cost for a PET/CT scan is £795 (lower quartile
£793, upper quartile £795). This cost was sourced from nuclear medicine service costs and was the most
conservative estimate (most costly). Costs pertaining to the different service descriptions are summarised in
Table 51.
A cost of £709 can therefore be derived as the additional cost per patient of scanning with PET/CT in place
of scanning with CT alone. If PET/CT is to be used for diagnosis subsequent to CT, then the additional cost
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FIGURE 14 European Quality of Life-5 Dimensions utility data over time by disease status.
TABLE 50 Outcomes in terms of EQ-5D AUC over 12 months by age
Age (years)
EQ-5D AUC (QALYs)
n Mean Standard deviation
All 452 0.554 0.30
< 25 2 0.656 0.23
25–34 3 0.813 0.15
35–44 17 0.526 0.26
45–54 62 0.540 0.28
55–64 108 0.554 0.30
65–74 165 0.565 0.31
75+ 95 0.539 0.31
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per patient is equivalent to the cost of the PET/CT scan, that is, £795. For all analyses, when PET/CT and
CT costs are considered alongside each other, both costs are taken from the same departmental source
for consistency.
Comparing the PET/CT lower quartile with the CT upper quartile gives a lower bound on the marginal cost
of £698. Comparing the PET/CT upper quartile with the CT lower quartile gives an upper bound on the
marginal cost of £714.
Frequency of resource use
The mean frequency of use of primary and secondary care services over the 12 months of the study is
shown in Table 52. The table in Appendix 7 provides the 3-monthly breakdown showing the number of
TABLE 51 Summary of CT and PET/CT costs
Service Point estimate (£) Lower quartile (£) Upper quartile (£)
Nuclear medicine CT 86 79 95
PET/CT 795 793 795
Clinical oncology CT 121 84 162
PET/CT 563 92 793
Medical oncology CT 136 84 174
PET/CT 602 547 793
TABLE 52 Frequency of contacts with primary and secondary care health services by 583 patients up to 12 months
(ITT cohort) measured by number of visits
Resource use category Mean frequency of service use over 12 months
Primary care
Cancer nurse 0.44
GP 0.47
Practice nurse (GP clinic) 0.56
Community nurse 0.72
Health visitor 0.00
Psychologist 0.01
Counsellor 0.02
Physiotherapist 0.05
Occupational health therapist 0.01
Care manager 0.04
Social worker 0.01
Home care worker 0.16
Care attendant 0.02
Carer’s support worker 0.01
Chiropodist 0.03
Dietitian 0.04
Self-help group 0.00
Other 0.22
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patients in each follow-up period. It can be seen that the most frequent resource use in primary care is for
community nurses, followed by practice nurses and general practitioners (GPs). For secondary care the
most frequent resource use is for outpatient visits.
Costs over the 12-month study period
Table 53 shows the sources of unit costs used in the economic model. Appendix 8 provides further
information on resource use data and unit costs.
TABLE 52 Frequency of contacts with primary and secondary care health services by 583 patients up to 12 months
(ITT cohort) measured by number of visits (continued )
Resource use category Mean frequency of service use over 12 months
Secondary care
Oncology inpatient ward (bed-days) 0.67
Medical inpatient ward (bed-days) 1.43
Continuing care/respite inpatient ward (bed-days) 0.05
Assessment/rehabilitation inpatient ward (bed-days) 0.13
Other inpatient ward (bed-days) 1.08
Intensive care inpatient ward (bed-days) 0.10
Inpatient consultations (including PAMs) (bed-days) 0.32
Outpatient visits (including consultations) (attendance) 3.00
Accident and emergency (attendance) 0.27
Day hospital (attendance) 0.39
PAM, patient-activated measure.
TABLE 53 Summary of sources of resource use data and unit costs
Item of resource use Source of resource usea Source of unit cost
Primary care
Cancer nurse CSRI Unit Costs of Health and Social Care 201374
GP CSRI Unit Costs of Health and Social Care 201374
Practice nurse (GP clinic) CSRI Unit Costs of Health and Social Care 201374
Community nurse CSRI Unit Costs of Health and Social Care 201374
Health visitor CSRI Unit Costs of Health and Social Care 201374
Psychologist CSRI Unit Costs of Health and Social Care 201374
Counsellor CSRI Unit Costs of Health and Social Care 201374
Physiotherapist CSRI Unit Costs of Health and Social Care 201374
Carer’s support worker CSRI Unit Costs of Health and Social Care 201374
Occupational health therapist CSRI Unit Costs of Health and Social Care 201374
Care manager CSRI Unit Costs of Health and Social Care 201374
Social worker CSRI Unit Costs of Health and Social Care 201374
continued
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The resultant mean total costs of service use by patients in the PET-PANC cohort are shown in Table 54, with
the full table including the 3-month breakdown provided in Appendix 10. These costs are in UK pounds
sterling for the year 2012–13. It can be seen that for primary care the highest cost was for GPs, followed by
community nurses and practice nurses. For secondary care the highest cost was for inpatient stays.
TABLE 53 Summary of sources of resource use data and unit costs (continued )
Item of resource use Source of resource usea Source of unit cost
Home care worker CSRI Unit Costs of Health and Social Care 201374
Care attendant CSRI Unit Costs of Health and Social Care 201374
Chiropodist CSRI Unit Costs of Health and Social Care 201374
Dietitian CSRI Unit Costs of Health and Social Care 201374
Self-help group CSRI Unit Costs of Health and Social Care 201374
Other CSRI Unit Costs of Health and Social Care 201374
Secondary care
Oncology inpatient ward CSRI Department of Health75
Medical inpatient ward CSRI Department of Health75
Continuing care/respite inpatient ward CSRI www.stlukes-hospice.co.uk/about-us/financial-
breakdown/ (accessed December 2014)
Assessment/rehabilitation inpatient ward CSRI Department of Health75
Other inpatient ward CSRI Department of Health75
Intensive care inpatient ward CSRI Department of Health75
Inpatient consultations (including PAMs) CSRI Department of Health75
Outpatient visits (including consultations) CSRI Department of Health75
Accident and emergency CSRI Department of Health75
Day hospital CSRI Department of Health75
Other CSRI Department of Health75
CSRI, Client Service Receipt Inventory; PAM, patient-activated measure.
a CSRI as part of the CRF (see Appendix 9).
TABLE 54 Mean costs over 12 months for the ITT cohort (n= 583)
Resource use category Mean cost (£)
Primary care
Cancer nurse 13.21
GP 77.89
Practice nurse (GP clinic) 26.22
Community nurse 49.48
Health visitor 0.34
Psychologist 0.58
Counsellor 1.04
Physiotherapist 1.89
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Cost-effectiveness analysis
Model 1: marginal costs of using positron emission tomography/computed
tomography for diagnosis
All patients (intention to treat)
The PET-PANC study has shown that CT (D1) had a sensitivity of 87.4% and a specificity of 69.8%, with
a diagnostic accuracy of 78.2% for the 583 ITT patients. PET/CT (D2) had a sensitivity of 90.3% and a
specificity of 76.1%, with an overall diagnostic accuracy of 82.8%. The increased accuracy corresponds to
an additional 27 correct diagnoses, corresponding to an increment of 5.9% (100 × 27/456) in accuracy rate.
The incremental cost per additional accurate diagnosis was £15,309 (955 CI £15,072 to £15,460),
corresponding to £69,810 (95% CI £68,727 to £70,499) per additional percentage gained in diagnostic
accuracy rate.
All in-range patients (per protocol)
In the per-protocol analysis, CT alone had a sensitivity of 88.5% and a specificity of 70.6%, with a
diagnostic accuracy of 79.1%. PET/CT had a sensitivity of 92.7% and a specificity of 75.8%, with an
overall diagnostic accuracy of 83.8%. The increased accuracy corresponds to an additional 26 correct
diagnoses out of 550 patients, corresponding to an increment of 6.0% in accuracy rate.
TABLE 54 Mean costs over 12 months for the ITT cohort (n= 583) (continued )
Resource use category Mean cost (£)
Occupational health therapist 0.33
Care manager 1.66
Social worker 0.69
Home care worker 3.27
Care attendant 0.67
Carer’s support worker 0.19
Chiropodist 0.78
Dietitian 1.26
Self-help group 0.03
Other 12.79
Secondary care
Oncology inpatient ward 433.53
Medical inpatient ward 1015.59
Continuing care/respite inpatient ward 21.13
Assessment/rehabilitation inpatient ward 46.04
Other inpatient ward 589.37
Intensive care inpatient ward 149.05
Inpatient consultations (including PAMs) 80.04
Outpatient visits (including consultations) 444.14
Accident and emergency 41.73
Day hospital 77.53
Other 274.53
PAM, patient-activated measure.
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For the per-protocol cohort, the incremental cost per additional accurate diagnosis was £14,998 (95% CI
£14,765 to £15,146), corresponding to £65,242 (95% CI £64,229 to £65,886) per additional percentage
gained in diagnostic accuracy rate.
Chronic pancreatitis
Considering chronic pancreatitis, CT alone had a diagnostic accuracy of 93.8% whereas PET/CT had a
diagnostic accuracy of 94.5%. An additional four patients in 550 were accurately diagnosed with PET/CT,
with an increase in diagnostic accuracy rate of 0.775%. This corresponds to an incremental cost per
additional accurate diagnosis of £97,488 (95% CI £95,975 to £98,450) or a cost of £503,035 (95% CI
£495,231 to £508,002) per additional percentage gained in diagnostic accuracy rate.
Malignant compared with benign disease
Considering malignant compared with benign disease, CT alone had a diagnostic accuracy of 82.2%
whereas PET/CT had a diagnostic accuracy of 88.9%. An additional 37 patients in 550 were diagnosed
correctly with PET/CT, with an increase in diagnostic accuracy rate of 8.2%. This corresponds to an
incremental cost per additional accurate diagnosis of £10,539 (95% CI £10,376 to £10,643) or a cost of
£47,637 (95% CI £46,898 to £48,107) per additional percentage gained in diagnostic accuracy rate.
Malignant cystic neoplasm
Considering malignant cystic neoplasm, CT alone had a diagnostic accuracy of 92.8% whereas PET/CT had
a diagnostic accuracy of 95.8%. An additional 18 patients in 550 were diagnosed correctly with PET/CT,
with an increase in diagnostic accuracy rate of 3.5%. This corresponds to an incremental cost per
additional accurate diagnosis of £21,664 (95% CI £21,328 to £21,878) or a cost of £110,269 (95% CI
£108,558 to £111,358) per additional percentage gained in diagnostic accuracy rate.
These analyses extend only to the point of diagnosis and exclude any costs beyond the initial scan
pertaining to the ongoing care and management of patients. To explore beyond this point, capturing the
costs and effects of differences in changes of management, a more complex economic model is required.
Model 2: budget impact of use of positron emission tomography/
computed tomography
We calculated the wider budget impact for commissioners for various scales of use of PET/CT.
In the UK in 2011 the incidence of pancreatic cancer was 9.7 per 10,000, corresponding to 8773
new diagnoses per year, making pancreatic cancer the 10th most common cancer in the UK
(see www.cancerresearchuk.org/cancer-info/cancerstats/).
Table 55 shows the breakdown of costs to the NHS and additional diagnoses based on 10%, 25%,
50% and 100% of these patients theoretically having had access to PET/CT.
TABLE 55 Budget impact of the use of PET/CT for diagnosing pancreatic cancer
Patients with access
to PET/CT (%)
Additional cost (£),
mean (LH, HL)
Additional accurate diagnoses, n
PDAC
Chronic
pancreatitis Malignancy
Malignant cystic
neoplasm
10 622,006 (612,355, 628,147) 41 6 59 29
25 1,555,014 (1,530,889, 1,570,367) 102 16 148 72
50 3,110,029 (3,061,777, 3,140,734) 203 32 295 144
100 6,220,057 (6,123,554, 6,281,468) 406 64 590 287
HL, PET/CT upper quartile cost, CT lower quartile cost (greatest marginal cost); LH, PET/CT lower quartile cost, CT upper
quartile cost (smallest marginal cost).
Note
The figure of 8773 pertains to actual diagnoses; the population with suspected pancreatic cancer (pre diagnosis) is larger
and thus there would be an increased impact if this population were to be considered.
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Model 3: modelling the change in management of patients as a result of use
of positron emission tomography/computed tomography in diagnosis
Model inputs
Incremental costs and outcomes were generated for the per-protocol population using a regression
analysis. The results of these regressions are presented for the primary model in Table 56 and for the
structural sensitivity analysis in Table 57. It should be noted that in many cases patients would experience
more than one management strategy. Negative coefficients for incremental costs for neoadjuvant
chemotherapy, further investigations, biopsy and follow-up do not reflect negative costs but suggest that
patients following these pathways generate less costs than average. Likewise, negative coefficients for
QALY decrements for adjuvant chemotherapy, resection (no metastases) and further investigations do not
indicate a QALY gain but a reduced QALY decrement compared with the average patient. Note that the
coefficient for resection (no metastases) is negative whereas the coefficient for resection (with metastases)
is positive, indicating a larger QALY loss. In Table 57, resection is treated as a single input regardless of
metastases. This is because there is some overlap in the recording of some resection and bypass patients
and we wished to avoid any double counting of increased costs and QALY decrements associated with
bypass surgery. The patients entered into the regression as ‘resection’ in this case were those who had
only a resection procedure and not a bypass.
Table 58 shows the adjustments in costs and utility for the structural sensitivity analysis based on data from
patients who underwent bypass or open and shut laparotomy in the PET-PANC study. As there were no
cost observations for open and shut laparotomy, no adjustment was made and the cost of care in this
instance was treated as equivalent to that for resection. Note that these values represent the total costs
and utilities of all treatments for these patients as we were interested in the differences between resection
and bypass and between resection and open and shut laparotomy. The differences are listed in the third
column (‘Adjustment from resection’); these were then applied to the ‘resection’ coefficients from Table 57
to calculate the values used in the model, which are presented in the final column of Table 58.
Table 59 presents the change in management model inputs for the per-protocol primary analysis (column 2)
and subgroup analyses of all patients (column 3), patients diagnosed with PDAC (column 4) and patients
TABLE 56 Model inputs from regression analysis: primary model
Management
Incremental costs
(n= 255)
QALY decrements
(n= 421)
Life-year decrements
(n= 550)
Mean SE Mean SE Mean SE
Neoadjuvant chemotherapy –3 7807 0.0276 0.1606 –0.0698 0.1000
Adjuvant chemotherapy 4980.71 2568 –0.0686 0.0410 –0.0477 0.0351
Palliative chemotherapy 4199.50 2500 0.1121 0.0386 0.1236 0.0315
Resection (no metastases) 5090 2313 –0.0662 0.0373 –0.0319 0.0306
Resection (with metastases) 15645 9521 0.1477 0.1237 0.1537 0.1153
Further investigations –1207 2070 –0.0636 0.0369 –0.0776 0.0298
Biopsy –1652 2018 0.0273 0.0339 0.0245 0.0274
Drainage procedure 4361 2721 0.0926 0.0449 0.0468 0.0381
Best supportive care 1321 2971 0.2693 0.0470 0.3262 0.0399
Follow-up, no further investigations –5618 7629 0.0053 0.1223 –0.1006 0.1144
Other 3739 2209 0.0037 0.0321 0.0123 0.0260
Constant 8337 228 0.4230 0.0374 0.1171 0.0305
SE, standard error.
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TABLE 57 Model inputs from regression analysis: structural sensitivity analysis
Management
Incremental costs
(n= 255)
QALY decrements
(n= 421)
Life-year decrements
(n= 550)
Mean SE Mean SE Mean SE
Neoadjuvant chemotherapy –99 7811 0.0305 0.1608 –0.0684 0.1001
Adjuvant chemotherapy 5135 2566 –0.0709 0.0415 –0.0491 0.0352
Palliative chemotherapy 4120 2501 0.1154 0.0393 0.1256 0.0315
Resection 5135 2314 –0.0590 0.0396 –0.0269 0.0305
Further investigations –1324 2068 –0.0613 0.0372 –0.0762 0.0299
Biopsy –1693 2019 0.0261 0.0343 0.0237 0.0275
Drainage procedure 4313 2722 0.0904 0.0521 0.0450 0.0381
Best supportive care 1278 2972 0.2703 0.0472 0.3269 0.0400
Follow-up, no further investigations –5809 7632 0.0041 0.1224 –0.1015 0.1146
Other 3672 2210 0.0305 0.1608 0.0131 0.0260
Constant 8461 2283 0.4213 0.0375 0.1160 0.0306
SE, standard error.
TABLE 58 Cost and utility adjustments for the model of bypass and open and shut laparotomy
Outcome
measure
Point estimate Adjustment from resection Values used in the model
Resection (n)
Open and shut
laparotomy (n) Bypass (n)
Open and shut
laparotomy Bypass
Open and shut
laparotomy Bypass
Cost (£) 15,863 (115) No observations 16,697 (13) 0 834 5135 5969
QALY
decrement
0.3432 (187) 0.8141 (3) 0.5370 (19) 0.4708 0.1938 0.4118 0.1348
Life-year
decrement
0.0769 (232) 0.3486 (4) 0.2689 (22) 0.2718 0.1920 0.2449 0.1651
TABLE 59 Modelled changes in management taken from changes in management as a result of the use of PET/CTa
Change
Within range
(N= 550), n
All patients
(N= 583), n
PDAC
(N= 316 of 550), n
PDAC and resection
(N= 217 of 550), n
Stop resection 59 64 35 35
Start resection 20 22 8 8
Stop palliative chemotherapy 1 1 0 0
Start palliative chemotherapy 27 28 23 21
Stop neoadjuvant chemotherapy 1 1 1 1
Start further investigations 28 29 14 11
Start best supportive care 1 1 1 1
a No management change recorded was listed as zero.
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diagnosed with PDAC for whom resection was the indicated treatment (column 5). Subgroup analyses
related to the 550 within-range patients. The model assumes that the only changes in management
are those deemed to be attributable to PET and that all costs and utilities not relating to a change of
management remain the same. Table 60 shows the change in management model inputs for the structural
sensitivity analysis, in which clinical opinion was used to judge whether patients would have likely
undergone a resection, bypass or open and shut laparotomy following the D1 diagnosis.
The results from the basic change of management model are presented in Table 61. For within-range
patients the incremental cost of PET/CT was estimated as being –£645 (95% CI –£2743 to £1314) for
nuclear medicine and –£912 (95% CI –£2927 to £1045) for clinical oncology and the mean QALY gain
associated with PET/CT was 0.0157 (95% CI –0.0101 to 0.0430). PET/CT dominates CT as PET/CT is both
less costly and more effective. Similar results were seen for the subgroup analyses, with the lowest cost
and highest QALY gain seen for the PDAC with resection group.
The results of the model that considers bypass surgery or open and shut laparotomy are presented in
Table 62. For within-range patients the incremental cost of PET/CT was estimated as being £419 (95% CI
–£138 to £930) for nuclear medicine and £152 (95% CI –£399 to £688) for clinical oncology and the
TABLE 60 Modelled changes in management including bypass and open and shut laparotomya
Change
Within range
(N= 550), n
All patients
(N= 583), n
PDAC
(N= 316 of 550), n
PDAC and resection
(N= 217 of 550), n
Stop open and shut laparotomy 2 3 1 1
Stop bypass 37 39 26 26
Stop resection 20 22 8 8
Start resection 20 22 8 8
Stop palliative chemotherapy 1 1 0 0
Start palliative chemotherapy 27 28 23 21
Stop neoadjuvant chemotherapy 1 1 1 1
Start further investigations 28 29 14 11
Start best supportive care 1 1 1 1
a No management change recorded was listed as zero.
TABLE 61 Model results per patient: primary model
Outcome measure
Within range All patients PDAC PDAC and resection
Nuclear
medicine
Clinical
oncology
Nuclear
medicine
Clinical
oncology
Nuclear
medicine
Clinical
oncology
Nuclear
medicine
Clinical
oncology
Incremental
costs (£)
–645 –912 –680 –947 –639 –906 1275 –1542
Incremental QALYs 0.0157 0.0163 0.0119 0.0175
Cost per QALY
gained (£)
PET/CT dominates
Incremental
life-years
0.0150 0.0155 0.0110 0.0161
Cost per LYG (£) PET/CT dominates
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mean QALY gain associated with PET/CT was 0.0078 (95% CI 0.0012 to 0.0172). For nuclear medicine,
the ICERs were £53,677 per QALY gained and £45,423 per LYG. Based on the upper end of the NICE
threshold, £30,000 per QALY, these estimates suggest that PET/CT is not cost-effective. Although the
ICER was lower for all patients, PET/CT was not cost-effective for any subgroup using nuclear medicine
costs for PET/CT. Using clinical oncology costs within the model, for within-range patients the ICERs were
£19,445 per QALY and £16,455 per LYG, which are borderline cost-effective at the lower NICE threshold
of £20,000 per QALY and cost-effective at the upper end of the NICE threshold. The most cost-effective
subgroup was again the PDAC with resection subgroup, with the ICER ranging from £4626 to £34,654.
Probabilistic sensitivity analysis results
Probabilistic sensitivity analysis was performed as described in the methods section. The results of the
10,000 simulations for both nuclear medicine PET/CT costs and clinical oncology PET/CT costs for both
model structures are plotted on cost-effectiveness planes in Figure 15. The planes illustrate the joint
distributions of the incremental costs and QALYs. Blue and black lines indicate £20,000 per QALY and
£30,000 per QALY thresholds, respectively. Points below the lines are considered cost-effective at
TABLE 62 Model results per patient: bypass and open and shut laparotomy
Outcome measure
Within range All patients PDAC PDAC and resection
Nuclear
medicine
Clinical
oncology
Nuclear
medicine
Clinical
oncology
Nuclear
medicine
Clinical
oncology
Nuclear
medicine
Clinical
oncology
Incremental
costs (£)
419 152 411 144 447 180 308 41
Incremental QALYs 0.0078 0.0084 0.0060 0.0089
Cost per QALY
gained (£)
53,677 19,445 48,683 17,027 75,069 30,252 34,654 4626
Incremental
life-years
0.0092 0.0096 0.0073 0.0108
Cost per LYG (£) 45,423 16,455 42,786 14,964 60,947 24,561 28,556 3812
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FIGURE 15 Cost-effectiveness planes. (a) Nuclear medicine costs in the primary model; (b) clinical oncology costs in
the primary model; (c) nuclear medicine costs in the bypass and open and shut laparotomy model structure; and
(d) clinical oncology costs in the bypass and open and shut laparotomy model structure. (continued )
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FIGURE 15 Cost-effectiveness planes. (a) Nuclear medicine costs in the primary model; (b) clinical oncology costs in
the primary model; (c) nuclear medicine costs in the bypass and open and shut laparotomy model structure; and
(d) clinical oncology costs in the bypass and open and shut laparotomy model structure.
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the given threshold. An ‘×’ marks the point estimate of the ICER. For the conservative estimate associated
with nuclear medicine in the primary model, 24% of simulations are in the north-east quadrant (higher
cost, higher QALYs), 3% are in the north-west quadrant (higher cost, lower QALYs), 64% are in the
south-east quadrant (lower cost, higher QALYs) and 9% are in the south-west quadrant (lower cost,
lower QALYs). For clinical oncology costs in the primary model, 17% of simulations are in the north-east
quadrant, 2% are in the north-west quadrant, 71% are in the south-east quadrant and 10% are in the
south-west quadrant.
Modelling bypass and open and shut laparotomy associated with nuclear medicine costs, 90% of
simulations are in the north-east quadrant, 4% are in the north-west quadrant, 6.19% are in the
south-east quadrant and 0.3% are in the south-west quadrant. For clinical oncology costs, 68% of
simulations are in the north-east quadrant, 4% are in the north-west quadrant, 27% are in the south-east
quadrant and 1% are in the south-west quadrant.
Cost-effectiveness acceptability curves were generated, indicating the probability that PET/CT is
cost-effective over a variety of cost-effectiveness thresholds. The CEACs are illustrated in Figure 16 and
show that, for the primary model, for nuclear medicine costs the probability of being cost-effective at the
£20,000 per QALY threshold is 82% and at the £30,000 per QALY threshold is 85%. For clinical oncology
costs the probabilities are 88% at the £20,000 per QALY threshold and 90% at the £30,000 per QALY
threshold; it is likely from this model that PET/CT would be cost-effective for the UK NHS. For the structural
sensitivity analysis and conservative nuclear medicine costs, the probability of PET/CT being cost-effective at
the £30,000 per QALY threshold is 28% and at the £20,000 per QALY threshold is 18%. At these costs it
is unlikely that PET/CT would be cost-effective from the perspective of the UK NHS. Using clinical oncology
as the source of PET/CT costs, the probability of PET/CT being cost-effective at the £30,000 per QALY
threshold is 60% and at the £20,000 per QALY threshold is 50%. Based on these costs, it is likely that
PET/CT would be cost-effective from the perspective of the UK NHS.
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FIGURE 16 Cost-effectiveness acceptability curves. (a) Nuclear medicine costs in the primary model; (b) clinical
oncology costs in the primary model; (c) nuclear medicine costs in the bypass and open and shut laparotomy model
structure; and (d) clinical oncology costs in the bypass and open and shut laparotomy model structure. (continued )
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FIGURE 16 Cost-effectiveness acceptability curves. (a) Nuclear medicine costs in the primary model; (b) clinical
oncology costs in the primary model; (c) nuclear medicine costs in the bypass and open and shut laparotomy model
structure; and (d) clinical oncology costs in the bypass and open and shut laparotomy model structure. (continued )
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Summary
Model 3 (change of management model, primary model) indicates that PET/CT dominates management
based on CT alone. This is largely because of the number of unnecessary surgeries avoided. The probability
of cost-effectiveness at a threshold of £20,000 per QALY ranges from 82% to 90%, according to the
source of PET/CT costs used. Our structural sensitivity analysis considers the likely prognoses of patients
who undergo contraindicated resection surgery. The ICER ranges from £19,445 per QALY to £53,557
per QALY depending on the source of PET/CT costs used. The corresponding probabilities of being
cost-effective range from 18% to 50% at the lower NICE threshold of £20,000 per QALY and from 28%
to 60% at the upper NICE threshold of £30,000 per QALY. For both models, PET/CT is seen to be most
cost-effective for the PDAC with resection subgroup. The ICER point estimate depends on the source
of PET/CT costs used and it is a matter of judgement which is chosen for analysis. We chose the most
conservative (and highest costs) for our base-case analysis.
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FIGURE 16 Cost-effectiveness acceptability curves. (a) Nuclear medicine costs in the primary model; (b) clinical
oncology costs in the primary model; (c) nuclear medicine costs in the bypass and open and shut laparotomy model
structure; and (d) clinical oncology costs in the bypass and open and shut laparotomy model structure.
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Chapter 5 Discussion
Introduction
The accurate diagnosis and staging of pancreatic cancer is essential to ensure that the most appropriate
management is planned for patients in a timely and efficient manner. The standard diagnostic pathway for
pancreatic cancer relies on contrast-enhanced CT as the mainstay for diagnosis with the addition of MRI
and EUS in patients with equivocal liver and pancreatic lesions, respectively. The role of PET or PET/CT in
the diagnostic algorithm for pancreatic cancer has been under review for many years. The benefits in terms
of diagnosis and management have been reported mainly in single-centre studies. The lack of multicentre
prospective confirmatory studies has meant that widespread take-up of PET/CT as a standard diagnostic
tool in pancreatic cancer diagnosis has not happened. The lack of cost-effectiveness data has also
hampered the widespread use of PET/CT in health-care systems. The PET-PANC study is the first
large-scale, multicentre diagnostic accuracy study of PET/CT in pancreatic cancer, which also modelled
the cost-effectiveness of this approach.
Principal findings
Diagnostic accuracy and incremental benefit of positron emission
tomography/computed tomography
Between 2011 and 2013, 583 patients with suspected pancreatic cancer from 18 UK sites underwent
PET/CT scans, of whom 550 had PET/CT scans completed according to protocol. The primary outcome
measure was diagnostic accuracy and incremental benefit of PET/CT for pancreatic cancer. Adherence to
the PET/CT protocol was essential to ensure that scans were at an accepted level for quality assurance.
This would mean that the results would be applicable across multiple sites. There were 33 scans that were
out of range, because of either abnormal blood glucose levels or PET uptake times; therefore, analyses were
undertaken on the whole population with PET/CT scans and the per-protocol population. Sensitivity and
specificity for the ITT and per-protocol populations were 90.3% and 76.1% and 92.7% and 75.8%,
respectively. The relative sensitivity and specificity of PET/CT compared with MDCT was significantly higher
in the per-protocol group, confirming that PET/CT was more accurate than standard MDCT. For the
whole population, only the relative sensitivity (not the specificity) of PET/CT compared with MDCT was
significantly higher. This highlights how the PET/CT protocol can affect accuracy in terms of the specificity of
PET/CT. Out-of-range scans in this study would lead to higher false-negative rates. Part of the reason for
out-of-range scans was high blood glucose levels at the time of scanning. In this study 17% of patients were
diabetic and this prevalence would very likely be replicated in pancreatic MDT populations across the country.
Good diabetic control is therefore essential for accurate PET/CT scans in this population. Overall, these results
confirm the significant superiority of PET/CT compared with MDCT in the diagnosis of pancreatic cancer.
The incremental diagnostic benefit of PET/CT in addition to MDCT was quantified using incremental
likelihood ratios. These demonstrated that PET/CT significantly increased diagnostic accuracy in all
scenarios. Following a positive diagnosis of pancreatic cancer on MDCT, a positive PET/CT scan increased
the odds of pancreatic cancer by 55% and a negative PET/CT scan decreased the odds of pancreatic
cancer by 95%. Following a negative diagnosis of pancreatic cancer on MDCT, a positive PET/CT scan
increased the odds of pancreatic cancer by 538% and a negative PET/CT scan decreased the odds of
pancreatic cancer by 46%.
Patients with no pancreatic cancer detected on PET/CT following a positive MDCT scan were unlikely to
have pancreatic cancer (NPV of 89%). In contrast, although a positive diagnosis on PET/CT following a
negative MDCT scan increased the odds of PDAC, the overall diagnosis was still highly uncertain (PPV of
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50%). This latter result suggests that if both tests are performed there is benefit in combining the results
rather than taking the PET/CT result alone. In particular, patients who were positive on MDCT and PET/CT
were much more likely to have PDAC than patients who were positive only for PET/CT (PPV of 80% vs.
50%). The result of MDCT is less important if the PET/CT result is negative (NPV of 93% if both tests are
negative vs. NPV of 89% if the PET/CT scan is negative after a positive MDCT scan). These results
demonstrate that there is a substantial diagnostic benefit for patients of receiving a PET/CT scan after a
potential pancreatic cancer is detected on MDCT.
We also assessed clinician certainty following PET/CT using both quantitative and qualitative
measurements. With both methods there was a significant increase in clinicians’ perceived certainty of
diagnosis after PET/CT (p = 0.0001). Clinicians were 12 times more likely to believe that they were more
certain in their diagnosis than they were to be less certain. Assessing the accuracy of the clinicians’
perceived certainty also indicated that the clinicians’ predictions (interpreting their level of certainty as a
probability) were significantly improved by the PET/CT scan result (p < 0.001). These results suggest that
the use of PET/CT increases the level of certainty and the predictions of the clinicians, which may
contribute to better planned management overall.
Impact of positron emission tomography/computed tomography on
diagnosis, staging and management
The difference in diagnoses following MDCT and then PET/CT drives the relative sensitivity and specificity
of PET/CT compared with MDCT. For pancreatic cancer diagnosis, there was a greater number of cases in
which the PET/CT diagnosis was correct than in which the MDCT diagnosis was correct, indicating that
PET/CT performs better. This was considered for patients with pancreatic cancer and patients with a
diagnosis of malignancy. PET/CT changed the diagnosis correctly for diagnoses of both pancreatic cancer
and not pancreatic cancer in 46 patients (8.3%). PET/CT incorrectly changed the diagnosis in 20 patients
(3.6%). Considering the diagnosis of malignancy in general, PET/CT correctly changed the diagnosis in
48 patients (8.7%) and incorrectly changed the diagnosis in 11 patients (2%). Therefore, in terms of
relative sensitivity and specificity, PET/CT has a significant impact on diagnosis compared with MDCT.
The accuracy of staging among patients with early-stage disease (lymph node-negative disease) was
slightly worse under PET/CT than under MDCT, with more incorrect (eight patients) than correct
(six patients) changes. However, the difference was not statistically significant (p = 0.79). Significantly more
patients with stage IIB disease (lymph node-positive disease) were correctly staged by PET/CT than by
MDCT, with 22 patients (21%) moving to the correct stage compared with five patients (5%) moving to
the wrong stage (p = 0.002). PET/CT had no significant effect on the accuracy of staging for patients in
stage III. Significantly more patients in staging group IV (metastatic disease) were changed to the correct
stage (27 patients) than moved to an incorrect stage (one patient) (43% vs. 2%; p < 0.001). The effect
of PET/CT was to change to the correct staging group significantly more often than to change from
the correct group to an incorrect group (p < 0.001). This change in stage was limited to stage IIB and
IV patients; there was no significant impact of PET/CT in staging larger tumours invading surrounding
structures (stage III). Overall, PET/CT more accurately staged patients in terms of identifying lymph node
disease in smaller tumours and metastatic disease.
The changes in diagnosis and staging also have implications for changes in the management of patients.
Anticipated management was documented after MDCT and PET/CT and actual management was then
recorded. Clinicians documented that PET/CT had influenced their management decisions for 45% of
patients. Overall, 30% of patients underwent a management change throughout the study. PET/CT
changed the management of 11% of patients in the overall study population.
The types of management changes resulting from the use of PET/CT were then analysed. The most
common alteration in management was the change from resection to no resection, which occurred in
60 patients, representing 11% of all patients and 21% of patients scheduled for surgery after MDCT.
In total, 13% of patients not thought to need surgical resection following MDCT were then planned
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for resection following PET/CT. Changes relating to the commencement or cessation of chemotherapy
were less common. The biggest impact of PET/CT was on those patients who were identified as having
resectable tumours on MDCT and who were then deemed not suitable for resection following PET/CT.
This would place PET/CT as an integral component of the staging process for patients who are thought to
have resectable tumours at MDCT, to identify patients who would not benefit from surgery because of
more advanced disease.
Impact of positron emission tomography/computed tomography on the
diagnosis of chronic pancreatitis
The prevalence of chronic pancreatitis was quite low in the patient population (41 patients; 7.5%).
Therefore, the power to assess the diagnostic technologies was limited. Both MDCT and PET/CT had
relatively high specificity (98.4% in each case) but low sensitivity for the diagnosis of chronic pancreatitis.
The sensitivity of PET/CT was higher than that for MDCT (45.2% vs. 36.6%); however, this effect did not
attain statistical significance (relative sensitivity 1.27; p = 0.066). Although a positive diagnosis of chronic
pancreatitis from the PET/CT or MDCT scan result greatly increased the odds of a patient having chronic
pancreatitis, there was still considerable uncertainty about the diagnosis. The main diagnostic dilemma
facing clinicians is when a patient already has chronic pancreatitis and pancreatic cancer is suspected.
In this population only one patient had chronic pancreatitis and pancreatic cancer. The sensitivity and
specificity of PET/CT in this study do not support the routine use of PET/CT in the diagnosis and assessment
of patients with chronic pancreatitis. The use of PET/CT to differentiate pancreatic cancer in patients with
chronic pancreatitis cannot be supported based on the findings of this study.
Benefits of positron emission tomography/computed tomography for
different subgroups
A GEE subgroup analysis was performed for all those patients who had out-of-range PET/CT scans either
because of an out-of-range uptake time or elevated blood glucose. The biggest effect was on the
sensitivity of PET/CT, which was reduced to 52.9% and was significantly worse than the sensitivity of
MDCT (70.6%) (p = 0.005). Taking each factor individually, patients with an out-of-range uptake time had
a PET/CT sensitivity of 71.4% and those with elevated blood glucose (> 10 mmol/l) had a PET/CT sensitivity
of 40%. These values confirm that it is essential that PET/CT be performed after the correct uptake time
and that PET/CT is unsuitable for patients with poorly controlled blood glucose.
Further subgroup analyses were undertaken for age, sex and WHO performance status. There was no
evidence of any differences in the sensitivity or specificity of either test with respect to sex or age.
However, both MDCT and PET/CT had a significantly higher sensitivity among patients with a WHO status
of ≥ 1 than among those with a WHO status of 0, but conversely had significantly lower specificity. In
terms of the eligibility criteria (pancreatic mass, jaundice and serum CA19.9 > 37 kU/l), both MDCT and
PET/CT had a significantly lower specificity among patients with jaundice because of distal obstruction of
the common bile duct or ampulla. Moreover, there was also evidence that PET/CT was not more effective
than MDCT in this group. There was no evidence of differences in sensitivity or specificity for the other
eligibility criteria. It can be noted that, based on pancreatic mass on CT, PET/CT sensitivity and specificity
were 93% and 76%, respectively, for diagnosing pancreatic cancer; based on jaundice, PET/CT sensitivity
and specificity were 95.6% and 52.6%, respectively; and based on elevated CA19.9, PET/CT sensitivity and
specificity were 92.2% and 72.5%, respectively. There were no major differences between these criteria
(apart from the specificity in jaundiced patients).
Impact of positron emission tomography/computed tomography on the
diagnosis of pancreatic tumours
The value of PET/CT in other pancreatic tumours was evaluated. The most frequent tumour types
were assessed.
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Malignant cystic neoplasm
The prevalence of malignant cystic neoplasm in the patient cohort was 1.5% (95% CI 0.5% to 2.5%).
The small number of patients diagnosed with malignant cystic neoplasm means that statistical tests
comparing the diagnostic tests have low power to detect small or moderate effects. Both MDCT and
PET/CT had a sensitivity of 75.0% (95% CI 45.0% to 99.9%). The specificity of PET/CT (96.1%, 95% CI
94.5% to 97.8%) was higher than that of MDCT (92.8%, 95% CI 90.6% to 95.0%). The 3.6% (95% CI
1.8% to 5.4%) improvement in specificity between tests is statistically significant (p < 0.001). PET/CT may
have a role in the diagnosis of malignant cystic neoplasms and would have a low false-positive rate.
The numbers of patients in this study are low and therefore larger studies would be needed.
Cholangiocarcinoma
The prevalence of cholangiocarcinoma in the patient cohort was 8.0% (95% CI 5.7% to 10.3%). The
small number of patients diagnosed with cholangiocarcinoma means that statistical tests comparing
the diagnostic tests have low power to detect small or moderate effects. Both MDCT and PET/CT had
a relatively high specificity (97.8% and 98.8%, respectively) but low sensitivity (25% in each case).
There were no significant differences in either sensitivity or specificity. Although a positive diagnosis of
cholangiocarcinoma from the PET/CT or MDCT scan result greatly increased the odds of a patient having
cholangiocarcinoma, there is still considerable uncertainty about the diagnosis. These results would not
support the use of PET/CT in this patient group.
Neuroendocrine tumour
The prevalence of neuroendocrine tumour in the patient cohort was 4.9% (95% CI 3.1% to 6.7%). The
small number of patients diagnosed with neuroendocrine tumour means that statistical tests comparing
the diagnostic tests have low power to detect small or moderate effects. Both MDCT and PET/CT had a
very high specificity (99.4% and 98.7%, respectively) but low sensitivity (44.4% in both cases). The relative
specificity and sensitivity are not significantly different. These results would not support the use of PET/CT
in this patient group.
Periampullary carcinoma
The prevalence of periampullary carcinoma in the patient cohort was 6.9% (95% CI 4.8% to 9.0%). The
small number of patients diagnosed with periampullary carcinoma means that statistical tests comparing
the diagnostic tests have low power to detect small or moderate effects. Both MDCT and PET/CT had
relatively high specificity (95.9% and 97.3%, respectively) but relatively low sensitivity (71.1% and 65.8%).
The relative specificity of PET/CT compared with MDCT is statistically significant (p = 0.034) but the
practical improvements are outweighed by the observed, although non-significant, reduction in sensitivity.
There is some evidence for the use of PET/CT in these tumours.
Malignant compared with benign disease
The prevalence of the different tumour types was low and therefore we undertook a global analysis of all
malignant disease compared with benign disease. The prevalence of any malignant disease among the
patient population was 69.8% (95% CI 66.0% to 73.7%). Both MDCT and PET/CT had a high sensitivity
with respect to detecting any malignancy (97.4% and 97.7%, respectively). The specificity of PET/CT was
considerably higher than that for MDCT (69.7% vs. 47.0%, relative sensitivity 1.46; p < 0.0001). PET/CT
had a statistically significant impact on the odds of malignancy. The results suggest particular benefits of
administering a PET/CT scan after a positive MDCT scan. These results confirm that PET/CT in addition to
MDCT is useful in the diagnosis of malignant compared with benign disease.
Additional analyses
Maximum standardised uptake value
The median SUVmax. for patients with pancreatic cancer was 7.5 and for patients who did not have
pancreatic cancer was 5.7. The SUVmax. optimal cut-off for a diagnosis of pancreatic cancer would be
6.2 according to the AUC. The drawback is that this test has an estimated sensitivity of only 70.3% and a
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specificity of only 59.4%. The optimum cut-off for a diagnosis of chronic pancreatitis was 6.4. This cut-off
value was similar to the optimal value for assessing PDAC, suggesting that an approach of assuming PDAC
for a SUVmax. of > 6.3 and chronic pancreatitis for a SUVmax. of < 6.3 has some merit.
Survival analysis
The 6- and 12-month survival rates for the overall patient population were 82.8% (95% CI 79.7% to
86.0%) and 69.0% (95% CI 65.1% to 73.1%), respectively. Patients who had a diagnosis of pancreatic
cancer had 6- and 12-month survival rates of 71.4% (95% CI 66.0% to 77.2%) and 50.9% (95% CI
44.9% to 57.6%), respectively. The survival times observed in the study were as expected for this type of
pancreatic MDT population.
Health economic evaluation
Health economic analysis was conducted from a NHS perspective. Our cost-effectiveness analysis was in
three parts: model 1, in which we calculated the marginal cost per additional correct diagnosis of PDAC
using PET/CT and MDCT alone; model 2, in which we calculated the budget impact of the use of PET/CT;
and model 3, in which we modelled the change in management of patients over a 1-year time horizon as
a result of the use of PET/CT for diagnosis. We undertook sensitivity analysis to explore uncertainty in costs
(univariate) and model structure (structural). PSA assessed the likelihood that PET/CT is cost-effective at
thresholds of £20,000 per QALY and £30,000 per QALY. We found evidence for the cost-effectiveness of
PET/CT in terms of change in management for patients with suspected pancreatic cancer. In the change
of management model, the primary model dominated management based on MDCT alone. This is largely
because of the number of unnecessary surgeries avoided. Structural sensitivity analysis involved varying our
base-case assumption that all patients received a resection so that some patients who were clinically
indicated received bypass or open and shut laparotomy. Alongside our main finding from the base-case
analysis that PET/CT dominated, the ICER in our structural sensitivity analysis ranged from £19,445 per
QALY to £53,557 per QALY depending on the source of PET/CT costs chosen. For both change of
management models, PET/CT was seen to be most cost-effective for the PDAC with resection subgroup.
Overall, our base-case analysis showed that PET/CT dominated MDCT alone, in particular for patients who
were suspected of having pancreatic cancer after standard diagnostic work-up and who were planned for
surgery. However, we note that QALY gains were small and our analysis was sensitive to our source of
published costs and to structural assumptions in the model.
Overall evidence
Many studies have evaluated PET or PET/CT in the diagnosis and management of pancreatic cancer.
However, these have been small single-centre studies that lack the applicability of multicentre prospective
series of patients. In general, PET/CT demonstrates better accuracy in the diagnosis of pancreatic cancer,
with particular benefit for detecting distant disease and altering management. Five meta-analyses have
compared PET with PET/CT and a variety of other imaging modalities.24,41,44,45,77 The sensitivities and
specificities in these meta-analyses are provided in Table 63. The sensitivity and specificity of 92.7% and
75.8% for PET/CT from the PET-PANC study are similar to those found in the latest meta-analysis by
Rijkers et al.41
There is a lack of comparison between PET/CT and MDCT in these meta-analyses. There are individual
series that have compared MDCT and PET/CT; generally, PET/CT is superior to MDCT when detecting the
primary tumour (Table 64).
It is apparent that there is variability in the reported sensitivities and specificities of PET/CT in individual
studies; however, again, the number of patients per study remains low.
The role of PET/CT in staging pancreatic tumours has been investigated in a number of studies and
meta-analyses.44,79,81 In general, the findings have been that PET/CT may be useful in staging primary
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tumours (and also small pancreatic tumours82) and distant disease. Sensitivity for detecting metastases
varies between 76% and 88%.44,79,81 The role of PET/CT in staging lymph node disease is more uncertain,
with sensitivity for nodal status of between 30% and 81%,44,79,81 although it is useful in detecting distant
lymph node disease.79 There is a lack of evidence for a role of PET/CT in assessing local resectability
of pancreatic cancer in terms of vessel involvement83 and MDCT remains the mainstay of imaging for
this. The PET-PANC study was most useful in accurately staging patients with stage IIb and stage IV
pancreatic cancer, illustrating a role for PET/CT in identifying locoregional lymph node disease and distant
metastases.
The role of PET/CT in the management of patients with pancreatic cancer has been evaluated in
studies from single centres and in meta-analyses.44,46–48,78,79,84 The effect size with regard to change in
management ranges from 41% to 10%.44,46–48,78,79,84 The largest study was a retrospective series of
285 patients over a period of 7 years. The addition of PET/CT changed management in 31 (10%) patients.
Metastases were found in 19 patients. Both this study and another recent review recommended that
‘these findings will be required to be validated in a prospective study along with cost-effective analysis’
(p. e505) and ‘the effects of PET/CT on patient survival and cost-effectiveness need to be further
investigated’ (p. 149).83 In this study PET/CT influenced the management of 45% of patients. The most
common change was changing from resection to no resection, which occurred in 60 patients, representing
11% of all patients and 21% of patients scheduled for some kind of resection after MDCT.
TABLE 64 Studies comparing MDCT and PET/CT in the diagnosis of pancreatic cancer
Study n
Sensitivity/specificity (%)
MDCT PET/CT
Zhang 201554 70 82/65 92/65
Ergul 201478 52 92/50 100/89
Zhang 201252 56 87.5/75 89.7/88.2
Kauhanen 200979 38 85/67 85/94
Casneuf 200739 46 Accuracy 88.2% Accuracy 91.2%
Heinrich 200546 59 93/21 89/69
Lemke 200480 104 76.6/63.9 89.1/63.9
TABLE 63 Meta-analyses comparing PET with PET/CT and other imaging modalities in the diagnosis of
pancreatic cancer
Study Studies, n
Sensitivity/specificity (%)
PET PET/CT CT DW MRI EUS
Rijkers 201441 35 90/76 90/76 –/– –/– –/–
Wang 201344 39 91/80 90/85 –/– –/– –/–
Wu 201277 16 –/– 87/83 –/– 85/91 –/–
Tang 201145 51 88/83 90/80 –/– –/– 81/93
Orlando 200424 17 92/68 –/– 81/66 –/– –/–
DW MRI, diffusion-weighted MRI.
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There are no prospective studies of the cost-effectiveness of PET/CT in pancreatic cancer. One study of
a series of 59 patients undergoing PET/CT for pancreatic cancer demonstrated a 16% change in
management.46 The use of PET/CT was found to be cost-effective in this limited study. The planned
economic analysis in the PET-PANC study found evidence of cost-effectiveness for PET/CT in terms of
management changes for patients. The most cost-effective use of PET/CT was in the subgroup of patients
who had resectable disease and who were planned for surgery.
The PET-PANC study has demonstrated that there is a clinical benefit from the use of PET/CT in the
diagnosis and management of pancreatic cancer and that it is cost-effective for patients who are being
considered for surgery.
Strengths
The PET-PANC study is the largest, prospective, multicentre study of the use of PET/CT in patients
with suspected pancreatic cancer to date. The study demonstrated that it is possible for multiple sites to
adhere to a PET/CT protocol and attain a high level of quality assurance in the majority of PET/CT scans.
The prospective data collected have been vital in establishing the accuracy of PET/CT in the diagnosis of
pancreatic cancer. They have also been invaluable in providing an insight into patient populations treated
in the major UK pancreatic centres and into variations in practice. The multicentre nature of the study
enabled the results to be interpreted and applied in a pragmatic way. The PET/CT quality assurance was an
excellent resource that was invaluable for this study and we were very fortunate that this was available at
the time of our research. The study recruited patients in a reasonable time frame.
We believe that, internationally, this is the first study to generate QALY data for the purposes of robust
economic evaluation in this patient group, using patient-level data from a UK cohort. This study generated
rich QALY data for patients over time, which were stratified by diagnosis: PDAC, double cancer, malignant
disease, benign disease and cysts. Analysis of the data and construction of economic models required close
collaboration between the principal investigator as a clinician familiar with modes of cancer treatment in
this population, the study statisticians and the health economists. The health economists were responsible
for designing data collection from the PET-PANC cohort, building the economic model and analysing
service use, costs and HRQoL data and undertaking the health economic analysis and sensitivity analysis.
The challenging part of the study was, collaboratively, how to tease out how PET/CT had changed the
management of a patient and the associated resource and outcome implications in a cohort rather than
randomised controlled trial study design.
Limitations
This was not a randomised controlled trial and therefore we do not have information from patients who
would have undergone only MDCT for comparison. There were some missing data for patients and there
were also issues with regard to estimating costs for PET/CT. What became clear was the significant impact
that variations in the cost of PET/CT had on estimates of cost-effectiveness, something to be explored
by the NHS with manufacturers to find a way of reducing purchase and operating costs. The health
economists responsible for building the economic model struggled with the lack of a control arm in the
PET-PANC study. This required significant clinical input about alternative management modes of patients
within the cohort. This engendered a particularly close working relationship between clinicians, statisticians
and health economists. We were surprised to find such a wide range of published cost estimates for
PET/CT (inconsistency across departments). Our analysis can be viewed as conservative as we chose the
highest cost estimate in our base-case analysis. We undertook a complete-case analysis of cost data and
did not impute QALY data other than to assume a zero value for the EQ-5D for patients who had died
over the 12-month follow-up period. To isolate the additional role of PET/CT in decisions about the
management of patients the change of management model accounted only for changes in management
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that were deemed clinically to be the result of PET/CT. Subsequent changes in management were
not modelled. Our base-case model did not consider the negative impacts of surgery where it is
contraindicated. We explored this in a structural sensitivity analysis. In our base-case analysis PET/CT
dominated CT alone; however, in our structural sensitivity analysis our findings were comparable to
estimates of cost-effectiveness in the diagnosis of other cancers, that is, borderline cost-effective with
respect to NICE thresholds.66–69
The PET-PANC study showed that the use of PET/CT has the potential to reduce unnecessary surgery, by
changing patient management, and provide quicker more accurate diagnoses, with associated patient
benefits and benefits to the NHS. The bypass and open and shut laparotomy data were considered too
weak (exceptionally small number of patients) for the primary model; however, we included it in a
structural sensitivity analysis. In the PET-PANC study there were also very few patients with metastases
who underwent a resection procedure. It is believed that the pathway of these patients is typical and
representative of such a patient group; however, with such a small number of patients the results need to
be interpreted with caution and the strength of the conclusion may be affected by the quality of these
data. Regardless of model structure, if the cost of PET/CT is taken from clinical oncology, it is likely that the
ICER lies below the NICE threshold of £20,000–30,000 per QALY. When costs are taken from nuclear
medicine, only the primary model indicates cost-effectiveness.
Implications for practice
This study was designed to evaluate the diagnostic accuracy of PET/CT and its effects on management and
cost-effectiveness in patients with suspected pancreatic cancer in a prospective, multicentre manner with
the aim of helping to address the issues around widespread application of this technology and the cost
implications for health care. Patients with suspected pancreatic cancer present unique challenges and
may have complicated patient journeys. Based on the evidence from the PET-PANC study, PET/CT adds
significant benefit to patients in terms of diagnosis, staging and management of pancreatic cancer.
The most cost-effective use of PET/CT would be in the subgroup of patients who are suspected of having
pancreatic cancer on MDCT and who are planned for surgery. Evidence is lacking for the use of PET/CT in
patients with chronic pancreatitis, other pancreatic tumours and pancreatic cysts.
Recommendations for future research
l The role of PET/CT in the diagnosis and management of intraductal papillary mucinous neoplasm is an
important topic as the number of patients diagnosed with incidental pancreatic cysts is increasing year
on year and their management and follow-up is challenging.
l The role of alternative radiopharmaceuticals for PET/CT should be assessed in terms of the diagnosis
and prognosis of pancreatic cancer.
l The role of PET/CT as a response marker in the treatment of pancreatic cancer should be evaluated.
l A randomised controlled trial comparing standard work-up (MDCT) with PET/CT in addition to standard
work-up would provide more data on outcomes associated with MDCT standard work-up alone. More
data are needed on the prognosis of MDCT-alone patients. We would like to suggest three routes for
further enquiry:
¢ Where possible, scrutiny of how patients fare with MDCT alone when PET/CT is not available.
These data would be useful for future economic modelling exercises.
¢ Extrapolation of what happens to patients beyond the 12-month follow-up used in the PET-PANC
study. Resources were not available to allow us to extend follow-up in this study.
¢ Stronger data on unnecessary surgery would add to the strength of the conclusion. Stronger data
on the impact of bypass surgery or open and shut laparotomy would add strength to the
conclusions of our structural sensitivity analysis.
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Conclusions
l This study was the first multicentre, prospective, large-scale study of PET/CT in the diagnosis, staging
and management of patients with suspected pancreatic cancer.
l PET/CT demonstrated significantly increased relative sensitivity and specificity compared with MDCT
and a significant incremental diagnostic benefit in addition to MDCT in the diagnosis of pancreatic
cancer.
l PET/CT corrected the staging of pancreatic cancer in a significant proportion of patients. PET/CT
influenced management in 45% of patients and prevented resection in 21% of patients scheduled
for surgery.
l PET/CT has limited use in chronic pancreatitis and other pancreatic tumours.
l Internationally, as the first cost-effectiveness study using robust QALY data from this patient group, the
PET-PANC study demonstrated that PET/CT is cost-effective for the UK NHS at current costs of PET/CT,
although we note that the QALY gains were small and the results were sensitive to the source of the
cost of PET/CT.
l The PET-PANC study demonstrated that, at current costs of PET/CT to the UK NHS, PET/CT is most
cost-effective for patients with suspected pancreatic cancer who are planned to undergo resection.
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Appendix 1 Union for International Cancer
Control TNM classification, 7th edition
(pancreas section extract)
Reproduced with permission from Union for International Cancer Control. The TNM Classification ofMalignant Tumours. L Sobin, M Gospodarowicz, C Wittekind, editors. 7th edition. Chichester:
Wiley-Blackwell; 2009.85
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Appendix 2 Quality of life questionnaire:
European Quality of Life-5 Dimensions
Sa
mp
le
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
Health Questionnaire
English version for the UK
(Validated for Ireland)
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Sa
mp
le
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain / Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety / Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
Sa
mp
le
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
100
0
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0.
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your health 
state is today.
Best imaginable 
health state
Worst imaginable 
health state
Your own health 
state today
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Appendix 3 Changes in staging of
pancreatic cancer
D4 stage: no tumour/IA/IB/IIA
D1
D2
No tumour/IA/IB/IIA IIB III IV
No tumour/IA/IB/IIA 171 3 1 4
IIB 4 4 0 0
III 2 0 4 1
IV 0 0 0 2
171 unchanged and correct, six changed correctly, 10 unchanged and incorrect, eight changed incorrectly, one changed
between incorrect stages.
D4 stage: IIB
D1
D2
No tumour/IA/IB/IIA IIB III IV
No tumour/IA/IB/IIA 50 21 1 3
IIB 3 19 0 2
III 0 1 3 0
IV 2 0 0 2
19 unchanged and correct, 22 changed correctly, 55 unchanged and incorrect, five changed incorrectly, six changed
between incorrect stages.
D4 stage: III
D1
D2
No tumour/IA/IB/IIA IIB III IV
No tumour/IA/IB/IIA 9 0 0 0
IIB 1 6 0 0
III 0 0 10 0
IV 0 0 1 0
10 unchanged and correct, one changed correctly, 15 unchanged and incorrect, one changed between incorrect stages.
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D4 stage: IV
D1
D2
No tumour/IA/IB/IIA IIB III IV
No tumour/IA/IB/IIA 10 0 0 15
IIB 0 4 0 5
III 0 0 0 7
IV 1 0 0 21
21 unchanged and correct, 27 changed correctly, 14 unchanged and incorrect, one changed between incorrect stages.
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Appendix 4 Distinguishing between pancreatic
ductal adenocarcinoma and chronic pancreatitis at
D1 and D2
D4: patients with neither pancreatic ductal adenocarcinoma
nor chronic pancreatitis
D1
D2
Neither CP only PDAC only CP and PDAC
Neither 158 1 12 1
CP only 0 4 1 0
PDAC only 24 1 47 0
CP and PDAC 0 0 0 0
CP, chronic pancreatitis.
There was an improvement in diagnosis for patients without either PDAC or chronic pancreatitis through
a reduction in those misdiagnosed with PDAC at D2 compared with D1. There was no reduction in the
diagnosis of chronic pancreatitis.
D4: patients with chronic pancreatitis only
D1
D2
Neither CP only PDAC only CP and PDAC
Neither 10 2 0 0
CP only 0 13 1 1
PDAC only 3 3 7 0
CP and PDAC 0 0 0 0
CP, chronic pancreatitis.
Among patients with chronic pancreatitis, 13 were misdiagnosed as having PDAC at D1, which reduced to
eight at D2.
D4: patients with pancreatic ductal adenocarcinoma only
Very few patients were misdiagnosed as having chronic pancreatitis rather than PDAC. Two patients at D1
with PDAC were suspected of having chronic pancreatitis, which reduced to one at D2.
D1
D2
Neither CP only PDAC only CP and PDAC
Neither 13 0 15 0
CP only 1 1 0 0
PDAC only 4 0 225 0
CP and PDAC 0 0 1 0
CP, chronic pancreatitis.
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Appendix 5 World Health Organization
performance status
1. Able to carry out all normal activity without restriction.
2. Restricted in physically strenuous activity but ambulatory and able to carry out light work.
3. Ambulatory and capable of all self care but unable to carry out any work; up and about more than
50% of waking hours.
4. Capable only of limited self care; confined to bed or chair more than 50% of waking hours.
5. Completely disabled; cannot carry out any self care; totally confined to bed or chair.
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Appendix 6 Economic evaluation studies of
positron emission tomography/computed tomography
in oncology
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First author Year
Country and
perspective Title Sample
Type of
cancer Type of analysis Aim of study Tree diagram Model Outcomes
Software
used Comment/notes
Søgaard
66
2010 Denmark; health-care
sector perspective
Preoperative staging of
lung cancer with PET/
CT: cost-effectiveness
evaluation alongside a
randomised controlled
trial
Randomised
controlled trial of
189 patients aged
18–80 years allocated
to conventional
staging (n= 91) or
conventional staging
plus PET/CT (n= 98)
NSCLC Cost-effectiveness
based on cost per
avoided futile
thoracotomy
To assess the
cost-effectiveness of
PET/CT as an adjunct
to conventional
work-up for
preoperative staging
of NSCLC
No CEACs for
alternative
scenarios
CEACs were
generated. Mean
cost per avoided
futile thoracotonomy
€19,314 with
comorbidities
included or €4495
with comorbidities
excluded and cost
saving of €899
Not specifed First economic
evaluation (as far
as the authors
are aware) of
PET/CT as part of
a randomised
controlled trial
Schreyögg67 2010 Germany; payer’s
perspective
Cost-effectiveness of
hybrid PET/CT for
staging of non-small
cell lung cancer
172 NSCLC patients
(132 men, 40
women) from a
prospective clinical
study who underwent
diagnostic, contrast-
enhanced helical CT
and integrated PET/CT
NSCLC (a) Cost-effectiveness
based on correctly
staged patient (for
those undergoing
surgery=77/172);
(b) cost–utility
was modelled
To evaluate the
cost-effectiveness of
staging NSCLC with
CT alone compared
with PET/CT
No Cox proportional
hazards model for
cost–utility analysis
Cost of diagnosis per
patient with PET/CT
was $783 compared
with $100 for CT
alone. (a) ICER was
$3508 per correctly
staged patient and
$4784 according to
resectability; (b) ICER
was $79,878 per
QALY gained
Not specifed
Auguste
68
2011 UK; NHS perspective An economic
evaluation of positron
emission tomography
(PET) and positron
emission tomography/
computed tomography
(PET/CT) for the
diagnosis of breast
cancer recurrence
Modelling study,
Monte Carlo
simulation
Recurrent
breast
cancer
Cost–utility. Mean
cost per patient:
(a) conventional
work-up £534,
(b) PET £1101,
(c) PET/CT £1333,
(d) conventional
work-up+ PET/CT
£1831
With respect to
recurrent breast
cancer: (a) review
published economic
studies and
(b) undertake
model-based
economic evaluation
of PET/CT compared
with conventional
work-up
Yes; model
structure p. 10
Decision tree.
Estimated mean
cost associated
with each
procedure and
assumed that
patients entering
the model were
aged 50–75 years
ICER for PET/CT:
£29,300 per QALY
compared with
conventional work-
up, £31,000 per
QALY compared with
PET and £42,100 per
QALY compared
with conventional
work-up+ PET/CT
TreeAge
Brush69 2011 UK; NHS perspective The value of FDG
positron emission
tomography/
computerised
tomography (PET/CT) in
pre-operative staging
of colorectal cancer: a
systematic review and
economic evaluation
Modelling study,
Monte Carlo
simulation
CRC Cost–utility Ascertain (a) whether
FDG PET/CT is likely
to be cost-effective
as an add-on test for
preoperative staging
in CRC, (b) in which
patient groups it
is likely to be
cost-effective and
(c) under what
circumstances it is
likely to be
cost-effective
Yes; staging
primary CRC
p. 84, staging
recurrent CRC
p. 94, staging
metastatic
recurrence
p. 102
Probabilistic
decision-analytic
modelling; five
models developed
Conventional
imaging modalities
for primary CRC in
terms of cost per
correct diagnosis and
cost per QALY were
favoured. Recurrent
models: (a) rectal
model ICER: £21,409
per QALY, (b) colon
model ICER: £6189
and (c) metastatic
model ICER: £21,434
per QALY
Not specified
CRC, colorectal cancer; NSCLC, non-small cell lung cancer.
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Appendix 7 Mean costs over 12 months for the
intention-to-treat cohort
Resource use category
Mean cost (£)
3 months’
follow-up
(n= 311)
6 months’
follow-up
(n= 272)
9 months’
follow-up
(n= 233)
12 months’
follow-up
(n= 243)
Primary care
Cancer nurse 10.94 8.63 25.70 7.58
GP 89.39 92.09 70.79 59.28
Practice nurse (GP clinic) 77.53 18.00 4.67 4.69
Community nurse 62.61 30.72 76.76 27.82
Health visitor 0.00 0.00 0.00 1.36
Psychologist 0.00 0.11 2.22 0.00
Counsellor 0.00 0.00 1.01 3.16
Physiotherapist 0.48 3.55 3.04 0.47
Occupational health therapist 0.26 0.56 0.00 0.51
Care manager 6.30 0.34 0.00 0.00
Social worker 2.55 0.00 0.04 0.16
Home care worker 7.72 0.66 0.26 4.44
Care attendant 0.14 2.10 0.43 0.00
Carer’s support worker 0.00 0.00 0.19 0.56
Chiropodist 0.34 0.83 1.00 0.95
Dietitian 1.23 1.90 1.35 0.55
Self-help group 0.00 0.11 0.00 0.00
Other 2.16 6.19 6.96 9.58
Secondary care
Oncology inpatient ward 776.22 375.85 260.81 321.22
Medical inpatient ward 2032.06 794.64 586.99 648.65
Continuing care/respite inpatient ward 72.32 8.44 0.00 3.78
Assessment/rehabilitation inpatient ward 145.82 27.83 0.00 10.53
Other inpatient ward 1283.76 522.46 136.71 414.56
Intensive care inpatient ward 388.65 94.10 54.93 58.52
Inpatient consultations (including PAMs) 131.71 42.51 10.47 135.45
Outpatient visits (including consultations) 433.75 484.13 467.04 391.64
Accident and emergency 48.21 60.76 35.25 22.69
Day hospital 71.00 129.43 80.61 29.08
Other 500.09 324.47 177.04 96.50
Total cost 6145.26 3030.41 2004.27 2253.73
PAM, patient-activated measure.
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Appendix 8 Sources of resource use data and
unit costs
Health-care resource Unit Unit cost (£) Details and source
Primary care
Cancer nurse Home/clinic visits 30/30 Per patient contact lasting 60 minutesa
GP Home/clinic visits 292/147 Per patient contact lasting 60 minutesa
Practice nurse (GP clinic) Home/clinic visits 52/40 Per patient contact lasting 60 minutesa
Community nurse Home/clinic visits 70/48 Per patient contact lasting 60 minutesa
Health visitor Home/clinic visits 71/49 Per patient contact lasting 60 minutesa
Psychologist Home/clinic visits 59/59 Per patient contact lasting 60 minutesa
Counsellor Home/clinic visits 59/59 Per patient contact lasting 60 minutesa
Physiotherapist Home/clinic visits 36/36 Per patient contact lasting 60 minutesa
Occupational health therapist Home/clinic visits 34/34 Per patient contact lasting 60 minutesa
Carer’s support worker Home/clinic visits 30/25 Per patient contact lasting 60 minutesa
Care manager Home/clinic visits 62/40 Per patient contact lasting 60 minutesa
Social worker Home/clinic visits 79/57 Per patient contact lasting 60 minutesa
Home care worker Home/clinic visits 20/19 Per patient contact lasting 60 minutesa
Care attendant Home/clinic visits 30/30 Per patient contact lasting 60 minutesa
Chiropodist Home/clinic visits 30/30 Per patient contact lasting 60 minutesa
Dietitian Home/clinic visits 35/35 Per patient contact lasting 60 minutesa
Self-help group Home/clinic visits 30/25 Per patient contact lasting 60 minutesa
Other Home/clinic visits Various
Secondary care
Oncology inpatient ward Inpatient day Various Department of Health75
Medical inpatient ward Inpatient day Various Department of Health75
Continuing care/respite inpatient ward Inpatient day Various www.stlukes-hospice.co.uk/about-us/
financial-breakdown/ (accessed
December 2014)
Assessment/rehabilitation inpatient ward Inpatient day Various Department of Health75
Other inpatient ward Inpatient day Various Department of Health75
Intensive care inpatient ward Inpatient day Various Department of Health75
Inpatient consultations (including PAMs) Appointment Various Department of Health75
Outpatient visits (including consultations) Appointment Various Department of Health75
Accident and emergency Attendance Various Department of Health75
Day hospital Day attendance Various Department of Health75
Other Various Various Department of Health75
PAM, patient-activated measure.
a Lesley Curtis, Unit Costs of Health and Social Care 2013.74
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Appendix 9 Client Service Receipt Inventory86
(version 3, 01/03/11)
Adapted from Beecham J, Knapp M. Costing Psychiatric Interventions. In Thornicroft G, Brewin CR,Wing J. Measuring Mental Health Needs. London: Gaskell; 1992. pp. 163–183.
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Appendix 10 Frequency of contacts with primary
and secondary care health services by 583 patients
up to 12 months
Resource use category
Mean frequency of service use at
3 months’
follow-up
(n= 311)
6 months’
follow-up
(n= 272)
9 months’
follow-up
(n= 233)
12 months’
follow-up
(n= 243)
Primary care
Cancer nurse 0.365 0.288 0.857 0.253
GP 0.548 0.514 0.443 0.382
Practice nurse (GP clinic) 1.566 0.449 0.117 0.113
Community nurse 0.929 0.447 1.098 0.408
Health visitor 0.000 0.000 0.000 0.019
Psychologist 0.000 0.002 0.038 0.000
Counsellor 0.000 0.000 0.017 0.053
Physiotherapist 0.013 0.099 0.084 0.013
Occupational health therapist 0.008 0.017 0.000 0.015
Care manager 0.158 0.006 0.000 0.000
Social worker 0.033 0.000 0.001 0.002
Home care worker 0.386 0.033 0.013 0.222
Care attendant 0.005 0.070 0.014 0.000
Carer’s support worker 0.000 0.000 0.006 0.019
Chiropodist 0.011 0.028 0.033 0.032
Dietitian 0.035 0.054 0.039 0.016
Self-help group 0.000 0.004 0.000 0.000
Other 0.082 0.245 0.198 0.349
Secondary care
Oncology inpatient ward (bed-days) 1.38 0.49 0.48 0.33
Medical inpatient ward (bed-days) 3.14 1.08 0.65 0.83
Continuing care/respite inpatient ward (bed-days) 0.16 0.02 0.00 0.01
Assessment/rehabilitation inpatient ward (bed-days) 0.36 0.10 0.00 0.06
Other inpatient ward (bed-days) 2.63 1.16 0.20 0.32
Intensive care inpatient ward (bed-days) 0.27 0.07 0.04 0.04
Inpatient consultations (including PAMs) (attendance) 0.68 0.17 0.07 0.39
Outpatient visits (including consultations) (attendance) 2.91 3.25 3.20 2.65
Accident and emergency (attendance) 0.32 0.38 0.24 0.14
Day hospital (attendance) 0.37 0.65 0.48 0.07
PAM, patient-activated measure.
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Appendix 11 List of study research sites and
principal investigators
Institution Principal investigator Institution address
Royal Liverpool University Hospital
NHS Trust
JP Neoptolemos Prescot Street, Liverpool, L7 8XP
University Hospital Southampton NHS
Foundation Trust
CD Johnson Tremona Road, Southampton, SO16 6YD
Portsmouth Hospitals NHS Trust M Abu Hilal Queen Alexandra Hospital, Southwick Hill Road,
Portsmouth, Hampshire, PO6 3LY
Leeds Teaching Hospitals NHS Trust A Smith Beckett Street, Leeds, LS9 7TF
Glasgow Royal Infirmary – NHS Greater
Glasgow and Clyde
C McKay 84 Castle Street, Glasgow, G4 0SF
University Hospitals Birmingham NHS
Foundation Trust
R Sutcliffe (S Bramhall,
Wye Valley NHS Trust)
Edgbaston, Birmingham, B15 2TH
Barts Health NHS Trust HM Kocher Whitechapel, London, E1 1BB
Royal Marsden NHS Foundation Trust D Cunningham Fulham Road, London, SW3 6JJ
University College London Hospitals NHS
Foundation Trust
SP Pereira 69–75 Chenies Mews, London, WC1EHX
Royal Free London NHS Foundation Trust B Davidson Pond Street, London, NW3 2QG
Royal Blackburn Hospital – East
Lancashire Hospitals NHS Trust
D Chang Haslingden Road, Blackburn, BB2 3HH
University Hospitals Coventry and
Warwickshire NHS Trust
S Khan Clifford Bridge Road, Coventry, West Midlands,
CV2 2DX
Ninewells Hospital – NHS Tayside I Zealley Dundee, DD1 9SY
King’s College Hospital NHS Foundation
Trust
D Sarker Denmark Hill, London, SE5 9RS
Morriston Hospital – Abertawe Bro
Morgannwg University Health Board
B Al Sarireh Heol Maes Eglwys, Morriston, Swansea,
SA6 6NL
Newcastle Hospitals NHS Foundation
Trust
R Charnley High Heaton, Newcastle upon Tyne, NE7 7DN
Nottingham University Hospitals
NHS Trust
D Lobo QMC campus, Derby Road, Nottingham,
NG7 2UH
Aberdeen Royal Infirmary – NHS
Grampian
M Nicholson Foresterhill, Aberdeen, AB25 2ZN
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Appendix 12 Sample search strategy
The following search terms were used: economic, cost analysis, positron emission tomography,PET, cancer, oncology.
Figure 17 captures our literature selection process.
Database searches (full-length
reports, duplications excluded)
(n = 11)
Potentially relevant references
(n = 70)
References excluded at
abstract screening stage
(n = 59)
Articles meeting 
inclusion criteria
(n = 4)
Reprints were not available
(n = 0)
Relevant references
(n = 11)
Articles included in the review
(n = 4)
Articles in languages other 
than English – articles excluded
(n = 0)
FIGURE 17 Literature selection process.
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